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Summary 
This thesis encompasses a range of experiments designed to characterise and 
validate a method of desensitising rodent hosts in the neonatal period to human 
tissue in order to promote the survival of human striatal grafts in the adult host. The 
successful application of this method is important to allow the preclinical testing of 
potential human donor cells for therapeutic transplantation, specifically in 
neurological disease. Demonstrating safety and functionality of transplanted human 
cells in rodent hosts requires long term assessment of surviving grafts, for which 
current immune suppression methods are insufficient. These experiments were 
therefore designed to determine the optimum parameters of a previously described 
method of desensitising rats to human tissue and to validate this method in mice. 
In order to determine whether the same type of human donor tissue must be used 
to inject neonatally as will be used for the later transplant; Chapter 3 compares 
survival of transplants of human neural tissue into the striatum of rats desensitised 
with a variety of human tissues. It was found that it is not necessary to use human 
neural tissue to desensitise hosts to human neural transplants and data is suggestive 
of improved survival using liver cells to desensitise as measured by graft survival 
and the host immunological response 
The aim of Chapter 4 was to investigate whether desensitisation in the neonatal 
period is specific to the species of tissue used, or whether a reduction in immune 
response to all subsequent transplants has been induced. Animals were desensitised 
and transplanted with tissue of either matching or mismatching combinations of 
human and mouse neural cells, including bilateral transplants using both species. 
Although no survival of mouse transplants was found in any condition, all human 
transplants were found to survive in hosts desensitised with human tissue and treated 
with cyclosporine A (CsA) demonstrating successful desensitisation to human tissue. 
Additionally, half of the human transplants in hosts desensitised with mouse tissue 
survived, raising questions about the possibility of common epitopes on human and 
mouse tissue used to desensitise. 
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Chapter 5 includes a number of experiments designed to determine whether 
mouse hosts could be desensitised neonatally to human neural tissue. Desensitisation 
was not found to be successful, however at least half of control hosts treated with 
CsA were also found to reject human transplants. The findings in this chapter 
suggest differences in the mouse as a host for human xenografts as compared to the 
rat. Additionally control animals in these experiments which received striatal grafts 
of mWGE, showed higher than expected rates of rejection. Therefore Chapter 6 
reconsiders mouse tissue transplantation protocols, testing different donor ages and 
cell preparations to improve transplant survival. Good survival was found in all 
preparations in this experiment, potentially related to one of the modifications to 
transplant protocols, and the use of younger donor tissue was found to produce larger 
transplants. 
These findings provide further support for the neonatal desensitisation method in 
rat hosts, and suggest the potential for use of non-neural tissue types for 
desensitisation of neonates. The data presented in this thesis also has implications for 
the mechanisms underlying the success of the method in the rat. However 
interpretation of initial mouse experiments was difficult as graft survival was 
generally poor and even mouse to mouse transplants did not survive to the level 
expected. Thus this highlights the need to reassess standard immunosuppression 
protocols in mice, and determine what differs between the rat and mouse rejection 
response to xenografts.  
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Chapter 1  
Introduction 
Cell replacement offers a therapeutic option for the treatment of a number of 
diseases of the central nervous system. Successful transplants of human primary 
foetal tissue in the clinic have been achieved in Huntington’s disease, with current 
work aiming to identify and characterise alternative potential human donor cells for 
transplantation to avoid ethical and logistical issues with the use of this tissue. 
Current research in regenerative medicine has offered a number of human 
progenitor cell types with the potential for use in this area, all of which require 
preclinical testing through xenotransplantation in animal models of disease. This 
necessitates immunosuppressive treatments to promote survival of donor cells for 
sufficient time to assess safety and efficacy of transplanted cells. Immunosuppression 
strategies available at present do not offer optimum parameters for the adequate 
assessment of the function of these human donor cells, therefore alternative methods 
are essential to progress this field of research. The work presented in this thesis 
includes characterisation and further validation of a method that has the potential to 
promote long term survival of human donor cells in rodent disease models, thus 
allowing full functional assessment of a transplant in a lesion model of Huntington’s 
disease. The neonatal desensitisation method discussed is referred to as 
“tolerising”, although with no assumptions of inducing true immunological 
tolerance. 
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1.1 Cell transplantation in neurodegenerative disease 
The ongoing investigations into neural cell replacement therapy provide a 
therapeutic strategy for a range of neurological disorders for which currently only 
limited or symptomatic treatments are available, and where there is an unmet clinical 
need for alternative effective interventions. Although drug treatments have the 
potential to alleviate symptoms, currently available pharmacological agents cannot 
repair damage sustained to the central nervous system (CNS). However, cell 
transplantation has the potential to replace cells lost due to the disease. Much 
research into cell replacement therapy has focused on conditions such as Parkinson’s 
disease (PD) and Huntington’s disease (HD), as the pathology of both comprises a 
relatively focused area of primary cell loss thus providing a target cell population to 
replace. This section reviews the cell transplantation literature in both of these 
diseases, but with an emphasis on HD, since the work presented in this thesis focuses 
on rodent HD lesion models. Although proof-of-principle has been demonstrated for 
the potential efficacy of human (h) primary foetal (PF) tissue transplantation, 
alternative tissue sources are required for effective translation of this therapy to the 
clinic. 
1.1.1 Parkinson’s disease 
PD is a common progressive neurodegenerative condition affecting 
approximately 1% to 2% of the population aged over 60. In Europe alone, recent 
estimates place the number at 1.2 million people (Gustavsson et al. 2011). The 
aetiology of PD is unclear although it is considered to be attributable to a 
combination of genetic and environmental factors. Known genetic causes have been 
identified in only about 10% cases and mainly in early onset PD (Alcalay et al. 
2010). Classical clinical features of PD include bradykinesia, rigidity and rest tremor 
progressing to gait disturbances and postural instability. Other non-motor 
impairments frequently develop including depression and dementia, laryngeal 
dysfunction and dysphagia, autonomic and sensory disturbances and the condition 
eventually progresses to cause significant disability with markedly impaired quality 
of life. The two main neuropathologic findings in PD are loss of the pigmented 
dopaminergic neurons in the substantia nigra pars compacta (SNc) which project to 
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the striatum, leading to a reduction in striatal dopamine levels (Olanow et al. 1996) 
and the presence of Lewy bodies at autopsy. 
The loss of dopamine is responsible for most of the characteristic motor 
symptoms observed in PD. Treatment therefore aims to alleviate this dopamine 
depletion. Currently the main pharmacological agents for treatment of PD include 
the dopamine precursor levodopa (L-Dopa); usually administered in combination 
with carbidopa, a peripheral decarboxylase inhibitor (PDI), dopamine agonists and 
monoamine oxidase-B (MAO-B) inhibitors. L-Dopa enters the remaining 
dopaminergic neurons where it is metabolised to dopamine, replacing the depleted 
endogenous neurotransmitter. Dopamine agonists exert their anti-parkinsonian 
effects by acting directly on dopamine receptors and mimicking the endogenous 
neurotransmitter. MAO-B inhibitors inhibit the activity of MAO-B oxidases that are 
responsible for inactivating dopamine. Symptomatic pharmacotherapy is successful 
to an extent, usually providing good control of motor signs for a number of years. 
However long term treatment, particularly with L-Dopa, results in the gradual 
increase in dyskinesias amongst other side effects and fluctuating motor responses 
with narrowing of the therapeutic window (Brooks 2000). Surgical procedures are 
reserved for patients with disabling motor symptoms uncontrolled by medication. 
Currently there is no proven neuroprotective or disease modifying treatment 
although a variety of agents are under investigation including the MAO-B inhibitors 
selegeline and rasagiline, which may possibly modify the outcome of PD (Lew 
2011), and gene therapy that may aid in the restoration of the nigrostriatal 
dopaminergic network (Coune et al. 2012). 
To determine the suitability of cell replacement for treatment in neurological 
disease necessitates the use of animal models in order to demonstrate safety and 
efficacy pre-clinically. Neurotoxin lesion models aim to mimic the degeneration seen 
in disease by inducing the loss of a specific cellular population. In animal lesion 
models of PD, 6-hyroxydopamine (6-OHDA) is injected and is selectively taken up 
by dopaminergic neurons in the substantia nigra which subsequently die. Successful 
neural cell transplants of human primary foetal tissue from the developing ventral 
mesencephalon (VM) tissue into 6-OHDA lesioned animals have been demonstrated, 
showing functional integration of grafts (Björklund and Stenevi 1979; Dunnett et al. 
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1981) and improvements on behavioural measures designed to assess motor deficits 
associated with the PD model (Brundin et al. 1986; Brundin et al. 1988). Whilst 
there are limitations with animal models in that the full spectrum of PD symptoms 
and disease progression is not replicated, these findings in experimental animals 
have led to numerous clinical trials in PD patients using hPF tissue. 
Early open clinical trials in small numbers of patients have produced a 
number of positive results with transplants successfully restoring dopamine levels in 
the striatum leading to functional improvements on measures of PD symptoms 
(Defer et al. 1996; Lindvall and Björklund 2004). Patients have shown reductions in 
Parkinsonian symptoms without additional L-Dopa treatment for a number of years 
after transplantation (Dunnett et al. 2001; Lindvall et al. 1990). Long term functional 
efficacy of grafts in the reduction of motor symptoms has since been demonstrated 
up to 16 years post-transplantation (Piccini et al. 1999), although with continuing 
decline in non-motor symptoms (Politis et al. 2012). Despite these findings, some 
negative outcomes have had a detrimental effect on the field. Later double-blind 
controlled clinical trials (including sham operations) in larger numbers of PD 
patients to evaluate the transplantation of human primary foetal VM, did not provide 
overall evidence of efficacy, and were reported to result in the emergence of 
dyskinetic side effects persisting after the withdrawal of L-dopa (Freed et al. 2001; 
Olanow et al. 2003). These data seemed to publicly represent negative outcomes of 
hPF transplants in PD, although some improvements were noted in patients with less 
severe disease (Olanow et al. 2003) and in younger aged patients (Freed et al. 2001). 
Whilst highlighting detrimental side effects for further investigation, these findings 
were subsequently not considered to be representative of the field since non-standard 
transplant techniques and assessments were used. The studies were also 
underpowered, with only short term follow up reported. Subsequent longer term 
follow up of patients from the Freed trial showed clinical improvement and graft 
viability sustained for up to 4 years after transplantation (Ma et al. 2010). The 
findings and experience from the earlier studies have led to initiation of the EU-
sponsored TRANSEURO project which aims to develop a better cell therapy 
approach for PD patients using PF dopaminergic cells and an initial open trial of hPF 
VM transplants in PD patients is now ongoing (Evans et al. 2012). 
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1.1.2 Huntington’s Disease 
HD is a genetic autosomal dominant neurodegenerative disorder with full 
penetrance. It is estimated to affect about 5 to 7 people per 100,000 in Western 
countries, although there is some evidence to suggest the prevalence may be 
significantly greater (Evans et al. 2013; Spinney 2010). Onset of the disorder is 
insidious with symptoms usually becoming manifest in midlife although it has been 
reported as starting in infancy and as old as in the 90s. The characteristic clinical 
features of HD include chronic motor, cognitive and behavioural changes that 
progress over 15-30 years resulting in profound disability (Novak and Tabrizi 2010). 
Motor symptoms include chorea, dystonia, bradykinesia, rigidity, postural instability, 
dysarthria, dysphagia, abnormal eye movements, tics and myoclonus. Cognitive 
symptoms include deterioration of executive function, short term memory problems 
and dementia. Psychiatric symptoms associated with HD include a high incidence of 
depression as a direct result of the disease (Paulsen et al. 2005b) with links to 
increased suicide risk in patients (Paulsen et al. 2005a). Patients with HD can also 
develop psychosis, obsessive compulsive symptoms, sexual and sleep disorders and 
personality changes. Most patients survive for 10 to 30 years after onset of HD with 
death being usually from intercurrent illness commonly pneumonia and 
cardiovascular disease (Sørensen and Fenger 1992).  
HD is caused by expansion of a polymorphic CAG trinucleotide repeat 
encoding of a polyglutamine tract within the Huntingtin gene (HTT) on 
chromosome 4, encoding for the huntingtin protein (htt), resulting in a mutant form 
of the protein. The genetic defect responsible for HD was mapped to chromosome 4 
in 1983 and first identified in a landmark study by the Huntington’s Disease 
Collaborative Research Group 10 years later (HDCRG 1993). The htt protein is 
essential for neural development although its function is not fully elucidated (Novak 
and Tabrizi 2010). In the normal population, HTT has between 10-29 repeats (Kumar 
et al. 2010). Greater repeat number is considered abnormal, with HD patients having 
between 36-121, and an inverse relationship exists between repeat length and age of 
onset on a population basis, with higher repeat length associated with a younger age 
of onset and greater severity (Ferrante 2009; Kumar et al. 2010). The underlying 
pathology of the disease is characterised by progressive neurodegeneration within 
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the CNS with prominent cell loss and atrophy in the caudate and putamen. In 
particular, the γ-aminobutyric acid (GABA)-ergic medium spiny projection neurons 
of the striatum are lost, with more involvement of the enkephalin containing medium 
spiny neurons (MSNs) that project to the external globus pallidum, than neurons that 
contain substance P and project to the internal globus pallidum. Because of 
preferential involvement of the indirect pathway of basal ganglia-thalamocortical 
circuitry this contributes to the characteristic chorea observed early in the course of 
HD. Other affected areas include the substantia nigra, cortical layers 3, 5, and 6, the 
CA1 region of the hippocampus, the angular gyrus in the parietal lobe, Purkinje cells 
of the cerebellum, lateral tuberal nuclei of the hypothalamus, and the 
centromedial-parafascicular complex of the thalamus (Walker 2007). Another 
pathological feature is the presence in the brain of intranuclear inclusions including 
amongst other things mutant huntingtin. Whilst initially these inclusions were 
considered to be toxic, more recently evidence from animal studies suggests that 
these inclusions may not be predictors of disease activity (Walker 2007). The 
mechanisms whereby this mutant gene produces cellular dysfunction are as yet not 
clear. As the mutant HD gene results from an expanded CAG repeat leading to a 
polyglutamine strand of variable length at the N-terminus it is suggested that this tail 
confers a toxic gain of function (Walker 2007). 
The disease is devastating to both patients and their families and currently 
there is no treatment available for HD that can prevent or slow progression of the 
disease. Treatments are aimed at management of symptoms and improvement of 
quality of life for patients. This may include physiotherapy to improve gait and 
balance, speech and language therapy, and a number of pharmacological agents that 
include dopamine-depleting agents such as tetrabenazene to treat chorea, 
anticonvulsants, antipsychotics and antidepressants (reviewed in Novak and Tabrizi 
(2010) and Novak and Tabrizi (2011)).  
Ultimately targeting the pathology/genetics of the disease is likely to develop 
optimum treatments. Currently, cell replacement therapy presents an alternative 
strategy for treatment of HD sufferers, with the potential to delay disease progression 
and alleviate symptoms. Following on from transplantation of dopaminergic cells in 
PD; HD was considered to be the next target for transplantation in the early 1990s 
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(Rosser and Bachoud-Lévi 2012). Delivery of developing striatal neurons from the 
foetal ganglionic eminence (GE) is targeted homotopically to the striatum with the 
aim of replacing striatal projection neurons and rebuilding lost connections. 
Transplantation in rats has shown that rat foetal striatal neurons survive and can 
integrate and differentiate into functional MSNs with the formation of relevant 
connections in the host brain (Dunnett et al. 2000; Isacson et al. 1984; Wictorin 
1992). Transplantation studies have been carried out in lesion models of HD, 
designed to mimic the cell loss seen in patients with the disease. One such model is 
an excitotoxic lesion model whereby quinolinic acid (QA) is injected into the 
striatum, targeting the death of MSNs (Beal et al. 1986). The injection of QA into 
the striatum damages GABA-ergic and substance-P containing neurons (typical of 
MSNs), and spares those known to also be spared in the clinical condition of HD 
(Ferrante 2009). This provides a valuable model with relevant cell loss in which to 
study HD pathogenesis and test potential therapeutic strategies. Transplantation of 
PF striatal tissue into rodents has also been successful in the reconstruction of 
disrupted circuitry in the QA lesion model, with grafts containing mature striatal 
neurons and forming relevant afferent and efferent connections in the host brain 
(Nakao and Itakura 2000; Nakao et al. 1999; Wictorin 1992). Additionally, 
improvements have been observed in a range of motor and cognitive behavioural 
tasks following PF transplants to the lesioned rat striatum (Dunnett et al. 2000; 
Nakao and Itakura 2000).  
A number of genetic models of HD have now been developed; the majority 
in mice (Ferrante 2009), with the recent production of a transgenic (Tg) rat model 
(von Hörsten et al. 2003). Three main types of mouse models have been generated 
with varying phenotypes (Ferrante 2009). First; mice expressing exon 1,  or 1 and 2 
of human HTT with varying CAG repeat lengths in addition to both alleles of murine 
wild type huntingtin (Hdh). These include the R6/2 mouse model, the first Tg model 
of HD to be generated (Mangiarini et al. 1996). Secondly; knock-in mice with the 
insertion of pathogenic CAG repeats into the existing CAG expansion of murine 
Hdh, such as the Hdh(CAG)150 (Heng et al. 2007; Lin et al. 2001). Finally mice 
expressing the full-length human HD gene, with varying CAG repeats (Hodgson et 
al. 1999; Hodgson et al. 1996; Reddy et al. 1998). Although a number of HD mouse 
models exist, as yet little successful transplantation has been carried out in these 
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hosts. Since mouse models of HD express much longer repeat lengths than those 
found in patients, they develop a much more widespread pathology, more similar to 
juvenile HD and due to this lack of specific cell loss do not provide ideal models for 
transplantation. Some transplant studies have been carried out in mouse models; 
striatal grafts of wild type mouse tissue transplanted into the R6/2 mouse model of 
HD have been found to survive and produce marginal behavioural improvements 6 
weeks after transplantation (Dunnett et al. 1998). A more recent study, however, 
found that transplantation of immortalised human striatal stem cells into the same 
host yielded very small grafts and no behavioural improvement (El-Akabawy et al. 
2012). This may be due to issues with survival of xenogeneic human tissue in the 
mouse hosts. 
The recent development of rat models of HD; including a Tg model 
(TgHD rat - von Hörsten et al. (2003)) and bacterial artificial chromosome 
(BAC)-HD model (Yu-Taeger et al. 2012) provide perhaps more appealing hosts, 
since the majority of transplants and functional improvements have been developed 
in rats. The TgHD rat model carries expansions of 51 CAG repeats under the 
endogenous rat HD promoter and has been reported as displaying a phenotype 
typical of late onset HD, as compared to the majority of mouse models with large 
CAG repeats, which show juvenile onset and rapid degeneration. The rat model is 
therefore suggested to be more true to the clinical presentation of HD (von Hörsten 
et al. 2003). However heterozygous TgHD rats display only subtle behavioural 
deficits, therefore requiring breeding of homozygous animals for testing (Brooks et 
al. 2009). The BAC-HD model contains the full length human HTT gene with 97 
CAG repeats, exhibiting a stronger phenotype than the transgenic, with earlier onset 
and faster progression of motor deficits (Yu-Taeger et al. 2012). However, these 
models are relatively new and much work remains for their characterisation. 
Therefore lesion models still continue to be useful in transplantation studies, 
providing relevant cell loss and identifiable motor deficits to target replacement and 
to assess the safety and function of donor cells. 
The successful transplantation of rat PF striatal tissue in a number of pre-
clinical trials in rat led to further successful trials in non-human primate models (See 
Nakao and Itakura (2000) for a review). Foetal striatal allografts in excitotoxic lesion 
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models in primates produced comparable data to rodent studies, with survival, 
differentiation and integration of grafts leading to improvements on both motor and 
cognitive tasks (Kendall et al. 1998; Palfi et al. 1998). Following these findings a 
number of clinical trials were initiated in HD patients, with the transplantation of 
hPF tissue. Due to ethical issues surrounding the use of double-blind trials and sham 
surgery in patients, examined in particular in reference to clinical trials in PD 
(Dekkers and Boer 2001; Macklin 1999), clinical trials of hPF tissue transplantation 
in HD patients have so far all been small, open-label trials with a focus on core 
assessment protocols, as emphasised for PD (Boer and Widner 2002). Initial safety 
studies showed no acceleration of disease progression or serious, irreversible side 
effects as a direct result of the transplants, though little clinical improvement was 
seen in many of the studies (Hauser et al. 2002; Rosser et al. 2002). The best 
functional improvements to date have been reported in a French cohort 2 years after 
transplantation on a range of neuropsychological tests and the UHDRS, 
corresponding with magnetic resonance imaging (MRI) signal indicative of 
surviving transplants, which stabilised for up to 6 years in some patients (Bachoud-
Lévi et al. 2006; Bachoud-Lévi et al. 2000; Bachoud-Levi et al. 2000).  
Post-mortem data from patients who died post-transplantation, though not as 
a result of the transplant, have shown graft integration and presence of relevant 
striatal markers within the graft (Capetian et al. 2009; Freeman et al. 2000). Over 
time the health of grafts has been reported to deteriorate, with minor infiltration of 
microglia (Cicchetti et al. 2009). However the analysis of the health of grafts here 
was carried out through comparisons between grafted cells and surrounding host 
tissue in transplants which were in situ for a long period of time (10 years) compared 
to recently transplanted cells (18 months - Cicchetti et al. (2009)). Since the 
surrounding host tissue in these cases could not be considered to be comparable, 
these findings may not be truly representative of the health of the transplants (Rosser 
and Bachoud-Lévi 2012). As no serious side effects or evidence of acceleration of 
the disease itself have been observed in transplant studies, ongoing work seeks to 
reduce variability in outcome through optimisation of transplant and 
immunosuppression protocols. See Dunnett and Rosser (2011) and Wijeyekoon and 
Barker (2011) for reviews of clinical studies carried out to date on hPF striatal 
transplantation in HD. 
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1.1.3 Alternative donor cells for transplantation 
Clinical trials have demonstrated that cell replacement therapy can be 
effective in the treatment of neurodegenerative disease; however the use of hPF cells 
as a donor source for transplantation poses numerous problems. Laws vary in the 
collection of tissue from elective termination of pregnancy (ToP) due to the ethical 
issues surrounding the procedure. The UK requires local ethical approval for the 
collection of such tissue which, in Wales is carried out through the South Wales 
Initiative for Foetal Transplantation (SWIFT) programme, and this work is licensed 
by the human tissue authority (HTA). Additionally, the decision to donate foetal 
material for research is made by the maternal donor separately to that of the decision 
for ToP, with separation between medical and research teams and no option to 
donate tissue to a specific recipient (Polkinghorne 1989). A number of foetal donors 
are necessary for each patient; potentially up to 6 in HD, and 8-12 in PD, owing to 
the number of cells of a specific striatal or dopaminergic phenotype required (Barker 
and de Beaufort 2013; Rosser and Dunnett 2007). Since primary tissue cannot be 
stored prior to transplantation for more than a maximum of 8 days in hibernation 
medium (Hurelbrink et al. 2000), clinical transplantation would rely on the 
availability of sufficient donor tissue within this time. Due to the nature of the 
procedure, in which patients receive unique transplants from different donor 
foetuses, there can be problems in the variability and purity of cells which may affect 
the success of transplants (Barker and de Beaufort 2013; Björklund and Lindvall 
2000; Kelly et al. 2011). Therefore as well as refining the transplantation method, 
current research aims to investigate alternative sources for potential transplant donor 
cells (Kim and de Vellis 2009). 
Proof-of-principle for cell replacement therapies in neurodegenerative 
diseases including PD and HD has been achieved with allografts of PF tissue. 
Alternative donor tissue is required to consist of comparable cell types at relevant 
stages of development to achieve replacement of cells lost in disease-related 
degeneration. Additionally, a large stable population of cells is necessary, preferably 
not dependent on direct derivation from foetal donors, which can be quality 
controlled and standardised across transplants. A number of potential cell types exist 
including; xenogeneic porcine cells, foetal derived neural precursor cells (NPCs) 
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which may be expanded in culture, embryonic stem cells (ESC) and adult bone 
marrow mesenchymal stem cells (MSC), and most recently induced pluripotent stem 
cells (iPSCs) and induced neurons (iN) which may be generated from adult somatic 
cells such as skin fibroblasts. Each donor cell type is associated with various benefits 
and pitfalls, and all require extensive pre-clinical assessment prior to clinical trials of 
safety and efficacy in HD patients. 
Xenogeneic donor cells 
The use of xenogeneic tissue has been proposed as a potential source of cells 
for CNS transplantation, in particular porcine cells. Donor cells derived from porcine 
foetal tissues offer the potential for generation of PF striatal tissue of a specific donor 
age. This can be produced from inbred breeding stock under standardised, controlled 
conditions and with tissue collection and preparation undertaken to sterile good 
manufacturing practice (GMP) standards. Porcine tissue also offers comparable size 
and developmental time-course to the human brain. However issues with xenograft 
rejection must be considered. Humans and other Old World primates have natural 
antibodies to the α-galactosyl (α-Gal) epitope, which is expressed by many porcine 
cell types, including endothelial cells in foetal and adult brain (Sumitran et al. 1999). 
Therefore the transplantation of porcine tissue results in binding of these natural host 
antibodies to the graft and activation of the complement system. This causes 
hyperacute rejection of solid tissue grafts, and requires that grafts are derived from 
dissociated neural tissue containing fewer donor endothelial cells and permitting 
avoidance of hyperacute rejection (Brevig et al. 2008). However, even this 
preparation is not protected from rejection. A number of methods have been used to 
promote survival of porcine transplants in rodent hosts including; treatment with the 
immunosuppressant CsA (Pakzaban and Isacson 1994), anti-CD4 monoclonal 
antibodies (Wood et al. 1996), and masking donor major histocompatibility complex 
(MHC) by pre-treating porcine donor cells with an antibody to MHC-I (Pakzaban et 
al. 1995). Although immunological issues can be navigated through donor cell 
preparation and immunosuppression, additional concerns with the use of porcine 
tissues include the potential for transmission of zoonotic viruses, such as porcine 
endogenous retrovirus (PERV). 
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Despite these factors a number of preclinical studies have been conducted 
demonstrating that surviving intra-striatal transplants of PF porcine VM in rat hosts 
can form connections (Isacson et al. 1995) and produce functional recovery (Galpern 
et al. 1996). An initial clinical trial of unilateral transplantation of embryonic porcine 
VM in PD patients was carried out, with either CsA immunosuppression or masking 
of MHC on donor cells. This study showed no adverse effects or evidence of 
transmission of PERV, with no observed differences between immunosuppression 
treatments on the clinical outcomes measured and in graft survival assessed through 
in vivo imaging. Reported clinical benefit was moderate one year after 
transplantation (Schumacher et al. 2000). Post-mortem data have shown evidence of 
some graft rejection, even in a CsA treated patient (Deacon et al. 1997). Similar 
results have been reported from transplants into patients with HD (Fink et al. 2000). 
Although a promising source of tissue, issues of rejection have presented problems 
with the transplantation of porcine embryonic tissue, thus more optimum donor cell 
types continue to be investigated. 
Currently, the cell types providing the most interest as potential donor cells 
suitable for transplantation in HD are stem cells. In the broad sense these are 
precursor cells which possess the ability for continuous renewal, although this can 
vary, and differentiation into many different lineages. Stem cell types currently 
under investigation for their potential use in transplantation include pluripotent cells 
such as ESC, derived from the inner cell mass of the blastocyst stage embryo, and 
more potency restricted stem cells derived from other sources including cord blood 
and bone marrow (MSCs). 
Pluripotent Stem cells 
A number of human ESC lines are available, including those of a GMP grade 
suitable for transplantation in the clinic. Protocols have been developed for the 
successful neural induction of human ESCs, allowing specification to the desired 
neuronal lineage (Chambers et al. 2009). Differentiation of ESCs directed to a 
dopaminergic phenotype has resulted in cells with some evidence of function 
following transplantation into animal models of disease (Rodríguez-Gómez et al. 
2007). Protocols have also been developed for differentiation of ESCs into GABA-
ergic striatal neurons, expressing MSN markers including DARPP-32 (Aubry et al. 
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2008; Carri et al. 2013; Ma et al. 2012; Parmar and Björklund 2012). Following 
transplantation into the QA lesioned mouse striatum of immunodeficient mouse 
hosts, these cells have shown expression of DARPP-32 and substance-P with some 
evidence of alleviation of motor deficits (Ma et al. 2012). An alternative protocol 
showed the same appropriate development of cells in vivo in immunosuppressed rat 
hosts following transplantation, however longer term follow up in immune 
compromised rats revealed problems with overgrowth of transplanted ESCs (Aubry 
et al. 2008). Moderate behavioural improvements have been reported with a different 
MSN differentiation protocol, however histological analysis at 6 and 9 weeks 
post-transplantation was again indicative of graft overgrowth (Carri et al. 2013). 
This highlights an important issue with the use of ESC derived cells in 
transplantation, which also applies to the other cell types discussed in this section. 
Prior to transplantation of cells differentiated from a pluripotent cell type, adequate 
specification and reduction in pluripotency markers must be confirmed to reduce 
risks of tumorigenesis in vivo. These cells must then be adequately tested pre-
clinically with long term assessments post-transplantation to determine the risk of 
overgrowth. Additionally, although ESCs can offer a source of cells with the 
potential for virtually unlimited proliferation and genetic modification (Steindler 
2007), the cells still require derivation from embryonic tissue. This introduces ethical 
issues comparable to that of the use of PF donor tissue, in addition to legislation 
regarding the development and maintenance of stem cell lines from this donor tissue.  
More recently, successful reprogramming of adult somatic cells to a 
pluripotent state has been achieved using a set of factors known to have a role in the 
maintenance of pluripotency in early embryos and ESCs; Oct3/4, Sox2 and Klf4, or 
increase proliferation in tumour cells; c-Myc (Takahashi and Yamanaka 2006). The 
resulting pluripotent cells may then be differentiated into required cell types for 
transplantation, as with ESCs. iPSCs have been successfully differentiated into 
neurons, and they offer the same advantages as ESCs, avoiding the need for foetal 
donors and also providing the additional potential for the generation of patient 
specific cell lines from adult fibroblasts (Takahashi and Yamanaka 2006). This raises 
the possibility of delivery of autologous transplants in patients, which may 
circumvent the need for immune suppression. However an investigation into the 
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rejection of mouse iPSC transplants in mouse hosts challenges this suggestion. Zhao 
et al sought to investigate the immunogenicity of iPSCs to determine whether such 
autologous transplants would be tolerated as assumed (Zhao et al. 2011). The 
authors showed that mESC derived from C57BL/6J (B6) mice could efficiently form 
teratomas following injection into B6 mouse hosts; whereas injections of miPSCs 
reprogrammed from B6 mouse embryonic fibroblasts (MEF) resulted in rejection 
accompanied by T cell infiltration. Following global gene analysis from teratomas 
formed by both cell types, several genes were reported to be overexpressed in miPSC 
derived teratomas which were shown to contribute to the immunogenicity of these 
cells (Zhao et al. 2011). Subsequent reports have disagreed with these findings and 
shown no immune responses to miPSC derived skin or bone marrow cells in B6 
mouse hosts (Araki et al. 2013). Therefore, whether successful autologous 
transplantation without immunosuppression can be achieved has not yet been 
determined. 
Concerns also derive from differences found in gene expression profiles of 
iPSC as compared to ESCs (Chin et al. 2009), and iPSC lines have been reported to 
develop epigenetic and chromosomal abnormalities with continued expansion in 
vitro (Pera 2011). Aside from these abnormalities; the identification that iPSCs 
retain some epigenetic memory for the original donor cell provides the potential to 
favour iPSC differentiation to a specific cell type, which may be used 
advantageously in developing differentiation protocols for cells for transplantation 
(Bar-Nur et al. 2011; Kim et al. 2010). Since cells are reprogrammed to a pluripotent 
state, and subsequently differentiated to the desired cell type, there are risks of 
persistent pluripotency from the reprogramming factors resulting in potential 
tumorigenesis following transplantation in vivo. Much work is required to 
characterise the differences between iPSC and ESC compared to PF tissue, and the 
various reprogramming methods available before they can be translated to the clinic, 
aside from the standard testing required to demonstrate safety and function pre-
clinically. 
Lineage restricted stem cells 
The presence of multipotent cells in the developing brain gives the potential for 
the expansion of these cells in culture, providing a potential source of NPCs for 
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transplantation. NPCs may be derived from the foetal CNS and cultured with the 
addition of growth factors such as epithelial growth factor (EGF) and fibroblast 
growth factor (FGF-2), allowing proliferation of cells which are already committed 
to a neuronal lineage (Svendsen et al. 1998), or even a striatal lineage. Although this 
presents an attractive donor source for transplantation, it has been shown that 
following expansion in culture, changes in gene expression occur, and the longer 
cells are expanded in culture the less they are able to differentiate and survive after 
transplantation in vivo (Zietlow et al. 2005; Zietlow et al. 2012). Although 
transplanted NPCs have been reported to improve survival of endogenous neural 
cells through intrinsic neuroprotection properties via the release of growth factors 
and immunomodulatory molecules at the graft site (Pluchino et al. 2009), the 
development of the relevant cell type in vivo is still required for true circuit repair. 
Thus the main theoretical benefit of these cells (the ability for expansion in culture to 
provide a constant source of cells which are committed to the relevant neuronal 
lineage) does not appear to be a reality. 
Following successful reprogramming of adult cells to a pluripotent state 
requiring subsequent neuronal differentiation; direct conversion of fibroblasts to 
neuronal cells has now been achieved (Vierbuchen et al. 2010). As these cells do not 
require differentiation from the reprogrammed pluripotent state, this avoids the 
issues associated with potential tumour formation. First demonstrated in mouse cells, 
three neural-lineage-specific transcription factors; Ascl1, Brn2 and Myt1l (BAM), 
were expressed in mouse postnatal fibroblasts resulting in efficient conversion to 
functional iNs in vitro (Vierbuchen et al. 2010)). Successful generation of iN from 
human fibroblasts with the same factors and the addition of another factor, NeuroD1, 
was subsequently achieved (Pang et al. 2011). Additionally, combining the BAM 
factors with expression of Lmx1a and FoxA2, two genes involved in the natural 
generation of dopaminergic neurons, has resulted in the generation of directly 
induced dopaminergic neurons with potential for use in transplantation in models of 
PD or for disease modelling in vitro (Pfisterer et al. 2011). 
Another lineage restricted stem cell type, MSCs, can be harvested from adult 
or foetal bone marrow, as well as a number of other tissues. These cells are 
characterised by plastic adherence, rapid proliferation and multipotency (Dominici et 
Chapter 1 Introduction 
16 
al. 2006). As these cells can be derived from adult bone marrow, this could avoid 
some of the ethical and practical issues associated with the use of foetal tissue. 
Although reportedly only a low percentage of MSCs can differentiate into neurons 
following transplantation into the QA lesioned rat striatum (Lescaudron et al. 2003), 
the cells possess other properties of interest. Numerous studies have reported the 
immunomodulatory capabilities of MSCs, demonstrating suppression of T cell 
proliferation (Di Nicola et al. 2002; Zappia et al. 2005). On transplantation, MSCs 
can provide neurotrophic support and improve survival of co-transplanted adult 
neural stem cells (aNSCs) leading to behavioural improvements in a model of HD 
(Dunbar et al. 2006; Rossignol et al. 2014). These findings will be discussed in 
further detail in section 1.2.3.   
The use of cells for transplantation from all stem cell types involves a 
number of common issues which must be addressed before translation to the clinic. 
First, differentiation into the appropriate neural phenotype must be confirmed, 
ensuring no pluripotent cells remain and no aberrant differentiation has occurred. 
Additionally, it must be determined whether producing and transplanting a pure 
population of cells for transplantation is adequate for survival of cells and repair in 
the host brain. For example, is it sufficient to produce a pure population of 
dopaminergic neurons to transplant in PD or will supporting cell types be required? 
PF tissue transplants have demonstrated success in both pre-clinical and clinical 
trials and this donor tissue will contain a heterogeneous population of cells including 
astrocytes and interneurons which will not be present in most stem cell derived 
neuronal populations. Thus it remains to be determined whether “support” cells may 
need to be present during differentiation of stem cells into the appropriate cell type, 
or added prior to transplantation to improve survival and functionality of transplants. 
In order to produce cells for clinical transplantation, protocols must be refined for 
adequate expansion to the number of cells required for patient transplants and all 
production will need to be carried out under controlled GMP approved conditions. 
In order to assess the suitability of novel cell types for transplantation in 
human patients, donor cells must first be tested via xenotransplantation into animal 
models of disease to determine safety and efficacy, and to optimise cell preparation, 
implantation, immunological management and assessment procedures (Steindler 
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2007). The evaluation of the suitability of donor tissue requires histological 
examination of the integration of the cells to determine whether relevant connections 
have been formed within the host brain. Behavioural testing is also necessary to 
determine whether surviving cells are functional, and improvement is observed on a 
battery of relevant tests of cognitive and motor performance. These measures require 
the cells to be fully differentiated in the host brain. Due to differences in 
developmental time span between humans and rodents, human tissue will mature and 
differentiate more slowly in vivo (from 15-30 weeks - Brundin et al. (1986)), 
therefore any improvements will not be observed until a longer time after grafting. 
As xenotransplantation elicits a strong immune response from the host, grafts are 
rejected fairly quickly in animals in the absence of immunosuppression. Xenografts 
in the rodent brain are usually rejected by around 20-30 days (Barker et al. 2000; 
Mason et al. 1986; Sloan et al. 1991), dependent on the type and location of the 
graft. Treatment is therefore required to prevent rejection by the host immune 
system. Currently, CsA is the most common method of immunosuppression used, 
however this requires daily injections and causes severe side effects in the animals 
which usually lead to termination of the experiment at around 12-16 weeks post 
transplantation; insufficient time for full differentiation of transplanted human cells. 
This creates a problem for the adequate pre-clinical assessment of potential donor 
cell types for neural transplantation in patients, as no current immunosuppression 
method permits full safety and functional assessment of the cells. 
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1.2 The immunological response to neural xenografts 
The immune system in all species serves a common function; to protect the 
organism against potential threats, whether this may be from pathogens such as 
bacteria and viruses, or foreign cells as in the case of transplantation. In order to 
identify and eliminate potential threats, the immune system must possess the specific 
ability to determine ‘self’ antigens from ‘non-self’ antigens. This phenomenon forms 
the basis of all immune responses; in the identification of foreign antigens, their 
removal, and the development of immunity. Following transplantation, the donor 
cells are the source of foreign antigen presented to the immune system. In the 
normal, healthy immune system, these are targeted by the host as ‘non-self’ antigens 
for elimination. Examples of failures in this ‘self’-‘non-self’ discrimination are 
found in autoimmune and immunodeficiency disorders. In autoimmune diseases 
such as multiple sclerosis (MS) or diabetes, the patients’ own antigens are not 
recognised as ‘self’ and are therefore targeted by their immune system. Conversely 
the immune system in immune-deficient individuals has a compromised or absent 
ability to stave off infection.  
In the case of transplants to the CNS; historically this was thought to be a site of 
some immunological privilege. It is now clear, however, that the rejection of neural 
transplants in immunologically competent hosts does occur, albeit to varying extents 
dependent on the type of transplant. The immune system of the CNS will therefore 
be discussed in further detail in this section, along with the mechanisms of rejection 
of cells transplanted into the brain. Although the issues of the immune response to 
allografts in clinical CNS transplants must be considered and elements of this section 
are relevant here, the focus of this discussion is on the rejection of pre-clinical 
transplants in animal models.  
1.2.1 The immune system in the CNS 
The brain has been traditionally considered to be an “immunologically 
privileged site” (Barker and Billingham 1978; Medawar 1948) due to the increased 
survival of cells transplanted to the CNS compared to the periphery. This was 
attributed to a number of properties of the CNS thought to provide relative protection 
from the immune system in comparison to other tissues. The presence of an 
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endothelial blood brain barrier (BBB) sealed by tight junctions restricts the diffusion 
of larger molecules from the blood into the brain and therefore prevents infiltration 
from circulating immune cells (Goldstein and Betz 1983; Mark Richardson et al. 
2005; Zappia et al. 2005). There is also a lack of professional antigen-presenting 
cells (APCs) (Laguna Goya et al. 2011) in the healthy CNS. Professional APCs; 
including dendritic cells (DCs), B cells and macrophages, are required to process and 
present antigen to T cells via MHC molecules in order to initiate an immune 
response (Wekerle et al. 1987). The lymphatic drainage from the CNS to the 
immune system itself is poor, also preventing the presentation of foreign antigens in 
the periphery (Barker and Widner 2004), although this has been disputed, suggesting 
there is an unconventional form of lymphatic drainage which can transport activated 
immune cells to the periphery (Hatterer et al. 2006). Additionally, neural cells 
exhibit very low expression of Class I (Joó 1993; Wekerle et al. 1987) and no 
expression of Class II MHC antigens (Einstein et al. 2007; Goldstein and Betz 1983; 
Martino and Pluchino 2006), thus providing some protection from recognition by 
host T cells (Barker and Billingham 1978). However, recently more has been 
discovered about the immune surveillance of the brain. The CNS is now considered 
to be a region of ‘relative’ immunological privilege (Galea et al. 2007); although 
transplanted cells are provided some protection, the activation of an immune 
response can still initiate graft rejection. Therefore, without immune suppression, 
long term survival of neural transplants is compromised. 
The mechanisms which offer such immunological privilege to neural cells 
transplanted into the brain only apply in the context of the normal, healthy CNS. 
Since the penetration of the brain and implantation of cells initiates an inflammatory 
response and damages the BBB itself, the immunological surveillance of the CNS 
will no longer be restricted and circulating immune cells may be able to enter the 
brain (Brundin et al. 1989; Finsen et al. 1991). In addition to BBB damage through 
surgery; it is now known that under inflammatory conditions the BBB becomes 
permeable to activated lymphocytes, allowing infiltration of T cells into the brain 
(Hickey 2001; Hickey et al. 1991; Kebir et al. 2007; Laguna Goya et al. 2011; 
Schmidt-Kastner et al. 1993). The loss of protection from the BBB is sufficient to 
promote recognition of donor cells by host immune cells, as demonstrated by Pollack 
et al, who showed that established grafts implanted in the neonatal period are 
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rejected following disruption of the BBB in adulthood as a result of an influx of 
immune cells (Pollack and Lund 1990). Transplants to the brain are therefore 
susceptible to rejection without immune suppression, and although there is some 
protection offered to the brain in comparison to other tissues, this is not absolute 
(Gorelik et al. 2012).  
Local trauma to the grafted area also promotes the release of pro-inflammatory 
cytokines increasing the permeability of the BBB and providing another mechanism 
for the ingress of immune cells into the brain. Studies have shown variability in the 
length of time for recovery of the BBB following transplants (Sanberg et al. 1988; 
Wakai et al. 1986). This may be due to variations in the inflammatory conditions 
around the graft; although the initial damage to the BBB from surgery has been 
repaired, increased permeability may continue. Demonstrating this, transplants have 
been shown to increase permeability of the BBB for a longer period of time than a 
lesion or vehicle injection (Sanberg et al. 1988). In the development of an 
inflammatory response; cytokines including tumour necrosis factor (TNF), 
interleukin-1 (IL-1) and interleukin-6 (IL-6) are produced by macrophages, 
microglial cells, astrocytes and cortical epithelial cells (CECs) in the CNS (de Vries 
et al. 1997). The release of such cytokines is thought to increase the permeability of 
the BBB and this effect has been demonstrated in vitro, with the administration of 
TNF-α, IL-1 and IL-6 to endothelial cell models of the BBB increasing transport 
across the barrier (de Vries et al. 1996; Deli et al. 1995). This finding has been 
confirmed in vivo a number of times; see de Vries et al. (1997) for a review. 
Additional cytokines including IL-17 and IL-22 have also been shown to affect the 
permeability of the BBB through disruption of tight junctions both in vitro and 
in vivo following their release by T helper (TH)17 lymphocytes, a subset of TH cells 
(Kebir et al. 2007). An opposing effect has been found for transforming growth 
factor-β (TGF-β), which is present in cerebrospinal fluid (CSF) and also inhibits 
MHC-II expression on APCs (See Fabry et al 1995). TGF-β has been shown to 
reduce leukocyte migration across CNS endothelial cells in vitro and through the 
BBB in vivo (Fabry et al. 1995) and its presence is known to suppress proliferation 
of T cells which may have passed through into the brain. 
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1.2.2 Neural transplant rejection 
The immune response to neural grafts involves a circuit with both afferent and 
efferent arms. The afferent arm of the immune response includes the recognition of 
antigens via antigen presentation, causing activation of lymphocytes and the 
generation of effector cells. Foreign antigenic material is presented to T cells by 
APCs (Sloan et al. 1991). In the resting state no professional APCs are present in the 
brain, however during inflammation resident microglia are capable of maturing into 
macrophages and dendritic cells (DCs); professional APCs which express MHC 
antigens and accumulate within the brain parenchyma (Santambrogio et al. 2001). 
Although donor cells both from the developing brain and host cells in the adult brain 
show low or no expression of MHC Class I or II, upregulation of both can occur 
following exposure to inflammatory signals in response to transplantation (Litchfield 
et al. 1997; Pakzaban and Isacson 1994). The up-regulation of Class I and II MHC 
molecules in neural tissue is induced by pro-inflammatory cytokines such as 
interferon-γ (IFN-γ) and tumour necrosis factor-α (TNF-α). Class II expression 
allows this afferent arm of the immune response to take place through recognition by 
CD4+ TH cells (Pakzaban and Isacson 1994). The presentation and processing of 
antigens requires the formation of MHC/antigen peptide complexes bound to the T 
cell receptor (TCR), known as signal 1 (see Figure 1.1 for a diagrammatic 
representation of this complex). 
Additionally, the formation of complexes by costimulatory molecules on APCs 
and their receptors on the surface of T cells (e.g. B7-CTLA4 and CD40-CD40L) is 
required for activation of the T cell (Barker and Widner 2004). These complexes are 
also shown in Figure 1.1. This is known as signal 2, with activation of signal 1 alone 
insufficient to trigger a clonal expansion, survival and differentiation of activated T 
cells (Lafferty and Cunningham 1975). The activation of T cells by TCR stimulation 
in the absence of this second signal can result in anergy or apoptosis of the 
responding T cell (June et al. 1990; Schwartz 1990). A number of costimulatory 
molecules exist which may support or inhibit T cell activation. Table 1.1 is not an 
exhaustive list, but includes well characterised costimulatory pairs implicated in 
transplant rejection (Kinnear et al. 2013). Four distinct groups of costimulatory 
families can be classified based on their structure; Ig superfamily members such as 
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CD28; TNFR family members such as CD40; cell adhesion molecules or integrins; 
and T cell Ig domain and mucin domain (TIM molecules (Kinnear et al. 2013). The 
best characterised are the Ig and TNFR families, some of which are represented in 
Table 1.1 and are discussed here. 
The first costimulatory pathway to be defined, and the most well characterised, 
is the B7/CD28/CTLA-4 pathway. CD28 is constitutively expressed on around 80% 
of human naïve T cells (around 50% of CD8+ and all CD4+), and almost 100% of 
murine T cells. Its expression is also increased following T cell activation (June et al. 
1990; Lenschow et al. 1996). The ligands for CD28; the B7 molecules CD80 (B7-1) 
and CD86 (B7-2) are expressed on APCs. CD80 expression is induced following 
activation on APCs and activated T cells, whereas although CD86 is constitutively 
expressed by APCs, its expression is rapidly upregulated following activation 
(Greenwald et al. 2005). In the presence of TCR stimulation (signal 1), costimulation 
via CD28 and the B7 ligands lowers the threshold for T cell activation and increases 
the expression of IL-2; which in turn promotes growth and proliferation of T cells to 
Figure 1.1 Key ligand pairs and signalling molecules involved 
in T-cell recognition. Peptide-MHC molecule = red. 
Activating/co-stimulatory molecules = blue. Inhibitory 
molecules = yellow. Reproduced from Huppa and Davis (2003) 
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become effector T cells (Lenschow et al. 1996; Wood and Goto 2012). 
Costimulation via CD28 also leads to the up-regulation of CTLA-4, and other 
costimulatory molecules including CD154 (CD40L) (Wood and Goto 2012). The 
function of these molecules is discussed below. 
An additional receptor for the B7 molecules, CTLA-4, is upregulated on T cells 
following activation and has a higher binding affinity for CD80/CD86, up to 10 to 20 
times greater than CD28 with a preference for CD80 (Wood and Goto 2012). 
CTLA-4 is also constitutively expressed by FoxP3 regulatory T cells (Tregs), with a 
role in Treg cell mediated suppression demonstrated by failure to activate Tregs and 
a lack of this suppression when CTLA-4 is blocked (Sakaguchi 2004). Following 
upregulation on activated T cells, CTLA-4 competes with CD28 for ligation with the 
B7 molecules, which limits CD28/B7 interactions resulting in decreased IL-2 
secretion and attenuation of the T cell response (Walunas et al. 1994). Loss of 
CTLA-4 has therefore been shown to be lethal in mice, resulting from massive 
proliferation of lymphocytes (Tivol et al. 1995). The balance between costimulation 
from CD28 and CTLA-4 is therefore required for T cell activation and prevention of 
the continuation of this response (Alegre and Najafian 2006). This interaction has 
provided a method attempting to induce tolerance to transplants, via blocking 
costimulatory molecules and disrupting these pathways, which is discussed further in 
section 1.3.2. 
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Costimulatory molecule Receptor expression Ligand Ligand expression Function 
CD28 Naïve T cells 
 
B7-1 (CD80), 
B7-2 (CD86) 
APC (induced upon activation) 
APC (constitutively) 
Stimulatory 
  
CTLA-4 (CD152) Naïve T cells, Tregs B7-1 (CD80)/B7-2 (CD86)  Inhibitory 
ICOS (CD278) Activated T cells ICOSL B cells, monocytes Stimulatory 
PD-1 (CD279) Activated T cells, B cells and 
myeloid cells 
DC macrophages 
PD-L1 
PD-L2 
Resting T cells, B cells, DC, 
macrophage, endothelial cells 
Inhibitory 
OX40 (CD134) Activated T cells OX40L B cells, macrophages, DC, vascular 
endothelial cells, mast cells, 
activated NK cells 
Stimulatory 
41BB (CD137) CD4+ and CD8+ NK cells 41BBL Mature DC, activated B cells and 
macrophages 
Stimulatory 
CD40 B cells, DC, macrophages CD40L (CD154) T cells, B cells, activated platelets, 
DC, esosinophils 
Stimulatory 
CD27 Activated T and B cells, NK 
cells 
CD70 Activated T and B cells, NK cells, 
DC 
Stimulatory 
Table 1.1 Costimulatory pairs involved in the immune response to transplants. Adapted from (Kinnear et al. 2013; Li et al. 2009). Well 
characterised costimulatory molecules are listed with their ligands and the cells on which each are expressed, showing whether costimulation 
results in inhibition or stimulation of an immune response. 
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CD40 and its ligand CD154 (CD40L) belong to the TNF(R) superfamily and 
their interaction results in activation of an immune response via activation of DCs 
(Yang and Wilson 1996). Although expressed constitutively at low levels on APCs, 
CD40 is significantly upregulated following cellular activation, including 
upregulation by CD28 expression on T cells, and its ligand CD154 (CD40L) is only 
expressed on activated immune cells (listed in Table 1.1). The subsequent activation 
of DCs results in further upregulation of costimulatory molecules and production of 
inflammatory cytokines promoting antigen presentation to T cells (Yang and Wilson 
1996). CD40 is also an important costimulatory molecule for B cells, inducing the 
proliferation and production of antibodies (Alegre and Najafian 2006).  
The immunological synapse formed through the binding of TCRs and MHC 
peptides on surfaces of APCs, and the ligation of costimulatory molecules lead to a 
third signal which produces a number of intracellular processes. These result in 
altered gene expression leading to upregulation of IL-2 and promotion of cell cycle 
progression and clonal expansion and differentiation of activated T cells (Wood and 
Goto 2012). Within this process, TCR-MHC-peptide engagement leads to 
recruitment and phosphorylation of several signalling molecules which ultimately 
leads to upregulation of IL-2. This generation of large amounts of IL-2 acts in an 
autocrine and paracrine way to create “signal 3”, promoting cell cycle progression 
and initiating clonal expansion and differentiation of activated T cells (Wood and 
Goto 2012). Figure 1.2 shows the pathways involved in signal 3, leading to T cell 
activation and expansion. This pathway will be relevant to the mechanism of action 
of immunosuppressant drugs discussed in section 1.3.1. 
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Figure 1.2 Diagrammatic representation showing a simplified outline of signalling molecules 
involved in “signal 3”, adapted from Wood and Goto (2012). Phosphorylation events result in 
activation of protein kinase pathways and the generation of secondary messengers IP3 and 
diaglycerol (DAG). Generation of DAG activates the transcription factor nuclear factor kappa B 
(NF-κB) (A). IP3 leads to the release of stored calcium and activation of calcineurin which 
dephosphorylates the transcription factor nuclear factor of activated T cells (NFAT), allowing 
translocation to the nucleus (B). Mitogen-activated protein (MAP) kinase cascades generate the 
third transcription factor; AP-1 (C). Activation of these transcription factors leads to upregulation 
of IL-2 which acts in an auto- and paracrine way to provide signal 3. 
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Following transplantation, antigen presentation may occur through a direct or 
indirect pathway. Direct recognition requires host T cells to identify MHC molecules 
expressed on donor cells, whereas indirect recognition occurs following the 
breakdown and presentation of donor peptides by MHC molecules on the host’s own 
APCs (Gould and Auchincloss 1999). Both direct and indirect presentation of 
antigens may have a role in xenograft rejection (Pakzaban and Isacson 1994). 
However it has been suggested that the indirect pathway is more important, since 
species differences between antigens of donor origin and the T cell receptors of the 
host may prevent recognition of directly presented donor MHC peptide complexes 
(Gill and Wolf 1995). Indeed, the relative contribution of indirect recognition is 
known to increase with greater species disparity (Auchincloss and Sachs 1998; Gill 
and Wolf 1995). Additionally, over time the number of donor cells within the graft 
with the ability to present antigen diminishes, reducing the role of the direct 
recognition pathway. However as long as the graft is present, the indirect pathway 
may present antigen and is therefore the dominant pathway in the long term (Wood 
and Goto 2012). 
Activation of T cells through antigen presentation and co-stimulatory molecule 
interaction results in proliferation of T cells specific for these antigens, and the 
generation of effector-cell populations which migrate to the graft site and cause graft 
rejection (Sloan et al. 1991). See Figure 1.1 for a diagrammatic representation of the 
T cell synapse and interaction with APCs (Huppa and Davis 2003). Lymphatic 
drainage from the brain through the movement of CSF allows the delivery of 
antigenic material to the peripheral lymphoid organs where immune competent cells 
can initiate an immune response (Cserr et al. 1992). Resulting responses from pro-
inflammatory cytokines such as interleukin-1 (IL-1) and IFN-γ promote proliferation 
of T lymphocytes (Hickey 2001). The release of TNF-α also allows an increase in 
the permeability of the BBB, allowing activated T cells to traverse into the brain 
(Barker and Widner 2004). This encompasses the efferent arm of the immune 
response, induced by expression of MHC-I allowing targeting by CD-8+ effector T 
cells (Pakzaban and Isacson 1994). This requires the passage of activated 
lymphocytes into the brain due to the increased permeability of the BBB by 
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proinflammatory cytokines and specifically vascular cell adhesion molecule-1 
(VCAM-1) (Merrill and Murphy 1997).  
In the case of neural xenografts, infiltration of host immune cells has been 
shown to primarily consist of macrophages and T cells, with only a low number of B 
cells (Finsen et al. 1991; Pedersen et al. 1997). During rejection, host DCs infiltrate 
the transplant along with these immune cells (Lawrence et al. 1990). The presence of 
CD4+ T cells is required for the rejection of xenografts, as shown by the use of CD4 
monoclonal antibodies for long term prevention of neural xenograft rejection (Wood 
et al. 1996). In addition to the cellular, T cell mediated aspects of neural xenograft 
rejection; it is possible that the humoral arm of the immune system is also activated 
during the host response. If pre-existing antibodies to donor tissue are present within 
the host; a rejection response can follow transplantation immediately, known as 
hyperacute rejection. This has been discussed in section 1.1.3 in the use of porcine 
tissue for transplantation, to which humans possess preformed antibodies which react 
to α-Gal. The development of antibodies specific to donor MHC antigens has been 
observed in some animals following the striatal transplantation of mouse VM 
(Brundin et al. 1989), however the disparity between these species is low. 
Confirmation of the involvement of a humoral response in more distant species has 
been shown in the delay in rejection of porcine neural tissue transplanted into 
immunoglobulin knockout (IgKO) mice as compared to wild type controls. The 
authors concluded that Ig have a role in the initiation of xenograft rejection. Grafts in 
IgKO mice were found to survive up to 4 weeks, at which stage infiltration of both 
CD4+ and CD8+ T cells resulted in graft rejection (Larsson et al. 1999). The 
interaction between the humoral and cellular immune responses in xenografts has 
been examined by Barker et al (Barker et al. 2000), who found that the inhibition of 
complement also reduces the cellular response. The involvement of complement and 
humoral responses provides an explanation for the inconsistent prevention of 
xenograft rejection with CsA treatment daily (Pakzaban and Isacson 1994), however 
the relationship between these humoral and cellular responses remains unclear.  
1.2.3 The effect of donor cell type and transplant location 
Correlations have been demonstrated between the level of MHC expression and 
graft rejection, with high levels of MHC-I expression relating to rejection of 
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transplants, and low levels relating to transplant survival (Mason et al. 1986). 
However the level of MHC expression on donor tissue is not the only factor relating 
to transplant rejection. Additionally, the lack of MHC expression on allogeneic 
NPCs has been shown to activate murine natural killer (NK) cells, which 
subsequently target transplanted cells for rejection (Phillips et al. 2013). NPCs from 
foetal brain have been reported to survive following transplantation to non-immune-
privileged sites (under the kidney capsule) for up to 28 days post-transplantation, as 
compared to transplants of mature neurons which were rapidly rejected (Hori et al. 
2003). It has therefore been assumed that some characteristics of these cells protect 
them from recognition by the host immune system following transplantation. It was 
shown that hosts were not tolerant to these transplants, since they could be rejected 
with sensitisation to donor tissue pre- or post-transplantation, therefore NPCs were 
presumed to survive due to a lack of sensitisation to donor tissue (Hori et al. 2003).  
Human foetal neural tissues have been shown to express low or no MHC, 
however following time in culture both MHC class I and II are up-regulated on 
NPCs (Odeberg et al. 2005). Despite this, NPCs were not reported to trigger an 
immune response when investigated in vitro by lymphocyte proliferation co-cultures. 
This is thought to be due to the fact that, although MHC expression was increased in 
NPCs after long-term expansion in vitro, expression of co-stimulatory molecules was 
not present (Odeberg et al. 2005). Transplantation studies have also suggested NPCs 
to be less immunogenic than primary tissue in porcine to rat xenografts, although 
these findings require assessment at further time-points post-transplantation 
(Armstrong et al. 2002). Up-regulation of MHC expression following time in culture 
has also been shown in rat NPCs (McLaren et al. 2001). A subsequent study has 
shown that although neural tissue from human foetal cortex and VM showed low 
MHC class I expression, following proliferation in culture the expression increased 
rapidly. However further investigation showed that this increased expression was 
possibly related to a change in cell type within the culture towards a glial phenotype, 
and that MHC class I was only found to be expressed on NPCs, glial progenitors, 
mature astrocytes and oligodendrocytes, but not on neurons (Laguna Goya et al. 
2011). This study, however, showed proliferative T cell responses in co-cultures with 
NPCs after a delay and attributed this delay to the contradictory findings with 
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previous studies, suggesting that this is why NPCs can still elicit rejection in vivo 
(Laguna Goya et al. 2011; McLaren et al. 2001; Odeberg et al. 2005). 
As with NPCs, an investigation into the immunogenicity of ESCs reported low 
levels of MHC Class I and II in undifferentiated cells (Drukker et al. 2002). 
Subsequent differentiation of ESCs elevated expression of MHC-I but not II, 
however the addition of IFN-γ was shown to upregulate both. Therefore, it is 
assumed that this upregulation of MHC would be possible in vivo following 
transplantation (Drukker et al. 2002). Following this study, analysis of the mouse 
immune response to human ESC kidney capsule transplants was characterised to 
determine the effect these findings had in vivo, with transplants into 
immunodeficient hosts as a control (Drukker et al. 2006). A number of different 
mouse strains were transplanted, with complete rejection of hESC transplants after 1 
month observed in immunocompetent mice. Transplants in mouse hosts which were 
deficient of T cells were not rejected, whereas no difference was found in mice 
deficient of B or NK cells as compared to immunocompetent hosts; indicating a role 
for T cells in xeno- rejection of hESCs. Transplants into humanised mice were not 
rejected, demonstrating allograft survival of ESC-derived transplants (Drukker et al. 
2006). 
As discussed in section 1.1.3; iPSCs have been reported to show differences in 
gene expression as compared to ESCs (Chin et al. 2009). Initially, iPSCs were 
thought to provide an optimum solution to the need for new donor cell types, in 
particular because cell lines could be developed to provide autologous transplants, or 
at least with banks of appropriate human leukocyte antigen (HLA)-typed cell lines. 
However more recent findings have shown unexpected variable immunogenicity in 
cell lines. Zhao et al found that autologous iPSC transplants were not tolerated in 
mouse hosts as predicted, and were infiltrated with T cells and rejected (Zhao et al. 
2011). These findings have subsequently been disputed by Araki et al, who found no 
rejection of their autologous iPSC derived transplants (Araki et al. 2013), however it 
is clear that there are genetic and chromosomal abnormalities in iPSC lines which 
must be considered when developing these cells for CNS transplantation. It has been 
proposed that differences between reprogramming methods determine this 
immunogenicity, with iPSCs generated using viral vectors proposed to be more 
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vulnerable to rejection than those derived via episomal approaches (Boyd et al. 
2012). 
Some differences in immunological responses following transplantation of 
stem cells may be used advantageously for cell replacement therapies. In particular; 
as described in section 1.1.3, MSCs have been shown to possess a number of 
immunomodulatory functions, as well as the other benefits to the graft environment 
following transplantation. Suppression of T cell proliferation by MSCs has been 
demonstrated in vitro and shown to be dependent on both cell to cell contact and the 
release of soluble factors (Di Nicola et al. 2002; Zappia et al. 2005). As the release 
of an array of cytokines and trophic factors has been found from MSCs 
(Haynesworth et al. 1996), these cells have been hypothesised to have the ability to 
suppress inflammatory responses following transplantation. Following injection, 
they have been reported to block the inflammatory and T cell response, preventing 
maturation of monocytes into DCs and preventing antigen presentation to T cells 
(Chiesa et al. 2011; Pluchino and Cossetti 2013). Although not necessarily providing 
an optimum cell source for neuronal differentiation; co-transplantation of MSCs with 
neural cell types such as adult neural stem cells has shown protection by MSCs can 
promote survival of transplanted neural cells in a rat model of HD (Rossignol et al. 
2014) 
Aside from the immunogenicity of donor cells, the extent of the immune 
response may vary dependent on a number of factors, including the disparity 
between donor and host, the preparation and delivery of donor cells, and the location 
of the graft (Barker and Widner 2004; Wood and Goto 2012). The transplantation of 
solid tissue grafts generates a more severe and rapid response due to the intact 
vessels within the tissue demanding the formation of connections with the host 
vasculature and the activation of complement-mediated hyperacute rejection 
(Auchincloss and Sachs 1998; Broadwell et al. 1992). Additionally the method of 
delivery may have a variable effect on the inflammatory response due to damage to 
the BBB (Brandis et al. 1997). The phylogenetic distance between donor and host 
also dictates the contribution of humoral and cellular host immune responses to 
xenografts; this may be due to the degree of difference between donor and host MHC 
(Mason et al. 1986; Pakzaban and Isacson 1994). As mentioned previously there 
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may be some innate antibodies which can induce rejection of xenogeneic donor 
tissue following transplantation, as in the case of porcine to human xenotransplants 
discussed in section 1.1.3.  
Reports have also suggested that younger donor tissue has an improved 
chance of survival (Brevig et al. 2008), due to a lower population of microglial 
precursor cells which may express MHC and act as APCs (Dalmau et al. 1997). The 
location of delivery of transplants can have an effect on the immune response, for 
example those transplants delivered closer to the ventricles are reported to be more at 
risk to rejection due to drainage of the subarachnoid space to cervical lymph nodes 
(Kida et al. 1993), the lack of BBB and the presence of MHC-II+ macrophages in 
the choroid plexus and the subarachnoid space (Vass and Lassmann 1990). In this 
context it is also relevant to consider the status of the host brain prior to 
transplantation, for example following previous damage to the system such as a 
lesion, or as a result of disease processes. Previous findings have suggested that 
transplants delivered just a few days after a QA lesion have improved survival as 
compared to those delivered after a week or more, due to the microglial environment 
in the graft site (Johann et al. 2007). 
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1.3 Immune suppression 
A number of methods may be used to evade the host immune response to neural 
xenografts, including treatment of the host with drugs or antibodies, transplantation 
into neonates or immune compromised hosts. Additionally modifications to the 
donor cells themselves have attempted to mask them from the host immune system, 
and attempts have been made to induce tolerance to donor tissue. However as yet no 
method has been successfully optimised which allows full functional testing of 
potential human donor cells for a range of diseases. This is a problem not only for 
cell transplantation strategies in neurodegenerative diseases, but also for a number of 
others including amyotrophic lateral sclerosis (ALS), stroke, MS and spinal cord 
injury. The following discussion is not exhaustive, but covers a range of commonly 
used methods to promote the survival of xenografts in rodent hosts. 
1.3.1 Immunosuppressant drugs 
Currently, the most commonly used immunosuppression regime for the 
xenotransplantation of human cells into rodent models is the use of 
immunosuppressant drugs. A number of drugs are available which are used clinically 
for preventing rejection of organ transplants. Some immunosuppressant drugs which 
are used in pre-clinical transplant experiments in animal models of disease for testing 
transplants of xenogeneic donor tissue are listed in Table 1.2, including their 
mechanism of action. Treatment with one or a combination of these drugs can 
promote survival of cells transplanted to the CNS, although much variability has 
been reported as to the success of these treatments in different hosts and with the 
transplantation of different cell types. One of the most regularly used drugs currently 
is CsA, an immunophilin ligand which binds cyclophillin, blocking the phosphatase 
activity of calcineurin which is essential in T cell activation, thus preventing the 
initiation of an immune response (Ho et al. 1996). The mechanism of action of CsA, 
and other drugs discussed here are shown in Figure 1.3 in the context of the 
immunological synapse. CsA and other immunosuppressant drugs are administered 
individually, or often in combination therapies to attempt to improve transplant 
survival (Sevc et al. 2013). 
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Immunosuppressive drug Mechanism of immunosuppressive action Cell target (molecule) 
Azathioprine Dampens proliferation of rapidly dividing cells Many purine synthesis pathways (competitive inhibitor) 
Mycophenolate mofetil Dampens proliferation of rapidly dividing cells Guanosine base synthesis (inosine monophosphate dehydrogenase) 
Corticosteroids  
(e.g. prednisone) 
Suppresses costimulatory signals (IL-1 and IL-6 platelet 
activating factor, prostaglandins, leukotrienes and TNF), 
oxygen burst and chemotactic and cytotoxic activities 
APCs (IκB kinase) 
Cyclosporine (CsA), 
tacrolimus (FK506 – TAC) Blocks promoters of gene transcription, such as NFAT Lymphoid cells (calcineurin) 
Sirolimus (rapamycin) Prevents dissociation of lκB and cytokine-driven G1 
accumulation 
Costimulatory pathway for the production of 
cytokines and signal transduction after cytokine 
signalling (mammalian target of rapamycin, 
MTOR) 
Table 1.2 Commonly used immunosuppressant drugs for preventing rejection of neural transplants including their mechanism of action and cell 
targets. Adapted from (Kahan 2003) 
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Although frequently used for immunosuppression in rat hosts, a number of 
studies have reported variability in graft survival in hosts treated daily with CsA 
(Jablonska et al. 2013; Larsson et al. 2001b). In our hands, CsA provides survival of 
human neural xenografts up to 75-80% in rat hosts (Kelly et al. 2009b) up to an 
absolute maximum of 20 weeks after transplantation due to toxic side effects of the 
drug.  Although effective, this method requires daily injections of the drug which can 
be stressful to both the animal and the experimenter, and the treatment is associated 
with severe adverse side effects with long term use including renal toxicity (Al 
Nimer et al. 2004; Bertani et al. 1987). Survival can be potentially assessed up to 20 
weeks, however, beyond 16 weeks the health of the animals starts to deteriorate, 
meaning functional testing is not possible. 
Figure 1.3 Mechanism of action of common immunosuppressant drugs, indicated in red. 
Cyclosporine (CsA) blocks phosphatase activity of calcineurin via binding to cyclophillin. 
Tacrolimus (TAC) binds FK binding protein 12 (FKBP-12), also blocking phosphatase 
activity of calcineurin. These both disrupt translocation of NF-κB to the nucleus and 
subsequent transcription of IL-2, thus blocking the initiation of T cell proliferation. 
Sirolimus binds FKBP-12, but this complex binds mammalian target of rapamycin (mTOR), 
inhibiting response to IL-2 and preventing cell cycle progression. Diagram adapted from 
(Wood and Goto 2012) 
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An alternative immunophilin ligand which also inhibits the phosphatase 
activity of calcineurin is tacrolimus (FK506, TAC). Tacrolimus binds to FK-binding 
protein, specifically FKBP-12. The formation of this complex, like CsA, inhibits 
calcineurin (Snyder et al. 1998), however TAC has been reported to be 10-100 times 
more potent in its inhibition of calcineurin (Kino et al. 1987). Finally, sirolimus 
(rapamycin) also binds to FKBP-12, but does not to block the activity of calcineurin, 
this complex inhibits mTOR by direct binding of mTOR1, inhibiting translation and 
response to IL-2, and preventing T cells from progressing from G1 to S phase of the 
cell cycle (Alemdar et al. 2007). Both of these drugs have been reported to have 
neuroprotective side effects, making them promising treatments for 
immunosuppression in CNS transplants (Alemdar et al. 2007). Treatments with both 
TAC and CsA have been reported to increase the survival of dopaminergic cells in 
vitro, and following transplantation in vivo (Castilho et al. 2000). Increases in neurite 
length and branching have also been observed following treatment with 
immunophilin ligands; with those that inhibit the phosphatase activity of calcineurin 
(CsA, FK506), inducing elongation of dopaminergic neurites, and those which did 
not (sirolimus) increasing branching (Costantini and Isacson 2000). However, as 
with CsA, these drugs can also induce severe side effects making their effective use 
in pre-clinical transplant studies a challenge. Systemic administration of TAC for 14 
days in mice to prevent the rejection of xenogeneic rat VM transplants resulted in 
good survival of transplants at 14 days post transplantation, and in surviving hosts at 
28 days post-transplantation, however death of host mice was reported in a large 
amount of host animals following withdrawal of immunosuppression due to severe 
toxic effects (Sakai et al. 1991). 
Side effects of these drugs include nephrotoxicity and hepatotoxicity (Finn 
1999; Sevc et al. 2013), and due to the short drug half-life at least once daily 
administration is necessary. Alternative preparations of drugs have been investigated 
to try and alleviate some of the side effects without affecting graft survival, and to 
improve the administration regimen of the drug. Alemdar et al tested the efficacy of 
liposomal preparations of TAC and sirolimus individually and combined, when 
transplanted directly with xenogeneic tissue (Alemdar et al. 2007). Rat hosts with 
6-OHDA lesions were transplanted with mouse VM alone or combined with one of 
the liposomal immunosuppressive preparations. Good survival of transplants was 
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found in immunosuppressed groups 6 weeks after transplantation, in particular in 
those receiving liposomal TAC with transplanted cells no side effects were reported. 
This preparation of TAC was designed to reduce adverse effects of the drug; since 
the liposomes are taken up mainly by the reticuloendothelial system, TAC does not 
distribute well to the CNS and kidney therefore reducing neuro- and nephrotoxicity 
(Alemdar et al. 2007). A more recent study has demonstrated survival of human 
xenografts in rat hosts immunosuppressed with subcutaneously implanted slow 
release TAC pellets, showing a reduction in immune infiltration and survival up to 3 
months post-transplantation (Sevc et al. 2013). These are promising methods which 
require further validation and assessment prior to implementation in transplantation 
studies. 
1.3.2 Costimulatory pathway blocking 
As previously described in section 1.2.2, two signals are required to initiate 
an immune response to transplants. First the formation of an MHC-TCR complex, 
and second the interaction of costimulatory molecules with their ligands. A body of 
research aims to determine whether manipulation of this interaction via 
costimulatory molecule blocking can produce tolerance to transplants. As discussed, 
ligation of costimulatory pairs can lead to a stimulatory or inhibitory response, 
therefore this must be considered when blocking for example the CD28/B7 pathway, 
since interfering with CTLA-4/B7 interactions can interfere with tolerance 
mechanisms (Li et al. 2009). However a number of experiments have reported 
successful tolerance to transplants following blocking of costimulatory molecules. 
Injection of allogeneic donor splenocytes into mouse hosts with treatment with an 
antibody to CD40L was shown to promote survival for at least 100 days without 
further immunosuppression, even though in vitro allo-responsiveness to donor cells 
was demonstrated. The authors suggested a state of “split tolerance” in mouse hosts 
(Markees et al. 1997). Additional studies have shown successful transplant tolerance 
following administration of a fusion protein containing the extracellular domain of 
CTLA-4 and the Fc portion of IgG; CTLA-4-Ig, designed to block CD28/B7 
interactions by binding B7 molecules. This takes advantage of the fact that B7 
molecules preferentially bind with CTLA-4. Studies have shown blocking of T cell 
proliferation in response to alloantigen stimulation in vitro, as well as the induction 
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of T cell anergy in response to treatment with CTLA-4-Ig (Li et al. 2009). 
Administration in vivo has been shown to induce donor-specific transplant tolerance 
to cardiac allografts, which could survive for at least 100 days after transplantation 
(Pearson et al. 1994). Optimal results have been reported when blocking both of 
these costimulatory pathways simultaneously (Larsen et al. 1996) 
A recent study aimed to use these methods with a triple costimulatory 
blocking therapy to induce tolerance to ESC and iPSC derived transplants (Pearl et 
al. 2011). Treatment comprised administration of three costimulatory receptor 
blocking antibodies (CTLA4-Ig, Anti-LFA-1 and anti-CD40L) at 0, 2, 4 and 6 days 
post-transplantation. The method was shown to successfully prevent rejection of 
xenogeneic human ESCs and iPSCs in adult murine hosts as compared with those 
which were untreated or treated with tacrolimus and sirolimus (a rapamycin 
inhibitor). Mouse hosts were shown to be tolerant to donor cells, exhibiting T cell 
anergy and no detrimental effects on the hosts’ immunity to other cell types were 
observed (Pearl et al. 2011). This could offer a potential method of avoiding immune 
rejection; however survival so far has only been demonstrated up to 8 weeks post 
transplantation. 
1.3.3 Transplantation into neonatal hosts 
In rodents, the early neonatal period is a time of immaturity in the immune 
system, when few or no mature T cells are circulating (Kingsley et al. 2007). During 
this time it is known that neural transplants in rats, including xenotransplants of 
mouse or human tissue, can survive long term in the neonatal brain (Englund et al. 
2002; Lund et al. 1987). Lund et al (1987) found that both mouse and rat retina 
transplanted into the neonatal rat brain survived up to a year after transplantation. 
However transplants in hosts over 8 days of age were rejected (Lund et al. 1987), 
demonstrating that the survival of neonatal transplants is restricted to the early 
neonatal period. Additionally the survival of these grafts has been shown to be 
unstable, without the induction of tolerance, since peripheral challenges including 
skin grafts and damage to the BBB result in rejection of the established xenograft 
(Pollack and Lund 1990). Despite this, it still provides a useful model with which to 
test donor cells, since long term survival allows assessment of the safety and 
differentiation of human donor cells in vivo (Kallur et al. 2006; Kallur et al. 2011; 
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Zietlow et al. 2012). Interestingly, it has been recently shown that this privilege 
afforded to xenografts delivered to the neonatal rat immune system is not replicated 
in mice (Mattis et al. 2014). The authors found that transplants of human iPSC 
derived NPCs and human foetal NPCs transplanted into neonatal mice were rapidly 
rejected, as compared to those transplanted into neonatal non-obese diabetic/severe 
combined immunodeficient (NOD/SCID) mice (Mattis et al. 2014). It was also noted 
that the only successful mouse neonatal xenotransplants to have been reported were 
carried out in an inbred shiverer model (Windrem 2002), but that all follow up 
studies were subsequently carried out in shiverer mice crossed with rag2 knockout 
(KO) mice (Wang et al. 2013a). 
Although this method can be used with some success in the safety and 
integration testing of human donor cells, there is a limit to how well the function can 
be tested. For example, if transplants are carried out neonatally, it does not allow the 
investigation of the improvement of function following a lesion. Additionally the 
implantation of cells into the neonatal brain cannot be considered to be comparable 
to that of the adult brain, since the neonatal brain provides a more permissive 
environment with the presence of more developmental signals. Thus it is not a good 
test of transplantation into the adult brain which is the usual therapeutic situation. 
Therefore, although providing some benefits, the neonatal transplant model is not 
feasible for the purpose of full pre-clinical assessment of human donor cells. 
1.3.4 Immune compromised hosts 
As mentioned previously immune compromised rats or mice may also be used 
as transplant hosts, preventing an immune reaction to xenografts. Numerous models 
exist in each species for assessment of the differentiation and integration of donor 
cells in the adult host brain. A number of groups have used athymic nude rats to 
investigate the phenotype of hPF and hESC derived cells in vivo (Hurelbrink et al. 
2002; Hurelbrink and Barker 2005; Nasonkin et al. 2009). The ability to assess the 
development of grafted cells long term in vivo is important to characterise changes 
which may not be detected with only short term survival as provided by 
immunosuppressant drug treatments. For example, in characterising the development 
in vivo of transplanted human ESC (hESC) derived striatal progenitors differentiated 
according to their protocol for directing ESCs to a MSN phenotype, Aubry and 
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colleagues transplanted into immunocompetent hosts to study short term graft 
survival, and nude rats for long term. Although the short term survival provided 
some positive results regarding their protocol, transplants into the nude rats showed 
overgrowth by around 2 months post-transplantation (Aubry et al. 2008). A number 
of models exist in mice, including SCID mice, Rag1 or Rag2 KO mice; with no 
mature B and T lymphocytes (Mombaerts et al. 1992; Shinkai et al. 1992). These 
rodents have been used for testing transplants of hESC derived striatal neurons (Ma 
et al. 2012), human glial restricted precursor cells (Janowski et al. 2012), and human 
iPSC derived oligodendrocyte progenitor cells (Wang et al. 2013a) 
However, to assess the functionality of grafts it is necessary to perform 
behavioural tests on the animals to determine whether improvements may be 
observed. As immune compromised hosts are so susceptible to infection, the 
opportunity to test them behaviourally is unfortunately limited, thus restricting 
findings from these studies to the development and integration of grafts without the 
ability to correlate these findings with a functional read-out. 
Other treatments, including the potential use of monoclonal antibodies to 
block T cell responses (anti-CD4/CD8), and blocking of costimulatory pathways 
offer the potential to induce tolerance to transplants (Robertson et al. 2007). The 
induction of tolerance by taking advantage of mechanisms discussed in section 1.4 is 
an additional method for promoting survival of transplants, for example through the 
induction of Treg differentiation, or the manipulation of DCs to induce tolerance 
(reviewed in Boyd and Fairchild (2010)). These offer potential methods to avoid 
rejection of donor cells both in pre-clinical or clinical transplant contexts, however 
they require further optimisation prior to successful application. Although the 
methods discussed here provide a range of different immunosuppression approaches 
to promote survival of human xenografts in rodent models of disease, none can 
provide an effective long term solution with which to test the full functional efficacy 
of donor cells. Either the host environment is inappropriate, or the model not robust 
enough for behavioural assessment. Drug treatments result in severe side effects, not 
allowing sufficient time for functional analysis, and transplant survival can be 
variable. Thus an alternative model is required for adequate testing of human donor 
cells for transplantation. 
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1.4 Immune tolerance 
 One approach, shown previously to successfully promote survival of skin 
allografts without immune suppression in adult rodents, is the induction of neonatal 
tolerance to allogeneic tissue after birth, when the immune system is still immature 
(Billingham and Brent 1956; Billingham et al. 1953). It is thought to be based on 
similar mechanisms to those governing self-tolerance in the normal immune system. 
This is achieved through self-antigen recognition by T cells, dependent on the 
development of immature thymocytes and their TCRs which in turn will be governed 
by the selection of self-antigens present during development of the thymus (Kyewski 
and Derbinski 2004). Self-tolerance is mediated by two coordinated mechanisms; 
‘central tolerance’ in the thymus, and ‘peripheral tolerance’ to allow removal of 
those cells in the periphery which may have escaped selection in the thymus. This 
section discusses the mechanisms of natural “self” tolerance, and how this relates to 
the induction of neonatal tolerance to allografts. 
1.4.1 Central tolerance 
Hematopoietic stem cells (HSCs) in the bone marrow can differentiate into red 
blood cells, platelets and cells of the innate and adaptive immune system, including 
T cells. Once immature T cells have developed from HSCs they migrate to the 
thymus to undergo maturation where they are subjected to the selection which allows 
the immune system to recognise and remember pathogens as well as to remain 
tolerant to “self” antigens, preventing autoimmunity. On arrival at the thymus 
through the corticomedullary junction, T cells are ‘double negative’ (DN) lacking 
expression of both CD4 and CD8 (Starr et al. 2003). In the thymic cortex 
thymocytes become committed to either an αβ or γδ lineage dependent on levels of 
Notch activity (Washburn et al. 1997). Those which become αβ T cells must 
undergo successful rearrangement of TCR β chain, then α chain followed by the 
upregulation of both CD4 and CD8, moving them to the double positive (DP) stage.  
As the development of T lymphocytes is dependent on random gene 
rearrangement of T cell receptor loci this ensures recognition of a diverse range of 
antigens which may be encountered, however it also means that some cells will bear 
self-reactive TCR specificities. In order to avoid autoimmunity a selection process is 
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required to remove auto-reactive cells prior to maturation and migration to the 
periphery. Cells are first subjected to positive selection dependent on the binding of 
their TCRs to MHC class I and II complexes presented on cortical thymic epithelial 
cells (cTECs) (von Boehmer 1994). DP T cells are positively selected if their TCRs 
interact with self MHC molecules on cortical epithelial cells. They are programmed 
for apoptosis unless signalling is received via TCR binding to self MHC, therefore 
those which show no self-recognition undergo death by neglect (Starr et al. 2003). 
αβ T cells respond to antigens via peptide binding to MHC class I or II molecules 
expressed on the cells surface. MHC class I molecules detect and present 
endogenous peptides, whereas MHC Class II molecules target exogenous peptides 
(Germain 2002). Antigen recognition by αβ T cells is therefore dependent on surface 
expression of CD4 or CD8. This surface phenotype is determined by the interaction 
between the cells TCR and the MHC complex; CD4 expressing T cells bind MHC 
class II and become helper or regulatory T cells and CD8+ cytotoxic T cells bind 
MHC class I (Palmer 2003; Swain 1983). 
After positive selection and commitment to either a CD4+ or CD8+ single 
positive (SP) lineage, thymocytes migrate to the thymic medulla for negative 
selection where those cells whose TCRs show high avidity binding with self MHC 
class I or II complexes undergo apoptosis (Metzger and Anderson 2011). This 
reduces the number of self-reactive T cells which can mature and move to the 
periphery and therefore the potential for an autoimmune response to be initiated. 
APCs are required for negative selection, therefore it is suggested to take place in the 
medulla due to its large population of APCs; medullary thymic epithelial cells 
(mTECs) and DCS, (Sprent 1995; Webb and Sprent 1990). Figure 1.4 shows a 
simplified diagram of T-cell development in the thymus (Germain 2002). 
The deletion of thymocytes which react to self antigens, requires the 
representation of self antigens within the thymus (Sospedra et al. 1998). Mature 
mTECs express CD80 and MHC-II, a subset of which express the transcription 
factor autoimmune regulator (Aire) for approximately one week prior to apoptosis 
(Gray et al. 2007). Aire deficiency results in autoimmune disorders (Capalbo et al. 
2012), as found in Aire-deficient mice, which display lymphocyte infiltration of 
multiple organs due to severe autoimmunity (Anderson et al. 2002). The expression 
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of Aire promotes the ectopic expression of tissue restricted self-antigens (TRA) to 
developing T cells in the thymus, establishing central T cell tolerance. These 
antigens are usually exclusively expressed in organ specific cell types, therefore this 
is referred to as promiscuous gene expression (Holländer and Peterson 2009); with a 
single mTEC capable of representing TRAs from a number of different peripheral 
tissues (Derbinski et al. 2001). Promiscuous gene expression of TRA on mTECs, 
and cross presentation of these antigens by DCs which capture and present TRA 
secreted by mTECs inform negative selection of T cells which are TRA-reactive 
(Gallegos and Bevan 2006). Although promoting the expression of peripheral TRAs 
in the thymus, mTECs are unlikely to express all self antigens present within the 
body sufficient for deletion of all self-reactive T cells. It has additionally been shown 
that populations of DCs can migrate to the thymus, transporting peripheral antigens 
for promoting central tolerance (Bonasio et al. 2006). 
Figure 1.4 T cell development in the thymus (reproduced from Germain 
(2002)) 
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1.4.2 Peripheral tolerance 
The maintenance of immune system homeostasis and tolerance to self antigens 
also relies on the control of self-reactive T cells by regulatory T cells (Tregs) 
(Sakaguchi et al. 2008). Natural Tregs develop in the thymus in response to 
signalling via TCRs, as with positive and negative selection, though the commitment 
to a Treg lineage is the result of TCRs which display an avidity range between that 
required for positive and negative selection (Metzger and Anderson 2011). Self-
reactive thymocytes which escape negative selection are therefore directed towards a 
Treg lineage (Kim et al. 2007). Additionally, a role for Aire has been implicated in 
the development of Tregs via antigen presentation from Aire+ mTECs (Hinterberger 
et al. 2010). The development of natural Tregs is characterised by expression of 
Foxp3, and this is responsible for the dominant form of T cell tolerance both in the 
thymus and the periphery. The absence of Tregs removes control of autoreactive T 
cells in the periphery resulting in lethal autoimmunity (Kim et al. 2007). 
An additional role for Aire in the promotion of peripheral tolerance has been 
proposed with the discovery of the expression of Aire in peripheral lymphoid organs; 
spleen and lymph nodes in mice (Zuklys et al. 2000), and just the lymph nodes in 
humans (Gardner et al. 2008). It is thought that extrathymic Aire expressing cells 
(eTACs) have the ability to tolerise peripheral T cells via deletional tolerance, 
comparable to negative selection in the thymus, with the presentation of a distinct set 
of TRAs from those expressed by mTECs in the thymus. This comprises a 
complementary role in tolerance for Aire in the periphery and the thymus (Gardner 
et al. 2008). Thus mechanisms in the periphery exist to suppress the activity of 
autoreactive T cells which may have escaped negative selection in the thymus, 
although the maintenance of this peripheral tolerance is likely to be controlled by 
central mechanisms. 
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1.4.3 Neonatal tolerance 
The induction of tolerance to allografts in mice has been described for decades 
with the finding that an injection of donor cells into neonatal mouse hosts can 
prevent subsequent rejection of a skin graft from donors of the same strain 
(Billingham and Brent 1956; Billingham et al. 1953; Medawar 1948). Previous work 
has subsequently shown the successful induction of tolerance to allogeneic skin 
grafts following injections of spleen (Adkins et al. 2004; Ridge et al. 1996), liver 
(West et al. 1994) or bone marrow cells (Modigliani et al. 1997). Hosts in these 
studies were demonstrated to be tolerant to allogeneic donor cells by the survival of 
donor skin grafts or cardiac allografts and a lack of host cytotoxic T lymphocyte 
(CTL) responses to donor spleen cells in vitro (Adkins et al. 2004; Modigliani et al. 
1997; West et al. 1994). 
Some mechanisms for the phenomenon of neonatal tolerance following 
injections of allogeneic cells during the neonatal period have been proposed, 
although a definitive conclusion has not been reached. It has been suggested that for 
tolerance induction, as with the natural development of “self” tolerance, the 
persistent presence of donor or “self” cells are required during the development of 
the immature immune system. Passive models suggest that neonatal tolerance occurs 
through negative selection of self-reactive T cells, as is the case in the natural 
development of self-tolerance. The presentation of donor antigens in the thymus, 
along with self antigens therefore allows donor reactive thymocytes to also be 
negatively selected. As few mature T cells exist neonatally, donor cells are able to 
reach the thymus to promote this deletion of donor reactive T cells (Morrissey et al. 
1983; Ridge et al. 1996). Active models suggest that newly developing T cells 
present in the neonatal host generate mainly T helper cell 2 (TH2) responses, 
protecting from self recognition and also reducing recognition of donor cells present 
at this stage (Bandeira et al. 1989).  
However, these models imply an inability of the neonatal immune system to 
mount an immune response. This does not seem logical, since the neonate would 
therefore have no natural defence against invading pathogens, which has been 
highlighted by Matzinger and colleagues. They have highlighted the ability of 
neonates to become immunised rather than tolerised to neonatally presented viruses 
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(Miller et al. 1994) which does not agree with these models (Ridge et al. 1996). 
They therefore propose a third model, the “Danger” model suggesting that it is not 
the host population of T cells which governs the induction of tolerance, rather it is 
what constitutes the population of injected donor cells which determines tolerance or 
immunity (Matzinger 1994; Ridge et al. 1996). When the population of cells used for 
neonatal administration does not include a large proportion of mature APCs, then a 
lack of co-stimulation of host T cells occurs resulting in a tolerising response. 
Conversely, if a large population of active APCs such as DCs are present in the 
injected suspension, an immunising effect will occur. The authors found exactly 
these responses when injecting spleen cells or isolated DCs (Ridge et al. 1996). 
Tolerance induction was found when injecting a large number of spleen cells 
neonatally, whereas injecting an enriched population of DCs primed T lymphocytes 
for attacking donor cells. Much variation has been found in this area, with some 
disagreement for this proposal from a study showing that neither donor T nor B cells 
are required for the induction of neonatal tolerance, since successful tolerance has 
been induced from injection of spleen and bone marrow cell suspensions from rag1-/- 
mice which contain neither of these populations, but may contain professional APCs 
(Chan et al. 2007; Modigliani et al. 1997). 
To successfully induce neonatal tolerance in mice has required the injection of 
large numbers of spleen cells, as well as other cell types (e.g. 1.5x107 – 1x108) 
(Ando et al. 1991; Peiguo et al. 2012). Studies suggest that the successful induction 
of tolerance in neonatal hosts is dose dependent with the injection of larger cell 
numbers increasing the potential of inducing tolerance (Peiguo et al. 2012), and the 
injection of low numbers of cells resulting in the opposite effect; priming of CTL 
(Adkins et al. 2004). This difference is thought to be due to the ratio between the 
number of injected donor cells and the number of circulating potentially responsive 
T cells within the host. It has been concluded that in order for successful induction of 
neonatal tolerance, all potentially responsive circulating T cells must be inactivated 
(Ridge et al. 1996). 
This phenomena has been demonstrated numerous times in tolerance to mouse 
allografts, though less success has been observed in the case of xenografts (Shen et 
al. 1996). It is possible that species differences in TCR recognition of xenogeneic 
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donor MHC molecules prevents the induction of neonatal tolerance, although this 
has been disputed by Borenstein et al. (2004). By taking advantage of a Tg mouse 
model expressing the human MHC class I allele (HLA)-B7, the authors found that an 
i.v. injection of 1.5x107 spleen cells from Tg mouse donors could induce tolerance in 
B6 mice, sufficient to promote survival of skin grafts from Tg HLA-B7 mouse 
donors. This demonstrates that the host B6 immune system was capable of 
recognising donor xenogeneic MHC molecules (Borenstein et al. 2004) and that the 
inability to induce tolerance to xenoantigens must be due to MHC-independent 
interactions with the recipient immune system. By staining of host spleen cells for 
HLA-B7, the authors could assess the level of chimerism in host mice. Low levels of 
HLA-B7 staining were found in peripheral lymphoid organs suggesting engraftment 
of donor cells into recipient bone marrow and implying a correlation between 
chimerism and the induction of tolerance. Successful integration of donor cells 
within the host, and the subsequent induction of chimerism has been frequently 
suggested as a requirement for, if not at least to strongly correlate with successful 
neonatal tolerance in mice (Borenstein et al. 2004; Chan et al. 2007). 
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1.5 Neonatal desensitisation 
One of the aims of the work in this lab group is the testing of potential human 
donor cells for transplantation in neurological disease. As this requires the 
xenotransplantation of human cells into rodent hosts, potentially for long periods of 
time, one problem that is regularly faced is that of adequate and tolerable immune 
suppression. Problems with the current available methods have already been 
discussed, highlighting the need for potential new models to achieve this goal. The 
knowledge that transplantation of xenogeneic tissue into the neonatal rat brain can 
survive for at least a year after transplantation without additional immune 
suppression (Englund et al. 2002; Lund et al. 1987) has been exploited in the design 
of a method of avoiding conventional immune suppression. As the developing 
immune system in the rat is known to provide an environment permissive of 
transplant survival, work was undertaken in this lab to determine whether the 
survival of a second transplant in adulthood may be promoted in this way. This was 
successfully carried out with the intraperitoneal (i.p.) administration of a suspension 
of human foetal cortex (hCTX) derived donor cells in neonatal rats, followed by a 
subsequent neural transplant of human whole ganglionic eminence (WGE) which 
was found to survive without the need for further immunosuppression (Figure 1.5). 
Figure 1.5 Schematic representation of the induction of neonatal desensitisation (courtesy of 
Kelly, CM). 
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This method was subsequently further developed to determine the characteristics 
of neonatal desensitisation in the rat (Kelly et al. 2009b). Intra-peritoneal (i.p.) 
injections of suspensions of human derived cells in neonatal Sprague Dawley (SD) 
rats were followed by adult transplants of these cell types. Survival of human cells 
was demonstrated up to 40 weeks after transplantation, and graft morphology was 
shown to be comparable to that found in immune suppressed animals. Side effects in 
CsA treated animals meant survival could not be assessed beyond 12-16 weeks as 
animals had to be culled according to animal licensing regulations. Transplants of 
human primary foetal neural tissue, foetal brain derived neural precursors and 
embryonic stem cell derived neural precursor cells were all shown to survive as long 
as, or longer than transplants into CsA treated animals following desensitisation with 
the relevant tissue (Table 1.3). Successful desensitisation could only be shown with 
inoculation of host animals up to postnatal day (P)5; those which received cells at 
P10 or in adulthood could not support the survival of a subsequent neural transplant. 
Additionally it was found that inoculation with dead cells was not sufficient for 
desensitisation of hosts (Kelly et al. 2009b). 
It is possible that, by desensitising animals neonatally (referred to as 
‘tolerising’); tolerance has been induced to donor tissue in these host animals. 
Although true tolerance in hosts has not been identified, the method and graft 
survival observed is comparable to that described historically in studies of allogeneic 
skin graft tolerance induced neonatally by injection of cell suspensions of donor 
origin (Billingham and Brent 1956; Billingham et al. 1953) as discussed previously. 
However, since tissue used for desensitisation is from a different foetal donor to that 
used to transplant, it seems illogical that desensitisation represents tolerance to 
human tissue, particularly since no control has been made for matching of HLA 
haplotypes. The induction of neonatal tolerance seems to require the persistent 
presence of donor antigen during the neonatal period, at a stage of immaturity in the 
immune system before mature T cells migrate out from the thymus (Kingsley et al. 
2007). This may result from the presence of viable cells with the potential for 
continued growth, or repeated injections of antigen in this period. This may then 
prevent the development of mature T cells which react with donor antigen, as in the 
case of the induction and maintenance of “self” tolerance. Neonatal tolerance 
induction in mice has commonly used spleen (Adkins et al. 2004; Ridge et al. 1996), 
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liver (West et al. 1994), or bone marrow cells (Modigliani et al. 1997) to provide 
this continuing source of donor antigen. It remains unclear whether human neural 
cells injected into SD rat neonates in previous experiments have resulted in the same 
“tolerance” as described in the neonatal tolerance field (Kelly et al. 2009b). Since 
human donor cells are derived from the developing brain, the potential for viability 
and proliferation exists in combination with the immaturity of the rodent immune 
system preventing their rapid rejection after injection. Additionally, as the rat 
immune system remains immature until 8-10 days after birth, an injection of cells at 
this time period would be protected from immediate rejection by the host immune 
system  
This method has the potential to allow the preclinical testing of grafts from 
different cell sources in animal models of disease, avoiding the issues associated 
with traditional immune suppression regimes. However a number of findings need to 
be resolved to support its routine use. Although it has been shown that the presence 
of viable cells during the early neonatal period is required to induce desensitisation, 
the mechanisms behind successful desensitisation of neonates remain unclear. It has 
not been determined whether tolerance has been induced to donor cells or whether 
desensitisation is only sufficient to prevent initial graft rejection, and the host may be 
capable of mounting an immune response to donor cells when recognised, for 
example in the case of a peripheral challenge, or damage to the BBB as is the case 
for transplants in neonatal hosts (Pollack and Lund 1990). Additionally, for routine 
long term use of the method in pre-clinical tests of potential human donor cells, 
validation is required to determine the optimum protocol for successful promotion of 
graft survival. The method has also only been demonstrated as yet in the SD rat with 
transplants to the intact striatum; ideally desensitisation could be applicable in other 
host strains, with various donor cells such as ESCs and iPSCs, as well as in other 
host species including mice. The ability to test human donor cells in mice allows 
testing in transgenic models of disease, determining the effect of the host 
environment on transplanted cells. 
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Neonatal Desensitisation Adult graft Tissue concordance Survival after transplant (weeks) Number of grafts surviving (%) 
None hCTX - 12 0/9 (0%) 
None hWGE - 2 0/7 (0%) 
CsA hWGE - 12 7/9 (77%) 
CsA hFNP - 12 6/8 (75%) 
mWGE mWGE Concordant 10 11/15 (73%) 
mFNP mFNP Concordant 10 11/13 (85%) 
hCTX hCTX Concordant 40 48/55 (87%) 
hWGE hWGE Concordant 25 10/15 (66%) 
hFNP hFNP Concordant 12 10/13 (77%) 
hES-N hES-N Concordant 12 9/12 (75%) 
hFNP hCTX Discordant 12 11/13 (85%) 
hCTX hFNP Discordant 12 11/14 (79%) 
hLiver hCTX Discordant 12 8/13 (62%) 
hCTX hWGE Discordant 10 19/23 (83%) 
Table 1.3 Graft survival in different desensitisation protocols, adapted from Kelly et al. (2009b). Hosts in all groups were SD rats. Data shows 
no surviving grafts in untreated hosts, with improved survival in hosts treated with CsA daily beginning from one day prior to transplantation. 
Greatest graft survival is seen in hosts desensitised neonatally with hCTX and transplanted with hCTX. hCTX = human primary foetal cortex, 
hWGE = human whole ganglionic eminence, hFNP = human foetal neural precursors derived from human foetal cortical tissue, mWGE = 
mouse whole ganglionic eminence, mFNP = mouse foetal neural precursors from mouse foetal cortical tissue, hES-N = human embryonic stem 
cell derived neural precursors, hLiver = human liver 
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To date a number of groups have shown interest in the use of the method for 
transplantation of a number of different human cell types in a variety of animal 
models. Some success has been found in inducing desensitisation in rats to human 
cells, including hESC-MSC transplanted following induced knee cartilage defects 
(Zhang et al. 2013). Host rats were desensitised neonatally with 1x105 hESC-MSC 
prior to adult transplants of a collagen bilayer scaffold seeded with hESC-MSC. The 
authors reported survival of transplants in desensitised hosts up to 8 weeks post-
transplantation, with rejection of cells in hosts which were not desensitised 
neonatally. In an assessment of the immune response one week after transplantation, 
a reduction in CD4+ T cells was found in desensitised hosts, thus the authors 
reported successful desensitisation to hESC-MSC (Zhang et al. 2013). In addition to 
this, Singhal et al aimed to investigate the potential of human Müller glia stem cells 
to differentiate into retinal ganglion cells (RGC) in a rat model of RGC depletion 
(Singhal et al. 2012). In this study, Lister Hooded rat hosts were desensitised 
neonatally with an injection of 1x105 human Müller stem cells prior to 
transplantation at 3-4 weeks of age with undifferentiated stem cells or RGC 
precursors. Survival was demonstrated 4 weeks after transplantation, however the 
authors also administered oral CsA, prednisolone and azathioprine to ensure survival 
of transplanted cells (Singhal et al. 2012). 
Other groups, however, have reported less success with the method in 
experiments with different types of donor cells and different host species. 
Jablonska et al compared three methods of immunosuppression, including neonatal 
desensitisation, to prevent rejection of human cord blood derived neural stem cells 
(HUCB-NSC) for transplantation into infarcted rats (Jablonska et al. 2013). Neonatal 
desensitisation with 1x105 HUCB-NSC failed to promote survival of adult 
transplants of these cells beyond 21 days post-transplantation. However; the authors 
also failed to prevent rejection of these cells with either daily CsA injections at a 
standard dose (10mg/kg), or a triple-immunosuppression protocol with daily CsA, 
azathioprine and methylprednisolone, therefore it cannot be assumed that graft loss 
in this case was due to ineffectiveness of the neonatal desensitisation protocol and 
strongly suggests a general problem with donor cell survival (Jablonska et al. 2013). 
The same group and collaborators attempted desensitisation in mice to human glial 
restricted precursor cells (hGRP) and in rats to HUCB-NSC with poor survival 
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observed in both cases, as compared to surviving transplants of both cell types 
demonstrated in Rag2-/- mice, thus reporting that the method could not be reliably 
replicated (Janowski et al. 2012). Although unclear why desensitisation in rats was 
unsuccessful considering previous findings from this and other research groups, it is 
possible that successful desensitisation may depend on the host model and the type 
of cells used (Kelly et al. 2009b; Kelly et al. 2012).  
More consistent issues have been recently highlighted with attempts to induce 
neonatal desensitisation to human donor cells in mouse hosts. In addition to the 
unsuccessful desensitisation in mouse hosts reported by Janowski et al. (2012), a 
recent paper systematically investigated the desensitisation protocol in three different 
strains of mice with three different types of human stem cells and found no 
successful promotion of xenograft survival using the method (Mattis et al. 2014). 
Survival was demonstrated in immune suppressed hosts up to 6 weeks after 
transplantation, although grafts were significantly smaller than earlier time-points. 
However, transplants in desensitised hosts were consistently rejected by 2 weeks 
post-transplantation along with a strong host microglial response. Interestingly the 
authors also investigated the survival of human iPSC derived neural precursor cells 
(iPSC-NPCs) and human foetal neural precursors (hFNPs) transplanted to the 
neonatal mouse striatum, finding no survival past 21 days post-transplantation, in 
contrast to surviving transplants demonstrated in immunodeficient NOD/SCID 
mouse hosts (Mattis et al. 2014). This is suggestive of a difference in both the 
neonatal and adult mouse immune system compared to that of the rat, in which 
neonatal desensitisation to human donor cells has been demonstrated successfully 
(Kelly et al. 2009b; Singhal et al. 2012; Zhang et al. 2013) as well as consistent 
survival of neonatal xenotransplants (Hurelbrink et al. 2002; Hurelbrink and Barker 
2005; Lund et al. 1987; Zietlow et al. 2012). 
Chapter 1 Introduction 
54 
1.6 Aims 
The overall aims of the experiments presented in this thesis are to further 
characterise and validate the desensitisation method described above. Although 
neonatal desensitisation has been demonstrated by both our lab group and others to 
be a successful method for evading immunological rejection of neural xenografts, the 
parameters of the method have not yet been defined and much variability has been 
observed in experiments using different species and different donor cell types. To 
date this group has only found confirmation of successful desensitisation in striatal 
and VM transplants of human neural tissue into Sprague Dawley (SD) rats which 
had been desensitised with tissue of the same type. Further investigation into the 
parameters and limitations of the method will allow its use in grafting studies in 
other species and strains to test the potential of a range of donor cells. In addition, 
studying the mechanisms of the method will provide valuable information on the 
induction of transplant tolerance relevant across a number of fields. All experiments 
have been carried out using the QA lesion model of HD, providing a suitable model 
of cell loss in which to transplant human donor cells and investigate survival without 
the complications of interaction with potential immune system differences in Tg 
models of HD. 
Primarily, the initial objective is to validate the method in the mouse using 
similar grafting protocols to those used previously in the rat (Kelly et al. 2009b). As 
an extension of this, the optimum numbers of cells required to inject neonatally to 
allow survival of xenografts must be investigated, as this may differ from species to 
species. Secondly, as the method has already been shown to be successful in the rat, 
a number of parameters are also examined in this species to determine what tissue 
type may be used to inject at birth and allow survival of transplanted neural tissue, 
for example using non-neural tissue to induce tolerance to a neural graft, and 
whether the technique may be applied successfully across other strains of rat. 
Finally, in addition to studying the parameters of the method, I also intend to 
investigate the underlying mechanisms of the method. 
.
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Chapter 2  
Materials and Methods 
2.1 In vitro methods 
All reagents and suppliers are listed in Appendix 1. Recipes for solutions and 
protocols are listed in Appendix 2. 
2.1.1 Collection and dissection of primary human tissue 
Ethical approval was granted for these studies by the Bro Taf Local Research 
Ethics Committee and more recently the Cardiff and Vale University Health Board. 
Human cortical tissue (ranging from 7-12 weeks gestation) was collected from the 
donation of the products of elective terminations of pregnancy (ToP). All tissue was 
donated through SWIFT, funded by the Medical Research Council (MRC) and a 
Welsh government grant. Consent for donation was given only after the completion 
of procedures for approval, consent and scheduling of ToP. Tissue was collected 
from medical termination of pregnancy (mToP) procedures (Kelly et al. 2011) and 
was transported to the laboratory in sterile hibernation medium (Hibernate E, Gibco, 
Paisley, UK). Ultrasound prior to the ToP was used to stage embryos; this was then 
confirmed at dissection by measurement of crown rump length (CRL), as shown in 
Appendix 3. After careful removal of the brain, the relevant tissue was dissected and 
prepared as a dissociated cell suspension1. 
2.1.2 Collection and dissection of primary mouse tissue 
All animal experiments and surgical procedures were conducted under the UK 
Animals (Scientific Procedures) Act 1986 as amended, and subject to local ethical 
                                                          
1
 Tissue collection and dissection for initial experiments was carried out by other members 
of the BRG (Claire Kelly, Sophie Precious, Rike Zietlow and Eduardo Torres) until the 
relevant licenses and training were completed and I was able to collect and dissect 
subsequent samples.  
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review and relevant personal, project and institutional licenses. All animals were 
housed in a natural light-dark cycle with ad libitum access to food and water. 
Pregnant CD-1 mice were purchased at late gestation (Harlan, Bicester, UK), killed 
via cervical dislocation and embryos collected at the specified donor age (E12 or 
E14) in Hanks’ Balanced Salt Solution (HBSS, Gibco). Brains were removed and 
striatal tissue dissected as shown in Figure 2.1 using a dissecting microscope in a 
laminar flow hood. 
 
Figure 2.1 A) Removal of brain from embryos. A single vertical cut is made just 
above the eye at the base of the brain back into the ventral mesencephalic flexure. 
Fine forceps are gently inserted under the skin to remove the overlying skin and 
meninges leaving the brain free to be pulled away. B) Striatum (WGE) removal. The 
brain is positioned on its ventral surface with the dorsal cortex facing upwards. A 
longitudinal cut is made through the medial cortex which once folded over exposes 
the striatum on the floor of the lateral ventricle. Iridectomy scissors are used to 
remove the striatum from both hemispheres. Cortical tissue is collected by carefully 
removing the overlying meninges (Adapted from Dunnett, 1996). 
2.1.3 Preparation of cell suspensions 
 Human or mouse tissue was incubated for 20 minutes at 37oC in bovine 
trypsin (Worthington, New Jersey, USA), after which DNase (Sigma, Gillingham, 
UK) and bovine trypsin inhibitor (Sigma) was added for a further 5 minutes. The 
tissue was washed in Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 
(DMEM/F12, Gibco) then centrifuged for 3 minutes at 1000 rpm. Cells were re-
suspended in DMEM/F12 and mechanically dissociated by trituration using a Gilson 
pipette with 200 µl tips. Cell numbers and viability were determined by trypan blue 
(0.4% trypan blue solution, Sigma) exclusion counting using a haemocytometer. Cell 
suspensions were only used if viability was found to be over 75% for neonatal 
injection and 80% for intracerebral transplantation. 10 µl of cell suspension was 
diluted with DMEM/F-12 and trypan blue, transferred to a haemocytometer with a 
glass cover-slip and viewed under the microscope. The number of living cells and 
total cells were counted in 5 squares of the haemocytometer to give an average cell 
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number per square. The number of cells per µl could then be calculated taking into 
account the dilution factor below: 
Cells counted/squares counted x dilution factor x 10 = cells/µl 
Following calculation, cells were re-suspended to the required concentration for 
desensitisation or transplantation 
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2.2 In vivo methods 
2.2.1 Animal care, anaesthesia and immunosuppression 
Pregnant dams (rat or mouse) were purchased (Harlan, UK) and housed 
individually until they gave birth with ad libitum access to food and water on a 
standard light-dark cycle. Pups were weaned at 28 days and mothers sacrificed or 
used as control host animals. Remaining control hosts were purchased as adults (~12 
weeks of age). After weaning animals were then housed in same sex groups of 2-4 
mice or rats per cage and experiments began in adults weighing 200-250 g for rats, 
or 20-25 g for mice.  
All surgical procedures were performed under isoflurane anaesthesia induced in 
an induction chamber with 5% isoflurane in oxygen at 0.8 L/min. Anaesthesia was 
maintained by passive inhalation of isoflurane (1.5-2.5%) in a mixture of oxygen 
(0.8 L/min) and nitrous oxide (0.4 L/min). Animals recovered in a warm recovery 
chamber before being returned to their home cage and health and weights were 
monitored for two days following surgery.  
For those animals receiving xenotransplants which were not tolerised, most 
received daily immunosuppression to allow graft survival. Daily i.p. injections of 
CsA (Sandimmun, 10mg/kg; Novartis, Hampshire, UK) were administered for the 
duration of the experiment, starting a day before transplantation.  
2.2.2 Neonatal Desensitisation 
Those pups to be desensitised were separated briefly from their mothers between 
post-natal day 0 (P0) and P4 to receive i.p. injections of 1 µl of cell suspension in 
sterile DMEM solution via a 1 µl handheld glass microsyringe. Cells were usually 
injected at a concentration of 1x105/µl, though this varied in some experiments. Care 
was taken to avoid transfer of odours and potential rejection of pups by the mother, 
with all handling carried out wearing disposable nitrile gloves. Following injections, 
pups were returned immediately to the mother. 
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2.2.3 Quinolinic Acid Lesions 
QA was dissolved in 0.1 M phosphate-buffer to make a 90 mM solution. 
Animals received a unilateral injection of QA to the right striatum. Prior to surgical 
procedures animals were administered sub-cutaneous injections into the scruff of 
meloxicam (Metacam) for analgesia; 5 µl for mice, and 30 µl for rats. The skull was 
then exposed; a small burr hole drilled above the right striatum and QA was injected 
via a cannula attached to a 10 µl Hamilton syringe driven by a mechanical pump.  
For QA lesions in mice the coordinates for injection sites were: 0.8mm rostral to 
bregma (AP) -2.0 mm lateral to midline (L) and -3.0/-2.8 mm ventral from dura (V).  
0.75 µl of 0.09 M QA was injected over 6 minutes, the needle was then left in place 
for 3 minutes to prevent reflux of toxin up the needle tract. The incision was sutured 
and animals were administered subcutaneous injections to the scruff of 0.5 ml saline 
glucose to prevent dehydration, and an intramuscular (i.m.) injection of 30 µl 
diazepam into the upper leg for sedation to prevent seizures following lesion.  
Rats received 2 simultaneous injections of QA over 3 minutes, for 1.5 minutes 
each at 2 depths. Stereotaxic coordinates from bregma were +0.4/+1.0mm (AP) and 
-3.5/-2.8 mm (L) at a depth of -5.0 mm and -4.0 mm below dura. Following infusion 
the needle was left in place for 3 minutes before removal. After suturing, animals 
received a subcutaneous injection of 5ml saline glucose and 0.15 ml diazepam (i.m.) 
as before. 
2.2.4 Striatal Transplants 
For transplants into adult mouse brain, 2 µl of cell suspension (1.25x105 or 
2.5x105 cells/µl) were delivered at a rate of 1 µl for 1.5 minutes each at two depths 
using a Hamilton syringe. Grafts were injected into the lesioned or intact right 
striatum using coordinates +0.8 mm (AP), -2.0 mm (L) from bregma at -3.2 and 
-2.8 mm below dura. After grafting, the needle was left at the graft site for a further 3 
minutes before being withdrawn. The incision was sutured and animals were 
administered subcutaneous injections of 0.5 ml saline glucose and 5 µl meloxicam.  
For transplants into adult rat brain, 2µl of cell suspension (2.5x105 cells/µl) were 
delivered at a rate of 1 µl/minute with 1 minute each at two depths using a Hamilton 
Chapter 2  Materials and Methods 
60 
syringe. Grafts were injected into the lesioned or intact right striatum using 
coordinates +0.7 mm (AP) and -3.1 mm (L) from bregma at -4.5 mm and -3.5 mm 
below dura. The needle was left in place for 2 minutes before being withdrawn. The 
incision was sutured and animals were administered subcutaneous injections of 5 ml 
saline glucose and 30 µl meloxicam. For bilateral transplants, the coordinates above 
were used to inject into the right striatum, and for the left; -0.7 mm (AP) and 
+3.1 mm (L) from bregma at the same depths as above. 
2.2.5 Perfusions and sectioning 
Animals were terminally anaesthetised by i.p. administration of sodium 
pentobarbital (Euthatal) and transcardially perfused with a prewash solution 
(phosphate buffered saline (PBS) at pH 7.3) for 2 minutes followed by 1.5% or 4% 
paraformaldehyde (PFA) solution at pH 7.3 for 4 minutes. The brains were removed, 
post-fixed in 1.5% or 4% PFA overnight and transferred the following day to 25% 
sucrose in prewash solution until they sank.  
Brains were sectioned coronally at 40 µm thickness using a freezing-stage 
microtome. Sections were stored either in 0.01% azide in Tris-buffered saline (TBS) 
in 96-well plates at 4oC, or in anti-freeze at -20oC.  
2.2.6 Cresyl Violet staining 
Brain sections (1 in 12 series) were mounted onto glass microscope slides 
double-subbed with 1% gelatin and allowed to dry overnight. Sections were soaked 
for 5 minutes each in increasing levels of alcohol from 70%, to 95% then 100% 
followed by 1:1 chloroform ethanol for 20 minutes. Slides were then put back 
through the decreasing alcohols for 5 minutes each from 100% to 95% to 70% 
followed by distilled water, before incubation in cresyl violet stain for 5 minutes and 
rinsing in water for 5 minutes. Stained sections were dehydrated in 70% and 95% 
alcohol, then destained in 2.5% acetic acid in 95% alcohol for 2-5 minutes until the 
desired level of staining was reached. Further dehydration was carried out in 95% 
and 100% alcohol, and then sections were cleared in xylene before coverslips were 
applied using DPX mountant. 
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2.2.7 Immunohistochemistry on free-floating tissue sections 
1 in 12 series of brain sections were washed thoroughly in TBS (pH 7.4) 
quenched with 10% hydrogen peroxide and 10% methanol in distilled water for 
5 minutes followed by three 5 minute washes in TBS. Sections were blocked for 
1 hour in 3% appropriate normal serum in 0.2% Triton X-100 in TBS (TXTBS), then 
without washing, block was discarded and primary antibody was added at the 
appropriate concentration in 1% serum in TXTBS and incubated overnight at room 
temperature. Sections were washed 3 x 10 mins in TBS before addition of a 
biotinylated secondary antibody at 1:200 dilution in 1% serum for 2 hours. Primary 
and secondary antibodies and the relevant blocking sera are all lised in Appendix 4. 
Three washes in TBS removed the secondary antibody solution and strepdavidin 
ABC (A and B both at 1:200 dilution in 1% serum in TBS; prepared 30 minutes 
before use) was added for a further 2 hours. The sections were washed 3 x 10 mins in 
TBS, followed by 2 x 5 mins washes in 0.05 M tris non saline (TNS, pH 7.4) and 
positive staining was visualized using diaminobenzidine (DAB) at 0.5 mg/ml in 
fresh TNS with 12 µl hydrogen peroxide (brown). Following staining, sections were 
washed twice in TNS before mounting on gelatinized class microscope slides.  
Sections were allowed to dry, then dehydrated in increasing levels of alcohol, cleared 
in xylene and coverslips were mounted using DPX mountant. 
2.2.8 Quantification and photomicroscopy of grafts 
Visualisation of grafts was carried out under a Leica DRMBE light microscope. 
Images were captured using a Leica DFC420 camera and Leica Application Suite 
(LAS) image analysis software. Graft areas were measured by drawing round areas 
of HuNu+ or NeuN+ staining on Image J software, or using Visiopharm stereology 
software. Estimates of graft volume were calculated using the formula: 
(∑a*M)/f 
a = area (µm2), M = section thickness and f = frequency of sampled sections (e.g. 
1:12) 
In grafts containing high numbers of cells, an Olympus C.A.S.T grid system was 
used for stereology. The graft area was first defined before counting cells in a 
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random selection of regions within this area. As a 3D counting frame was not used, 
cell counts were adjusted with the Abercrombie correction. The total number of cells 
(C) in the graft per section were therefore calculated using the following formula: 
Σc = total number of cells counted 
ΣA = sum of all inclusion areas 
Σa = sum of all sample areas 
f = frequency of sectioning (e.g. 12) 
M = section thickness 
D = Average cell diameter 
C = Σc x (ΣA/Σa) x f/(D+M) 
For smaller surviving grafts, total cell counts for HuNu or NeuN were carried 
out using ImageJ. The phenotype of cells in transplants of mouse WGE in Chapter 6 
was assessed with counts of DARPP-32. Total cell counts were estimated with the 
following formula, including the Abercrombie correction: 
f*A*M/(D+M) 
f = frequency of sectioning, A = cell counts for all sections, M = section 
thickness, D = Average cell diameter 
2.2.9 Semi-quantitative evaluation of host immune response to neural xenografts 
To quantify the host T cell and microglial response to neural xenografts in all 
experiments, the extent of immunostaining for CD4, CD8 and CD11b (OX-42) was 
graded on a scale according to the defined criteria shown in Figure 2.2 (Duan et al. 
1995; Larsson et al. 1999) 
2.2.10 Statistical analysis 
All analyses were carried out using SPSS for windows statistical software 
(SPSS 20, IBM). The number of surviving grafts between experimental groups was 
initially compared using chi-squared analyses where possible. Quantification of 
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mean graft volume and mean total cell numbers within surviving grafts were 
compared by analyses of variance (ANOVA) as described in each chapter. Non-
parametric data; semi-quantitative ratings of immune marker staining were compared 
with Kruskal-Wallis tests. 
 
Grade Criteria 
0 No specific immunostaining in the graft area 
1 Low number of positive cells, distributed as scattered single cells or 
clustered in a few small patches in or around the graft 
2 Several positive cells distributed as single cells or clustered in multiple, prominent patches 
3 Dense immunostaining of the graft area and a large number of positive cells in and around the graft 
4 Very dense immunostaining of the whole graft area and a very large 
number of positive cells in and around the graft 
Figure 2.2 Criteria for grading staining of immune cell markers (Duan et al. 1995) 
0 4 3 2 1 
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Chapter 3  
Comparing desensitisation using neural and non-neural tissue 
3.1 Summary 
The aim of the experiments included in this chapter was to investigate whether 
successful xenograft survival requires that neonatal desensitisation of host rats is 
performed using cells of the same type as those subsequently transplanted in 
adulthood. To date survival of human neural xenografts has been achieved using 
human neural cells to desensitise post-natally. Preliminary data suggested that using 
mismatched tissue types reduced xenograft survival. The ability to use non-matched 
cells, such as cells from another part of the foetus, adult cells, or renewable sources 
such as stem cells, would reserve scarce neural cells for grafting in adulthood. 
Furthermore, it would increase the likelihood of having a readily available source of 
cells for desensitising neonates, substantially facilitating transplant experiments and 
reducing animal wastage. Such experiments could also begin to clarify some of the 
mechanisms and limitations of desensitisation. The experiments reported here 
therefore assessed the survival of hPF cortical xenografts in the rat striatum in hosts 
desensitised neonatally with extra-neural cells compared to those in hosts 
desensitised with hPF cortical cells from the same donor embryo. Initial results 
suggested that successful desensitisation was more likely when using neural tissue 
for desensitisation. However further investigation comparing additional tissue types 
showed good survival of transplants, suggesting that it may not be necessary for the 
tissue used for desensitisation and transplantation to match, but that some tissue 
types, including liver and kidney, may be more effective for desensitisation of host 
rats to xenogeneic tissue. 
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3.2 Introduction 
In the initial demonstration of successful neonatal desensitisation in rat hosts by 
Kelly et al, a number of different desensitisation protocols were tested (Table 3.1). 
These experiments suggested that the use of neonatally administered human liver 
cells to induce desensitisation to a subsequent transplant of hCTX tissue was less 
successful than that of neural tissue; 62% graft survival compared to up to 87%, 
although survival of transplants in hosts desensitised to neural tissue ranged between 
66%-87% (Table 3.1; from Kelly et al. (2009b)). Routine studies carried out in rat 
hosts in this group have therefore used human neural tissue to desensitise neonatally 
and promote the survival of later transplants of neural tissue. Although the use of 
matched tissue has been essential to demonstrate that survival of transplanted cells 
can be achieved without additional immune suppression, it would be preferable to be 
able to use an alternative, less valuable source of tissue to desensitise host neonates. 
This would make available more tissue both for transplantation and desensitisation, 
particularly if neonatally injected cells could be derived from a renewable source of 
cells such as human FNPs. Additionally, it is possible that a wider spectrum of 
human cells, or “any” human cell type may be sufficient to induce desensitisation, 
which would open up possibilities even further.  
Previous investigations of the phenomenon of neonatal tolerance have 
demonstrated successful tolerance induction to peripheral allografts in mice 
following neonatal injections of spleen, liver, and bone marrow cells (Adkins et al. 
2004; Modigliani et al. 1997; West et al. 1994). Hosts in these studies were 
demonstrated to be tolerant to allogeneic donor cells by the survival of donor skin 
grafts or cardiac allografts and a lack of host cytotoxic T lymphocyte responses to 
donor spleen cells in vitro (Adkins et al. 2004; Modigliani et al. 1997; West et al. 
1994). Although this has not been successfully replicated in a discordant xenograft 
paradigm, such as human to rat/mouse, it has been shown that under certain 
conditions tolerance can be induced to xenogeneic antigens (Borenstein et al. 2004). 
Tolerance was successfully induced in host mice in this study to donor cells from 
transgenic mice expressing a human MHC Class I allele (Borenstein et al. 2004). 
Various mechanisms have been proposed for the induction of neonatal tolerance, 
with Matzinger and colleagues highlighting the potential importance of the specific 
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population of cells injected to induce neonatal tolerance, suggesting that the types of 
cells used for inoculation would dictate whether an immunising or tolerising 
response ensued (Matzinger 1994; Ridge et al. 1996). 
Tissue injected (i.p.) 
neonatally (P0-1) 
Tissue transplanted 
to adult striatum 
Survival after 
transplant (weeks) 
Number of grafts 
surviving (%) 
hPF cortex hPF cortex 40 48/55 (87%) 
hPF striatum hPF striatum 25 10/15 (66%) 
hFNP hFNP 12 10/13 (77%) 
hES-N hES-N 12 9/12 (75%) 
hFNP hPF cortex 12 11/13 (85%) 
hPF cortex hFNP 12 11/14 (79%) 
Human liver hPF cortex 12 8/13 (62%) 
hPF cortex hPF striatum 10 10/12 (83%) 
Table 3.1 Previously tested desensitisation protocols; adapted from Kelly et al. 
(2009b). Showing successful desensitisation using primary neural tissues, (hPF 
cortex and striatum), hFNP, hES and human liver in various combinations. hPF 
cortex injected neonatally shows the highest rate of survival with adult transplants of 
hPF cortex (87%). hPF = human primary foetal tissues hFNP = human foetal neural 
precursors derived from human primary foetal cortex, hES-N = embryonic stem cell 
derived neural precursors 
To investigate whether desensitisation could be achieved with alternative hPF 
tissues, an initial experiment was carried out comparing the use of neural tissue and 
non-neural tissue (skin) from the same foetal donor to desensitise SD rats. Hosts 
received transplants in adulthood of hCTX tissue to the intact or QA lesioned 
striatum, and survival was assessed at a short time point (6 weeks) following 
transplantation. This was followed up in a subsequent experiment with the 
comparison of the survival of hCTX transplants to the intact striatum in rat hosts 
desensitised with three different donor tissue types from one human foetal donor; 
liver (hLiver), kidney (hKidney) and cortex (hCTX) 12 weeks after transplantation. 
Since graft survival was found to be comparable in transplants delivered to the intact 
and QA lesioned striatum, all transplants in this study were delivered to the intact 
striatum. Survival was assessed at 12 weeks in this case to demonstrate that grafts 
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were surviving due to effective desensitisation and that in previous studies a longer 
rejection response wouldn’t have resulted in graft destruction past 6 weeks. 
Successful desensitisation with non-specific human donor tissue allows inferences to 
be made about the mechanisms of desensitisation, suggesting the antigen recognised 
is “human” but not related to tissue type. 
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3.3 Experimental Design 
3.3.1 Desensitisation and transplantation of rat hosts 
Table 3.2 outlines the design of the first experiment; detailed methods for all 
procedures are presented in Chapter 2. Experiments were carried out in two parts. 
Firstly; hosts were desensitised with hCTX (n=13) and human skin tissue (hSkin) 
(n=12) from the same foetal donor. Neonatal hosts were obtained from 2 pregnant 
SD rats (Harlan). In adulthood, at ages 8-12 weeks, half received QA lesions and all 
were transplanted with hCTX from a separate foetal donor. Survival was assessed at 
6 weeks post transplantation (Table 3.2).  
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Table 3.2 Experimental design; comparing graft survival at 6 weeks post 
transplantation in rat hosts desensitised neonatally with hCTX or hSkin cells 
For the second experiment; hosts were desensitised with hCTX (n=11), hLiver 
(n=10) and hKidney (n=10) from one foetal donor followed by transplants to the 
intact adult striatum of hCTX from a different foetus, and survival was assessed 12 
weeks after transplantation (Table 3.3). Neonatal hosts for this study were obtained 
from 5 pregnant SD rats (Harlan). No animals in either experiment received 
immunosuppression and cells were all delivered neonatally as i.p. injections in 1µl 
DMEM/F12.
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Table 3.3 Experimental design; comparing graft survival at 12 weeks post 
transplantation in rat hosts desensitised neonatally with hCTX, hLiver or hKidney 
cells 
3.3.2 Histology and Immunohistochemistry 
At 6 or 12 weeks post-transplantation (according to experimental design) 
animals were transcardially perfused and brains processed histologically as described 
in Chapter 2. A 1:12 series of sections were stained with CV and further 1:12 series 
were processed for single label immunohistochemistry using the primary antibodies 
listed in Appendix 4. A human specific antibody (HuNu, Millipore, UK) was used 
to identify surviving human cells and various immune markers were stained to assess 
the host response. The same basic protocol was used for all antibodies and is 
outlined in Chapter 2. Briefly, sections were quenched in 10% methanol and 
hydrogen peroxide before a 1 hour blocking step in 3% normal serum. Primary 
antibodies were incubated overnight with 1% normal serum followed by 2 hour 
incubation in secondary antibodies and 2 hour incubation in streptavidin ABC kit. 
Since all were mouse antibodies, biotinylated anti-mouse IgG (1:200, Vector) 
secondary antibody was used. Staining in all cases was visualised using the DAB 
method. 
3.3.3 Quantification of graft survival and host immune response 
Surviving grafts were identified initially with CV staining and confirmed with 
HuNu. Graft survival at both 6 and 12 weeks after transplantation was compared 
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with Chi-square tests. Counts of surviving transplanted human cells as identified by 
HuNu staining were carried out using stereological techniques for survival assessed 
after 6 weeks. Positively stained cells were counted in each section of a 1:12 series, 
allowing the number of surviving cells per graft to be calculated as described in 
Chapter 2. These could then be compared between animals tolerised with different 
tissue types. To assess survival of 12 week transplants from the second experiment, 
graft volumes were estimated by tracing the graft area as stained by HuNu on 
consecutive sections through the striatum on Image J. Total cell numbers and graft 
volumes were compared by one-way ANOVA. To quantify the host T cell and 
microglial response to neural xenografts in all experiments, the extent of 
immunostaining for CD11b (OX-42), CD8 and CD4 where possible, was graded on 
a scale (0-5) described in detail in Chapter 2 (Duan et al. 1995; Larsson et al. 1999). 
Gradings of these markers were compared with non-parametric Kruskal-Wallis tests. 
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3.4 Results 
3.4.1 Experiment 1: Graft survival at 6 weeks post transplantation in rat hosts 
tolerised with hCTX or hSkin 
Surviving grafts were initially identified in Nissl-stained sections using CV and 
staining with HuNu confirmed the survival of transplanted human cells (Figure 3.1). 
At 6 weeks post transplantation, hCTX tissue transplanted into non-
immunosuppressed adult rat brains was seen to survive in animals which had been 
desensitised neonatally with both hCTX and hSkin tissue. No significant difference 
was found in graft survival between hosts with QA lesions and those which received 
transplants to the intact striatum, χ2 (1, N = 25) = 1.93, p = 0.165, therefore data was 
compiled to analyse the effect of desensitisation group on graft survival. Some 
healthy surviving grafts were found in both groups, although 62% of grafts survived 
in animals desensitised with hCTX tissue compared to 17% in animals desensitised 
with hSkin tissue (Figure 3.2). However, this difference was not found to be 
statistically significant; χ2 (1, N = 25) = 3.532, p = 0.060, which is likely to be due to 
the small numbers of surviving transplants in this experiment, since a comparison of 
the data in Figure 3.2B shows a strong trend towards greater survival in hosts 
desensitised with hCTX. Mean surviving cell numbers and graft volume are 
displayed in Figure 3.3 and Figure 3.4, showing larger surviving grafts in hosts 
desensitised with hCTX. Graft volumes and cell counts were not compared, since 
there were only two surviving grafts in hosts desensitised with hSkin. 
Chapter 3  Desensitisation with different tissues (rat) 
72 
 
Figure 3.1 Photomicrographs of sections from rat hosts desensitised 
with neural (A, C) and non-neural (B, D) tissue stained with CV 
(A, B) and HuNu (C, D) and transplanted with hCTX into the intact 
striatum at 6 weeks post transplantation. Lower magnification images 
are inset showing small surviving transplants in the right striatum 
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Tissue injected 
neonatally 
Lesion 
Number of surviving 
grafts (%) 
Total 
(%) 
Mean cell 
number (HuNu+) 
Combined mean 
cell number 
Mean graft 
volume (µm3) 
Combined mean 
graft volume (µm3) 
hCTX 
QA 3/7 (42.8%) 
61.5% 
25.1x104 
20.9x104 
11.7x108 
9.6x108 
None 5/6 (83.3%) 16.7x104 8.3x108 
hSkin 
QA 0/6 (0%) 
16.6% 
- 
9.4x104 
- 
4.9x108 
None 2/6 (33.3%) 9.4x104 4.9x108 
A 
Figure 3.2 A) Graft survival at 6 weeks post transplantation. 
B) Percentage of surviving hCTX transplants in both lesioned and 
unlesioned hosts 6 weeks after transplantation in adult rat hosts 
desensitised neonatally with neural or non-neural tissue. Survival 
percentages are displayed at the base of bars, with total numbers shown 
at the top 
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Figure 3.3 Mean graft volume as measured with HuNu+ staining 6 weeks 
after transplantation (excluding rejected grafts) 
Figure 3.4 Mean numbers of surviving human cells 6 weeks after 
transplantation in adult rat hosts desensitised neonatally with neural or 
non-neural tissue (rejected grafts excluded) 
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3.4.2 Host immune response to neural xenografts 6 weeks after transplantation 
Sections (1:12 series) at 6 and 12 weeks post transplantation were stained for rat 
T cell (CD4, CD8) and microglial markers (CD11b – OX42) in order to determine 
the extent of the immune response to human neural tissue grafts in animals which 
were desensitised neonatally with neural and non-neural human embryonic tissue. 
Figure 3.5 shows staining with CD11b (OX42, Serotec) specific for activated rat 
microglia/macrophages, and CD8+ T cells. In these examples, staining can be seen 
along the needle tract and surrounding the grafted area. CD11b staining was graded 
and differences compared with a non-parametric Kruskall-Wallis test, showing no 
difference in the host microglial response to surviving xenografts in hosts 
desensitised with neural vs non-neural tissue; H (1) = 0.21, p = 0.885 (Table 3.4). 
Staining for CD4 is not shown, and grading was not carried out for either T cell 
marker, as due to issues with storage of tissue sections described in Appendix 5, not 
all sections could be stained successfully and quantified.  
Desensitisation/Grade 0 1 2 3 4 
hCTX  + ++++ +++++++ + 
hSkin  ++++++++ + +++  
Table 3.4 CD11b immunoreactivity in sections from animals desensitised with 
hCTX or hSkin cells and transplanted with hCTX at 6 weeks post-transplantation. 
Each + corresponds to one host; a red + denotes a rejected graft. 
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Figure 3.5 Tissue sections from hosts desensitised with hCTX or hSkin, tissue 
and transplanted with hCTX stained for CD8+ T cells and CD11b+ microglia at 6 
 weeks post transplantation. Staining shows infiltration of microglia and T cells in 
the grafted area. These examples show more severe infiltration in the host 
desensitised with hSkin, however there were no differences in immune response 
between the two groups. 
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3.4.3 Experiment 2: Graft survival at 12 weeks in rat hosts transplanted with 
hCTX, hLiver and hKidney 
Successful graft survival in hosts desensitised with non-neural tissue was 
demonstrated in this experiment as identified with CV and HuNu staining, with 
100% of transplants surviving in both non-neural groups (liver and kidney). 
However, only 36.4% of transplants in those desensitised with human cortical tissue 
were found to survive (Table 3.5 and Figure 3.8). Surviving grafts in the majority of 
hosts were found to be very large, spanning the whole striatum (Figure 3.9). A 
chi-squared test showed there to be significantly more grafts surviving in hosts 
desensitised with liver or kidney cells than those desensitised with hCTX; 
χ
2
 (2, N = 31) = 16.44, p < 0.001. Graft volume was calculated from areas measured 
using Image J (Figure 3.6). No differences in graft volume were found between 
hosts desensitised with different donor tissue types (F (2,21) = 0.347, p = 0.711). 
Tissue injected 
neonatally 
Number of 
surviving grafts  
Total (%) 
Mean graft 
volume (µm3) 
Liver 10/10 100% 5.2x107  
Kidney 10/10 100% 5.4x107 
Cortex 4/11 36.4% 3.6x107 
Table 3.5 Surviving human transplants in desensitised hosts 12 weeks after 
transplantation
Figure 3.6 Estimated mean graft volumes of surviving transplants in 
desensitised hosts 12 weeks after transplantation 
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3.4.1 Host immune response to neural xenografts 12 weeks after transplantation 
To investigate the host immune response to transplants of hCTX, staining was 
carried out for T cell (CD8+ and CD4+) and microglial (CD11b) markers (Figure 
3.8) and quantified according to the grading system described previously (Table 
3.6). This is represented graphically in Figure 3.7. Non-parametric Kruskall-Wallis 
tests were carried out for all immune marker grading of sections containing surviving 
grafts. No significant differences were found between desensitisation groups for any 
stains; test statistics are shown in Table 3.6.  
Stain Group 
Grade 
H(2) p 
0 1 2 3 4 
CD8 
hLiver ++ ++++ + +++  
0.957 
 
hKidney +++ +++++  + + 0.620 
hCTX +++++ +++++   +  
CD4 
hLiver ++ ++ +++ +++  
1.327 
 
hKidney + +++++ +++  + 0.515 
hCTX ++ +++++ +++  +  
CD11b 
hLiver  ++++ ++++++   
1.150 
 
hKidney  +++++++ ++ +  0.563 
hCTX ++++++ +++  +   
Table 3.6 Grading of immune marker staining in sections from rat hosts desensitised 
with different human tissue types and transplanted with hCTX at 12 weeks post-
transplantation. A + represents the highest score for each rat with red + indicating 
hosts with rejected grafts. 
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Figure 3.7 Grading of immune marker staining in rat hosts 
desensitised with different tissue types. Each circle 
indicates the highest graded section for each animal. Red 
circles denote sections without surviving grafts. 
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Figure 3.8 Photomicrographs of sections from rat hosts desensitised with human liver, kidney, and cortex showing survival of transplants and 
the host immune response 12 weeks after transplantation. Images show large surviving grafts in desensitised hosts, with some labelling of T cells 
and minor infiltration with microglia. 
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Figure 3.9 A representative surviving hCTX graft in a host desensitised neonatally with hLiver, showing that surviving hCTX transplants were 
large, filling the whole striatum 
Chapter 3  Desensitisation with different tissues (rat) 
82 
3.5 Discussion 
The aims of the experiments described in this chapter were to determine whether 
it is necessary to use the same tissue type to desensitise hosts neonatally as is used to 
transplant in adulthood, or whether it is sufficient to use other tissues from the same 
donor species. Being able to desensitise with alternative tissue would reserve scarce 
neural tissue needed for transplantation as well as giving more insight into the 
mechanisms of the method and specificity of the desensitisation. In Experiment 1, 
host rats were desensitised with differing tissue types (hCTX or hSkin) at birth, but 
all transplanted with the same tissue (hCTX) in adulthood in order to compare 
survival between the two groups. The findings from this study suggest that better 
survival may be achieved with transplants of matched tissue, indicating that the 
tissue used for desensitisation should be of the same type as that used to graft. A 
second experiment investigated the potential of other hPF tissue types for use in the 
desensitisation of rat hosts. Neonatal rats were desensitised with hCTX, hLiver, or 
hKidney, and again all received transplants of hCTX in adulthood. This study 
showed relatively poor survival of transplants in hosts desensitised with hCTX as 
compared to 100% of grafts surviving in the other two groups, however this was still 
only 25% less survival between Experiment 1 and 2. 
The findings from both experiments therefore do not suggest that the tissue used 
for desensitisation must be the same as that used to transplant, rather that the results 
may be variable dependent on the type of tissue used. It is not clear why survival in 
the second experiment of this chapter was so poor in hosts desensitised with hCTX, 
although this may be an anomaly due to poor quality cortical tissue from this specific 
donor foetus since previous experiments, including some presented in this thesis, 
have shown more consistent survival to a degree which may be achieved with 
conventional immune suppression (Kelly et al. 2009b). The previous finding that 
liver was less successful as a donor source for desensitisation may also be due to this 
variability. Additionally, the previous finding that 62% of grafts survived following 
desensitisation with liver cells still shows that survival is better than may be 
expected with no treatment and not far from the 75% of grafts which survived 
following daily treatment with CsA (Kelly et al. 2009b). The variable survival of 
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different tissue types in these experiments may be explained to an extent by 
considering previous work in the field of neonatal tolerance. 
Neonatal (and in utero) tolerance induction has been described for decades using 
a similar method to that described here (Billingham and Brent 1956; Billingham et 
al. 1953). Previous work shows the induction of tolerance to allogeneic skin grafts 
following an injection of spleen (Adkins et al. 2004; Ridge et al. 1996), liver (West 
et al. 1994) or bone marrow cells (Modigliani et al. 1997) though less success has 
been observed in the case of xenografts (Shen et al. 1996). This may be due to 
species differences in T cell receptor recognition of xenogeneic MHC molecules; 
although this suggestion has been rejected by Borenstein et al (Borenstein et al. 
2004) who found that tolerance to xenogeneic MHC molecules could be induced in 
B6 mice, promoting survival of skin grafts. Donor spleen cells (1.5x107) from a 
transgenic mouse strain expressing the human MHC class I allele human leukocyte 
antigen (HLA)-B7 were injected intravenously (i.v) to induce tolerance in normal B6 
mice, therefore demonstrating that the host immune system was capable of 
recognising donor xenogeneic MHC molecules (Borenstein et al. 2004). 
Some mechanisms for the induction of neonatal tolerance to allogeneic tissue 
have been proposed, although a definitive conclusion has not been reached. Passive 
models suggest that, as with natural self-tolerance, neonatal tolerance occurs through 
negative selection of self-reactive T cells. The presentation of donor antigens in the 
thymus, along with self antigens therefore allows donor reactive thymocytes to also 
be negatively selected. As few mature T cells exist neonatally, donor cells are able to 
reach the thymus to promote this deletion of donor reactive T cells (Morrissey et al. 
1983; Ridge et al. 1996). Active models suggest that newly developing T cells 
present in the neonatal host generate mainly TH2 responses, protecting from self 
recognition and also reducing recognition of donor cells present at this stage 
(Bandeira et al. 1989).  
However, Matzinger and colleagues highlight the ability of neonates to become 
immunised rather than tolerised to neonatally presented viruses (Miller et al. 1994) 
which does not agree with these models (Ridge et al. 1996). They therefore propose 
a third model, the “Danger” model suggesting that it is not the host population of 
T cells which governs the induction of tolerance, rather it is what constitutes the 
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population of injected donor cells which determines tolerance or immunity 
(Matzinger 1994; Ridge et al. 1996). When the population of cells used for neonatal 
administration does not include a large proportion of mature APCs, a lack of 
co-stimulation of host T cells occurs resulting in a tolerising response. Conversely, if 
a large population of active APCs such as DCs are present in the injected suspension, 
an immunising effect will occur. The authors found exactly these responses when 
injecting spleen cells or isolated DCs (Ridge et al. 1996). Tolerance induction was 
found when injecting a large number of spleen cells neonatally, whereas injecting an 
enriched population of DCs primed T lymphocytes for attacking donor cells. Much 
variation has been found in this area, with some disagreement for this proposal from 
a study showing that neither donor T nor B cells are required for the induction of 
neonatal tolerance, since successful tolerance has been induced from injection of 
spleen and bone marrow cell suspensions from Rag1-/- mice which contain neither of 
these populations, but may contain professional APCs (Chan et al. 2007; Modigliani 
et al. 1997). 
In the context of the experiments described in this chapter, a suspension made 
up of cells from neural tissue, including hCTX, is unlikely to include a large 
population of mature APCs, since DCs only migrate to the CNS or mature from 
resting microglia as a response to pro-inflammatory signals (Santambrogio et al. 
2001; Shrikant and Benveniste 1996). Additionally hCTX taken at this stage in 
embryonic development is likely to be a highly proliferative source of tissue, as 
confirmed by the large surviving transplants and positive staining for Ki67 found in 
transplants as documented in Chapter 4 (See Appendix 6). The presence of a viable 
source of proliferating cells which are not rejected by the immature neonatal immune 
system will potentially provide a constant source of antigen to be processed as self 
during immune system development. It is possible that the non-neural tissue 
suspension in the first experiment of this chapter, made up of donor skin cells, 
contains a higher number of resident DCs (Langerhans cells) which are present in the 
skin, increasing the chance of an immunising effect. This more closely agrees with 
the suggestion that the presence of donor APCs may be more likely to have an 
immunising rather than a tolerising effect. It also suggests that other types of tissue, 
which does not necessarily match that used to transplant in adulthood, could still be 
Chapter 3  Desensitisation with different tissues (rat) 
85 
used to successfully desensitise host animals to xenogeneic tissue, as in the case of 
neonatal tolerance to allogeneic tissue in mouse hosts. 
The second experiment described in this chapter aimed to determine whether 
this was the case by investigating the survival of hCTX transplants in hosts 
desensitised using hLiver and hKidney cells. These tissues were chosen in part as an 
‘alternative’ tissue source for injection as opposed to cortex or skin cells. Liver was 
more specifically chosen due to its successful use in the induction of neonatal 
tolerance to allografts in mice (West et al. 1994). Whilst, spleen would have been an 
ideal source of donor cells based on findings from previous neonatal tolerance 
research (Adkins et al. 2004; Ridge et al. 1996), this proved difficult to obtain from 
the human embryos at the ages available. Successful desensitisation with liver cells 
in this experiment, with 100% survival of hCTX grafts is congruent with these 
findings, despite the use of donor cells from different embryos. It has previously 
been noted that liver transplants are more readily accepted in a number of 
mammalian species including pigs and rats, even across MHC differences, and can 
even have a tolerising effect in adult hosts (Calne 2000; Calne et al. 1969; Calne et 
al. 1967). It has been suggested that this is due to the nature of the APCs present in 
the liver, in particular in the human liver. Kupffer cells, the liver’s macrophage 
population, myeloid DCs, and liver sinusoidal endothelial cells (LSECs), have all 
been shown to secrete immunosuppressive tolerance inducing signals including 
IL-10; which down-regulate MHC-II, CD80 and CD86 (Knoll et al. 1995; Sato et al. 
1996). Additionally, induction of Tregs has been identified by liver APCs, which 
may also contribute to immune tolerance (Moseman et al. 2004). These factors 
combined with the nature of the immature neonatal immune system may be 
conducive to the induction of tolerance in our host rats. For a review on these 
findings, see Crispe (2011). Although suggestive of reasons for why desensitisation 
with liver cells may have promoted survival of hCTX transplants, the same findings 
have not been observed with kidney, thus the reason for this finding is unclear. 
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3.6 Conclusions and future work 
Findings from these experiments demonstrate that it is possible to use 
alternative, non-neural hPF tissue types to desensitise hosts to human tissue to a 
sufficient degree for promotion of survival of hCTX transplants. The data also 
suggest that using other types of tissue may provide more consistent survival of 
hCTX grafts to the rat striatum up to 12 weeks after transplantation. Replication of 
these findings is required to confirm whether this is the case, as well as confirmation 
with human WGE transplants to show that desensitisation with these tissue types is 
an appropriate method to promote survival of striatal tissue in a rat HD model, and 
that survival of hCTX tissue is not more likely due to the rapid proliferation of these 
cells. Further experiments using alternative tissue such as NPCs expanded in culture 
for desensitisation would also be valuable. This could provide a more constant 
source of cells with which to desensitise neonatal host animals, avoiding difficulties 
with the acquisition of hPF tissue.  
Transplantation studies can show whether desensitisation with these alternative 
tissue types is sufficient to promote long term survival of hCTX transplants to the rat 
striatum and allow inferences to be made regarding the potential mechanisms. 
However in order to confirm whether the population of cells itself influences the 
efficacy of desensitisation it is necessary to characterise the donor tissue. Therefore, 
future work aims to analyse the differing donor tissue types with fluorescence 
activated cell sorting (FACS) analysis to determine the presence of mature APCs as 
measured by expression of MHC-II and CD11c (Shortman and Liu 2002; Shrikant 
and Benveniste 1996). Additionally it would be valuable to determine whether 
desensitisation is induced as a result of the presence of cells of a hematopoietic 
lineage inducing chimerism in hosts, since this has frequently been suggested as a 
requirement for, or at least to strongly correlate with successful neonatal tolerance in 
mice (Borenstein et al. 2004; Chan et al. 2007). This could be achieved by assessing 
the presence of human cells in host lymphoid organs. Collecting data from these 
studies along with data from transplant survival in hosts desensitised with these 
populations of donor cells will provide more understanding of which population of 
cells administered neonatally induces the best cell survival and the potential 
mechanisms involved.  
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Another important question to be investigated is to the fate of the donor cells 
injected into neonatal hosts. This would give insights into the mechanisms involved, 
allowing determination of how long donor cells remain present in the host and how 
they are taken up by the neonatal rat immune system, as well as whether they 
ultimately induce some form of chimerism in the host. A number of possible 
methods may be used for such investigations. Potentially labelled cells could be 
combined with imaging techniques to track the location of injected cells. Or 
alternatively, as donor cells are of a different species origin, it may be possible to use 
antibody staining in histological sections to identify human cells within neonatal rat 
tissues. The main issue is initial determination of the location of cells, as there is no 
clear idea of distribution and hence no indication of where to begin looking within 
the neonate. An initial experiment has been designed to elucidate this matter, by 
collection of a number of organ samples at various time-points following injection 
and using reverse transcriptase-polymerase chain reaction (RT-PCR) to identify the 
presence of human genes within the rat host. Although this experiment has been 
carried out, due to difficulties with optimisation of PCR primers and protocols, data 
collection is not complete and the results cannot yet be analysed. 
Ultimately, neonatal desensitisation will be required to promote the survival of 
transplants of human donor cells for sufficient time to complete full functional 
assessment of transplants. These experiments will aim to test donor cells derived 
from hESCs and hiPSCs, most likely in comparison to hPF tissue, demanding the 
demonstration of successful desensitisation to these cell types. Previous work has 
shown successful desensitisation (75%) up to 12 weeks in animals desensitised and 
transplanted with hESC-derived neuronally directed cells (Kelly et al. 2009b). Future 
work will determine whether desensitisation of rat hosts using hPF tissue can be used 
to promote survival of hESC derived neuronal cells directed towards a striatal 
phenotype for sufficient time to assess the potential of these donor cells (up to 40 
weeks). 
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Chapter 4  
Tolerance Specificity 
4.1 Summary 
To further comprehend the practical limitations and potential underlying 
mechanisms of neonatal desensitisation, the experiments in this chapter were 
designed to explore the specificity of the induced desensitisation in terms of the cells 
used to desensitise the animals and cells transplanted subsequently in adulthood. The 
objective was to investigate whether neural transplants of hPF tissue would only be 
tolerated following prior desensitisation to tissue of the same species. Demonstrating 
“tolerance” to be species specific would suggest that desensitisation is not a result of 
a general reduction in the sensitivity of the immune system, and that the host is still 
capable of rejecting a transplant from a different donor species. Survival of 
transplants of PF hCTX or mWGE, or both (bilateral- mWGE on one side and hCTX 
on the contralateral side) was compared in rat hosts desensitised with tissue from 
either the same or different species, or treated daily with CsA. Results were 
unexpected, in that no surviving mouse transplants could be identified in any 
condition but surviving transplants of hCTX were found in all groups, including 
hosts that had been desensitised with mouse tissue. hCTX transplant survival 
persisted where a contralateral transplant of mWGE was rejected in all hosts 
desensitised with hCTX or treated with CsA as well as some hosts desensitised with 
mWGE∗. Data is suggestive of at least 50% survival of hCTX transplants in hosts 
desensitised with tissue from a different donor species, implying desensitisation to a 
common epitope present on mouse and human cells, or potentially a general 
reduction in immune sensitivity. Further work is required to identify the reason 
behind these findings, and these objectives are discussed in this chapter. 
                                                          
∗
 Some tissue processing and histology for this experiment was carried out by a technician in 
the BRG; Tom Steward. All surgical techniques, and quantification and analyses of 
histological stains were carried out by myself 
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4.2 Introduction 
A previous study by Kelly et al showed that rat hosts can be neonatally 
desensitised to human neural tissue, allowing long term survival of a subsequent 
transplant to the striatum in adulthood (Kelly et al. 2009a). This was demonstrated 
initially with transplants into the intact striatum of SD rats using a range of neural 
donor cells (regions of the primary foetal brain, FNPs, ESCs), but in most cases with 
the same types of cell being used for neonatal injection and striatal implantation in 
adult brain. However, Kelly et al also presented preliminary evidence that graft 
survival (hCTX) could be achieved when the neonatal injections were performed 
with cells from a different region of the foetus (liver). Further evidence that neural 
cells (primary foetal cortex) can survive following desensitisation to extra-neural 
tissue (liver, kidney and skin) is presented in Chapter 3. Taken together these 
findings provide further support for neonatal desensitisation as a model for 
pre-clinical testing of potential human donor cell types, but they also suggest a 
broader desensitisation than first assumed, with hCTX transplants surviving 
following desensitisation with a range of tissue types. This chapter seeks to explore 
this further, by identifying whether this desensitisation extends to tissue from 
different donor species, or whether it is specific to cells from the donor species 
which were used for neonatal inoculation. 
This experiment was conducted in order to demonstrate that rats inoculated 
neonatally with hPF tissue have been specifically desensitised to human tissue, as 
opposed to survival of neural transplants being due to a global reduction in the host’s 
capacity to mount an immune response to a neural xenograft. To achieve this, rat 
hosts were desensitised with either mWGE or hCTX. The pups were allowed to 
mature to adulthood and were then either transplanted unilaterally with cells from the 
same donor species as used for desensitisation or with a mismatching donor cell 
type, or were transplanted bilaterally with a graft of each tissue type. Since mice 
could be time-mated to produce a ready supply of foetal donor tissue, it was possible 
to use mWGE for desensitisation and transplantation. However, difficulties in the 
supply of hPF tissue meant that cortical tissue, which is much more plentiful than 
WGE, had to be used for both stages of the experiment in order to generate sufficient 
donor cells. Immune suppressed controls were included for all transplant groups to 
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confirm that any rejection seen was due to the mismatch of 
desensitisation/transplantation tissue and not due to problems with the transplanted 
tissue itself. It was hypothesised that unilateral transplants would survive following 
desensitisation to tissue from the same donor species, and that unmatched transplants 
would be rejected. To confirm that this was specific to desensitisation within one 
host animal, bilateral transplants were included, with the hypothesis that the matched 
species transplant would persist, whereas the unmatched transplant would be 
selectively rejected.  
The interpretation of this study was complicated by the lack of survival of any 
mouse transplant in any condition. This made it impossible to assess the differential 
effect of species-matched and mis-matched conditions on the survival of mouse 
grafts. However, there was clear and unambiguous survival of human grafts, so this 
arm of the experiment could be analysed and revealed that desensitisation did not 
appear to be specific to the donor species tissue injected neonatally. Specifically, 
surviving hCTX transplants were found in hosts desensitised with mWGE. This 
survival was robust enough to persist, even in the presence of a contralateral rejected 
mWGE transplant, although fewer hCTX grafts survived following desensitisation to 
mouse cells than to human cells. 
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4.3 Experimental Design  
SD rat hosts were desensitised (P0-2) to either mWGE or hCTX and 
transplanted with various combinations of donor tissues (see Table 4.1). For 
desensitisation; hCTX tissue was collected and dissected from one donor embryo, 
and mWGE was dissected from two time mated CD-1 mice at E14 and E15 (Harlan, 
UK). Desensitised hosts consisted of 34 neonates (18 male and 16 female; from 
3 pregnant SD rats, Harlan). A group of hosts were not desensitised, and received the 
same transplant combinations with daily injections of CsA (10mg/kg) starting from 
one day prior to transplantation. These hosts arrived at >200g from the supplier 
(Harlan, n = 24). As desensitisation was dependent on the birth of rat pups at the 
same time as the presence of donor tissue, mWGE desensitised hosts were derived 
from two different litters which received neonatal injections from different litters of 
mouse embryos. Hosts were then randomly assigned to each transplant condition. All 
neonatal injections consisted of 1x105 donor cells in 1 µl DMEM/F12.  
Transplants were carried out in hosts >200g; in desensitised hosts this was 
between 8 and 16 weeks of age. Due to availability of human tissue, and time 
constraints, transplants had to be carried out on two separate occasions. CsA treated 
control groups were therefore divided between transplant groups to ensure 
differences were due to host treatment rather than donor transplant tissue. Donor 
tissue for hCTX transplants was collected and dissected from two embryos; 
CRL 35.5mm (group 1) and 46.7mm (group 2). Donor tissue for mWGE transplants 
was again collected and dissected from time-mated CD-1 mice at E14. All 
transplants consisted of 5x105 donor cells in 1 µl DMEM/F12. Transplant survival in 
all cases was assessed 12 weeks after transplantation. To clarify the complex design 
of these experimental groups, the design is outlined in Table 4.1. 
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Table 4.1 Design of experiment to determine whether desensitisation is specific to tissue from the donor species used for neonatal injection. All 
transplants were delivered to the intact striatum. The side of transplant delivery was counterbalanced across groups. hCTX = human primary 
foetal cortex, mWGE = mouse whole ganglionic eminence. Bilateral transplants consisted of an hCTX transplant to one striatum and an mWGE 
transplant to the other, again the side of transplant delivery was counterbalanced. All animals were desensitised with an i.p. injection of 
1x105 cells and transplanted with 5x105 cells 
 Transplant group 1 Transplant group 2 
P0-2 Desensitised mWGE CsA Desensitised hCTX 
          
8-16 
weeks 
Transplant 
hCTX 
(n=6) 
Transplant 
mWGE 
(n=6) 
Transplant Bilat 
(mWGE/hCTX) 
(n=6) 
Transplant 
hCTX 
(n=8: 4 per 
transplant group) 
Transplant 
mWGE 
(n=8: 4 per 
transplant group) 
Transplant Bilat 
(mWGE/hCTX) 
 (n=8: 4 per 
transplant group) 
Transplant 
hCTX 
(n=5) 
Transplant 
mWGE 
 (n=5) 
Transplant Bilat 
(mWGE/hCTX) 
 (n=6) 
          
Graft survival assessed at 12 week post-transplantation 
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4.4 Results 
4.4.1 Graft survival 12 weeks after transplantation 
CV staining was carried out to identify surviving grafts. The presence of 
surviving human xenografts could be confirmed with HuNu staining, however no 
definitive marker could be used to detect surviving mouse transplants. Despite this it 
was clear from CV staining that no mouse transplants survived in any treatment 
group, including CsA treated control animals (Figure 4.1). The percentage of 
surviving transplants in each group is represented in Figure 4.1 and Table 4.2. As 
no transplants of mouse donor tissue survived, analysis was carried out only on 
surviving unilateral or bilateral human transplants from all treatment groups. 
Significantly more hCTX transplants were found to survive in hosts desensitised 
with hCTX than those desensitised with mWGE; χ2 (5, N=39) = 13.65, p < 0.05 
(Table 4.2).  
The volume of surviving human grafts was measured from HuNu staining and is 
also shown in Table 4.2. In order to reduce heterogeneity of variance, log 
transformation was carried out on the data prior to analysis. Graft volumes and the 
number of surviving transplants are displayed in Table 4.2. Representative surviving 
hCTX transplants in CsA treated hosts from each transplant group are shown in 
Figure 4.2. The majority of surviving transplants were very large, with CV staining 
in swirls throughout the striatum. The centres of the grafts were found to contain 
proliferating cells as stained by Ki67 (See Appendix 6). A two-way ANOVA was 
conducted on the transformed data to determine the effect of transplant group and 
treatment on surviving hCTX graft volume. This revealed a highly significant main 
effect of transplant group; F (1, 25) = 15.970, p < 0.001 with larger graft volume 
seen in transplants from group 1, which received the earlier gestation tissue (Figure 
4.4). No significant main effect of treatment was found; F (5, 25) = 0.286, p = 0.916. 
Additionally no interaction was found between transplant group and treatment; 
F (1, 25) = 0.016, p = 0.901, indicating that greater graft volumes observed in hosts 
desensitised with mWGE (Figure 4.3) were due to the donor tissue used in the 
different transplant groups rather than the effect of the treatment (desensitisation 
with hCTX/mWGE or daily CsA). Figure 4.5 shows examples of rat host brain 
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showing the region where an mWGE graft has been lost, and typical staining seen in 
a bilateral graft. 
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Treatment 
group 
Tissue 
Transplanted 
Number of 
surviving human 
grafts (%) 
Number of 
surviving mouse 
grafts (%) 
Mean graft 
volume (µm3) 
DhCTX 
(neonatally) 
hCTX 5/5 (100%) - 30.5x108 
mWGE - 0/6 (0%) - 
Both (bilat) 6/6 (100%) 0/6 (0%) 34.2x108 
DmWGE 
(neonatally) 
hCTX 3/6 (50%) - 128.5x108 
mWGE - 0/6 (0%) - 
Both (bilat) 4/6 (66.7%) 0/6 (0%) 99.8x108 
CsA (from 
transplantation) 
hCTX 8/8 (100%) - 74x108 
mWGE - 0/8 (0%) - 
Both (bilat) 8/8 (100%) 0/8 (0%) 79.2x108 
Table 4.2 Percentage of surviving transplants in hosts desensitised and transplanted 
with hCTX or mWGE, and the mean graft volume of hCTX grafts. 
DhCTX = Desensitised neonatally with hCTX tissue; DmWGE = Desensitised 
neonatally with mWGE tissue; CsA = treated daily with CsA. 
Figure 4.1 Survival of hCTX grafts in hosts desensitised with mWGE or hCTX or 
treated daily with CsA 12 weeks after transplantation. No surviving mWGE grafts 
were found in any group, thus these bars are not shown 
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Figure 4.2 Representative surviving hCTX transplants in hosts treated daily with CsA from 
transplant groups 1 and 2 stained with CV (A,D) and HuNu (B,C,E,F). Transplants from group 1 
(A-C) were found to be significantly larger than those from group 2 (D-F); 
F (1, 25) = 15.970 p < 0.001. Surviving human transplants were large in the majority of cases, in 
particular in group 1 transplants, which had a swirling appearance resembling overgrown, 
proliferating transplants 
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Figure 4.4 Graft volume of hCTX transplants in rat hosts at 12 weeks 
post-transplantation. Transplants were carried out on two separate days (Group 1 
and Group 2) due to availability of human tissue. Hosts received either a unilateral 
transplant of hCTX, or bilateral transplants of both mWGE and hCTX 
Figure 4.3 Graft volumes of hCTX transplants in rat hosts either desensitised with 
hCTX (DhCTX); mWGE (DmWGE) or treated daily with CsA. Hosts received 
either a unilateral transplant of hCTX, or bilateral transplants of both mWGE and 
hCTX. 
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Figure 4.5 Photomicrographs of a CV stained section from a control host treated 
daily with CsA and transplanted with mWGE showing a lack of transplanted cells 
at 12 weeks, and only a needle tract remaining (A,B). A host transplanted 
bilaterally showing no mWGE graft in the left striatum (C,D) and a surviving 
hCTX transplant in the right striatum (D-F). All staining displayed is CV except 
for panel E which shows HuNu staining of surviving human cells. This staining 
was typical of mWGE and bilateral transplants. 
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4.4.2 Host immune response to transplants at 12 weeks 
The immune response was assessed with immuno-staining for both CD8+ and 
CD4+ T cells, and the microglial marker CD11b (OX42). Stains were graded with 
the rating scale described previously, and differences assessed using non-parametric 
Kruskal-Wallis analyses of variance. No significant differences were found in any of 
the immune markers between the three transplant groups (DhCTX, DmWGE, and 
CsA), indicating that surviving transplants in desensitised hosts were likely to 
continue to survive comparably to those receiving daily CsA immune suppression; 
CD4: H (5) = 4.678, p = 0.456; CD8: H (5) = 6.494, p = 0.261; CD11b: 
H (5) = 4.416, p = 0.491. Examples of grading for each stain can be found in Figure 
4.6. Although at 12 weeks post-transplantation no immune response may be 
expected, since the initial inflammatory response to transplants would have subsided 
and rejected transplants would no longer yield a response, these findings confirm 
that transplants in desensitised hosts are not undergoing chronic rejection in the host 
brain. Figure 4.7 and Figure 4.8 show the spread of immune marker grading for 
CD4, CD8 and CD11b in all transplanted hosts, highlighting the lack of variability 
between groups. 
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Figure 4.6 Examples of grades assigned to immune marker staining for CD4+ and CD8+ T cells 
and CD11b+ microglia. No section was assigned a Grade 4 for microglial staining therefore no 
picture is shown. Grade 0 shows no staining in the grafted area, with only a scar from the needle 
seen. Increases in staining for each grade can be seen in and around the grafted area according to 
the rating scale described in Chapter 2. Arrows point to staining in lower grade images. 
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Figure 4.7 Gradings for CD4+ and CD8+ T cells in transplanted rat hosts at 12 weeks post-transplantation. Each circle corresponds to one 
host, with a red circle for rejected transplants. In the case of bilateral transplants, the grade is assigned to the side containing the hCTX 
graft since all mWGE transplants were rejected. Analyses were only conducted to compare surviving transplants. 
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Figure 4.8 Grading for the microglial marker CD11b (OX42) in transplanted rat hosts at 12 weeks post-transplantation. Each circle corresponds 
to one host, with a red circle for rejected transplants. For bilateral transplants, the grade is assigned to the side containing the hCTX graft since 
all mWGE transplants were rejected. Analyses were only conducted to compare surviving transplants. 
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4.5 Discussion 
The aim of the experiment described in this chapter was to determine whether 
desensitisation of the rat host to a neural transplant is specific to the species of the 
foetal donor tissue used; that is, do the cells used for desensitisation and neural 
transplantation need to be from the same species? Host rats were desensitised 
neonatally to either mWGE or hCTX, and a separate group of adult naïve rats were 
treated daily with CsA from one day prior to transplantation for the duration of the 
experiment. Subsequent transplants of hCTX or mWGE were delivered to the adult 
striatum, or a bilateral transplant of both tissue types. Good graft survival was found 
in human to rat transplant groups treated with CsA or desensitised to hCTX, 
confirming previous findings. However, contrary to the original hypothesis, more 
than 50% of hCTX transplants survived in host rats that had been desensitised with 
mouse tissue. The reason for this finding is not clear. Potentially some factors related 
to the neonatal inoculation may have rendered the host immune system more tolerant 
to transplants in general, and this would require further studies using additional 
interspecies transplants to resolve. Alternatively, certain surface antigens on the 
mouse donor tissue may bear sufficient similarity to the human tissue to prevent 
recognition of this transplant by the host immune system. An untreated control 
group, in which hosts receive a neural transplant but no immune suppression or 
neonatal desensitisation, was not included as many such controls have been included 
in previous studies and long term (> 4 weeks) survival has never been seen in a 
single case. However, given the unexpected nature of the result, it would be 
important to replicate this finding with the inclusion of a “no treatment” group to 
confirm that survival of hCTX in hosts desensitised to mWGE was due to this 
desensitisation rather than some other factor. 
In hosts receiving bilateral transplants, the hCTX graft was found to survive in 
all hosts desensitised with hCTX or treated with CsA as well as in 50% of hosts 
desensitised with mWGE. In all of these cases large surviving grafts could be 
identified, of a comparable size to unilateral transplants, despite the simultaneous 
delivery of an mWGE graft, which was subsequently lost. Thus, the presence of 
tissue from a different donor species in the brain apparently had no effect on the 
survival of hCTX transplants. Furthermore, the subsequent loss of mWGE grafts 
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(through whatever mechanism, possibly rejection) did not cause rejection of hCTX. 
Previous reports have shown a second allogeneic or syngeneic CNS graft is likely to 
induce the rejection of both grafts, although this is in a situation in which grafts have 
been delivered sequentially (Widner and Brundin 1993), whereas in the current 
experiments grafts were delivered concurrently.  
No surviving transplants of mouse tissue were found in any treatment group. 
This finding occurred not only in desensitised hosts but also in those treated with the 
conventional immunosuppression regime of daily CsA, which has previously been 
shown to promote survival of a mouse transplant (Pakzaban and Isacson 1994). 
Additionally, neural mouse to rat xenografts have been reported to survive 
previously even in the absence of immunosuppression (Brundin et al. 1985; Daniloff 
et al. 1985a; Daniloff et al. 1985b; Daniloff et al. 1984). The fact that mouse 
transplants were rejected even under immunosuppression suggests a problem with 
the donor tissue. This could be attributed to issues with the cell suspension used for 
transplantation, related to the donor tissue from that specific litter of mice. However 
since the control animals were transplanted in both transplant groups this is unlikely 
to be the case. Alternatively it is possible that there is a problem with the treatment 
of the cells for dissociation to a single cell suspension. Cell suspensions were 
prepared in these experiments using a standard 20 minute trypsin digest prior to 
trituration of the cells. There has been a suggestion that this treatment is too harsh for 
the mouse tissue (Breger, L., personal communication), and that a shorter digest in 
trypsin (e.g. 10 minutes) would improve the survival of tissue following 
transplantation. This raises questions about the preparation of mouse donor tissue for 
transplantation. If this was the case, then mWGE transplants were unlikely to have 
been rejected by the host immune system, rather the cells would not have survived 
the dissociation and transplantation process, in which case contralateral grafts of 
hCTX would not have been affected by rejection of mWGE grafts. To determine 
whether this was the case would require repeating the experiment and assessing 
immune marker staining at an early point after transplantation to characterise the 
immune response. 
In this experiment, human donor tissue was derived from hPF CTX, whereas 
mouse donor tissue was from PF mWGE. Although ideally the same donor tissue 
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would have been used from each species, issues with the availability of human donor 
tissue meant that more hCTX was available for desensitisation and transplantation. 
Whilst hCTX tissue is more abundantly available than WGE for transplants 
investigating the properties of neonatal desensitisation, its use to transplant may not 
necessarily be appropriate to determine the survival of transplants since ultimately 
this will need to be applied to the relevant tissue type. The surviving human 
transplants both from the work in this chapter and Chapter 3 were found to be very 
large. Investigation of this aspect by staining for the mature neuronal marker, NeuN, 
and the proliferative marker, Ki67 (see Appendix 6) showed the presence of 
immature, proliferating cells in the core of the graft. Further staining with 
doublecortin would be helpful, to confirm that these proliferating cells are of a 
neuronal origin, as opposed to connective tissue or meninges, which may have been 
dissected in error. Since the developing cortex would be highly proliferative, there is 
a possibility that the survival of transplants of this tissue may diverge from that 
observed with a different tissue type such as the WGE, and may explain why these 
transplants are more likely to survive in hosts even following desensitisation with 
tissue from a different donor species. 
An additional finding from this study was a difference in graft volume of human 
transplants between hosts transplanted in the first group as compared to the second, 
with larger transplants found in group 1 than group 2. Cells transplanted in group 1 
host animals were derived from a younger foetal donor (CRL 35.5mm) than those in 
group 2 (CRL 46.7mm). Since large differences were observed between the graft 
volumes from these foetal donors, this highlights the variability which may be 
observed dependent on the age of the donor foetal tissue. The effect of this on 
desensitisation and graft survival should be considered in future experiments. Due to 
the scarcity of human foetal tissue, donor tissue of a large age range has been used in 
experiments to investigate desensitisation and graft rejection, since there is no 
intention of assessing functionality of transplanted cells at this stage of the studies. 
However, this experiment and previous studies have suggested that younger donor 
tissue may result in better graft survival following transplantation to the CNS 
(Brevig et al. 2008). This has been demonstrated in both mouse to rat (Zimmer et al. 
1988) and human to rat neural xenografts (Freeman et al. 1995), as well as being 
found in mouse to mouse transplants (see Chapter 6). This has been attributed to the 
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lack of microglial precursor cells in younger donor tissue (Dalmau et al. 1997) which 
may act as donor APCs, since microglial precursors have been shown to express 
MHC antigens and co-stimulatory molecules in vitro, with the ability to stimulate 
naïve T cells (Frei et al. 1987). Since the appearance of larger transplants was 
different to the smaller ones, in that they had a swirling appearance in staining with 
CV similar to overgrowing transplants, there is the potential that this is due to 
differences in dissection between the two donor embryos, in addition to the 
difference in age. 
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4.6 Conclusions and Future Work 
Due to the lack of survival of mWGE transplants and the need for an untreated 
control group it cannot be definitively concluded as to whether desensitisation is 
specific to species type. However, this experiment did show survival of at least half 
of hCTX transplants in hosts desensitised with tissue from a different donor species 
(mWGE). This finding requires further investigation to determine whether this 
outcome is due to desensitisation to an epitope which spans both human and mouse, 
or whether this is due to a more general phenomenon, including comparisons with 
untreated controls and with transplants of WGE rather than CTX. Therefore this 
experiment requires replication with this additional control group and modifications 
to the preparation of mouse donor tissue to aid in survival of transplants. 
A second experiment is currently being planned in order to determine the donor 
specificity of desensitisation to xenogeneic tissue and, in addition, to determine 
whether tolerance to neonatally injected tissue extends beyond the CNS. This could 
provide evidence for the induction of tolerance via an established skin graft method 
as opposed to a CNS transplant which may be considered to be a more protected 
environment than the periphery and thereby promoting survival. It would also be 
possible to use the skin grafting method as an immune challenge for neural grafts. 
Previous studies have shown that if a peripheral skin graft if the same donor tissue is 
applied to an animal which already has a surviving neural graft of tissue from the 
same species (rat to rat), rejection will occur (Duan et al. 1997). It would be 
interesting to determine whether any tolerance induced through neonatal 
desensitisation is strong enough to prevent this phenomenon. In particular since it 
has been shown that the acceptance of neural grafts transplanted into rat neonates is 
not stable and that a peripheral challenge, such as a skin graft, induces rejection at 
later time-points (Pollack and Lund 1990). These experiments were not possible for 
the purpose of this thesis due to the necessary animal licence amendments required 
needing Home Office approval which was not granted within sufficient time to 
conduct the experiment. 
The findings from this chapter have raised questions about whether the standard 
tissue dissociation method used to prepare donor cells for transplantation is too harsh 
for use with mouse tissue. This is addressed to some extent in Chapter 6 and is also 
Chapter 4  Desensitisation with different species (rat) 
108 
the subject of further systematic studies to examine the effect of various treatments 
with trypsin and trituration of mouse WGE on the viability of cells, their phenotype 
in vitro and following transplantation in vivo. Such information will inform the 
design of future experiments to further explore the specificity of desensitisation.
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Chapter 5  
Can mouse hosts be desensitised to human foetal tissue transplants? 
5.1 Summary 
The experiments discussed in this chapter were designed to investigate whether 
mouse hosts could be successfully desensitised neonatally to human primary foetal 
(hPF) neural tissue to allow survival of a neural xenograft in adulthood. Previous 
work in this thesis and from this lab group has demonstrated successful long term 
xenograft survival in rat hosts as a result of desensitisation following an i.p. injection 
of hPF cells in the early neonatal period. It is important to determine whether this 
may be achieved across species and in transgenic mouse models of disease. These 
experiments use a QA lesion model of HD in CD-1 mice neonatally desensitised to 
human neural tissue, treated with CsA, or untreated. Hosts received striatal 
transplants of human or mouse neural tissue to determine whether grafts could 
survive for up to 12 weeks post-transplantation†. 
Experiment 1 compared survival of human xenografts and mouse grafts in 
desensitised and untreated mouse hosts. As poor survival was seen in all groups, 
Experiment 2 included a CsA treated control group, however a lack of transplant 
survival was still observed universally. Desensitisation and transplantation protocols 
were modified in Experiment 3; increasing the number of cells transplanted, and 
reducing the time between lesion and transplant. Varying numbers of cells were used 
for desensitisation, and transplant survival was compared with immunosuppressed 
hosts. As initial staining suggested good survival in mice desensitised with the 
greatest number of cells, Experiment 4 tested even higher cell numbers. However, 
further investigation revealed poor survival of human cells in the majority of hosts. 
This has made it impossible to assess the desensitisation method in mice, but has 
highlighted a general problem with mice as transplant hosts, addressed in Chapter 6. 
                                                          
†
 The experiments described in this chapter are published in NeuroReport (Roberton et al 
2013). The compilation of data reported in the Combined Results section was carried out by 
David Harrison (DJH) for this manuscript. 
Chapter 5  Neonatal desensitisation (mouse) 
110 
5.2 Introduction 
Preclinical testing of human donor cells requires transplantation into rodent 
models of disease in order to assess functional efficacy and confirm safety. Lesion 
models of both PD and HD may be used, allowing behavioural assessment of a 
deficit post lesion to measure any improvement following transplantation. 
Neurotoxic lesion models can replicate some features of disease including relevant 
cell loss and histological changes, resulting in some disease related behavioural 
deficits. Genetic models can provide a more relevant model of some aspects of the 
neuropathological features of a disease, but tend to represent its more extreme forms 
and can also be difficult to standardise. However, in neurodegenerative disease, 
genetic models can more accurately mimic the progressive nature of disruption to 
particular circuitry in the brain. This is relevant in the study of cell transplantation in 
order to identify whether this progressive disease process also affects the 
development and survival of transplanted cells (Nakao and Itakura 2000). 
For a number of years, efficient genetic modification has been established in 
mice, resulting in the development of thousands of genetically modified mouse 
strains, including models of neurodegenerative disease. Several HD models are well 
established, containing insertions of either the full length HD gene, or the expanded 
CAG repeat fragment as discussed in Chapter 1; section 1.1.2, and long term 
assessment of pathology and behavioural phenotypes of a number of these mouse 
lines using an established battery of tests of motor and cognitive deficits is underway 
(for reviews see Brooks and Dunnett (2013); Brooks et al. (2012)). Although a 
number of Tg rat models of neurodegenerative diseases now also exist including 
models for HD (von Hörsten et al. 2003) and PD (See Welchko et al. (2012) for a 
review), the technology for ESC-based gene-targeting in rats is relatively immature 
in comparison (Zheng et al. 2012). Therefore, mouse models of disease currently 
exist in greater numbers and have been more extensively examined than those 
created to date in rats.  
The ability to test human donor tissue in such mouse models of disease would 
open up a variety of Tg tools. For example, investigating the effect of transplanting 
cells into a degenerating environment, as in the case of HD, where differences have 
been observed in immune system activation and inflammation in patients as well as 
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in Tg models (Björkqvist et al. 2008; Ellrichmann et al. 2013; Kwan et al. 2012). 
Mouse models with modifications to the immune system exist in abundance in 
comparison to the rat, thus achieving desensitisation of mice would allow the use of 
these to elucidate the mechanisms underlying the method.  
As in human to rat grafts, there is a need to circumvent xenograft rejection; 
therefore the use of neonatal desensitisation to avoid conventional immune 
suppression would permit full behavioural assessment of transplant function and a 
long term assessment of the cells in vivo to determine whether they are also affected 
by the degenerative disease process. As yet neonatal desensitisation has only been 
validated using rats. Although the desensitisation method has been validated by other 
groups in rat transplant experiments (Singhal et al. 2012; Zhang et al. 2013), there is 
a suggestion that it does not translate well to the mouse (Janowski et al. 2012; Mattis 
et al. 2014). Studies investigating mouse desensitisation have used a range of 
different cell types in different transplant paradigms into different strains and 
species. This suggests the utility of the method could vary dependent on host or 
donor tissue type, and therefore highlights the importance of adequate validation 
with systematic analyses of these variables. 
The primary aim of the experiments described in this chapter was to determine 
whether neonatal desensitisation to neural tissue in mice is sufficient to allow 
survival of a human neural transplant in adulthood. All experiments described in this 
chapter were carried out in QA lesioned CD-1 mouse hosts. This strain was chosen 
as their large litter sizes provide sufficient animal numbers for transplant 
experiments. Additionally, infanticide levels in this strain are low, allowing brief 
separation of pups from the mothers for a neonatal injection without resulting in a 
loss of host animals. Although the CD-1 strain provides a good host for 
transplantation, the majority of genetic models of disease are bred onto a BL/6 
background, and a larger body of work has been carried out in the behavioural 
characterisation of this strain. Therefore although we aim to seek ‘proof of principle’ 
for desensitisation and transplantation protocols in CD-1 mice, ultimately the aim 
would be to successfully transplant into BL/6 hosts and models of disease. An 
additional pilot experiment described in Appendix 7 attempted to investigate the 
potential for neonatal desensitisation in this strain. 
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This chapter includes findings from four mouse transplant experiments 
investigating; i) survival of transplants to the QA lesioned and intact striatum of 
human and mouse foetal tissue in desensitised and naive mouse hosts; ii) survival of 
striatal transplants of human and mouse tissue in desensitised, CsA treated and 
untreated mouse hosts; iii) survival of human xenografts in mice treated with CsA or 
desensitised with three different cell numbers of human foetal tissue, and; 
iv) survival of human xenografts in mice tolerised with increasing numbers of human 
cells. Experiments are described sequentially with a discussion of the outcomes of 
each, and how this drove the design of the subsequent experiment, with a final 
discussion of the findings and conclusions from this chapter. Successful 
desensitisation of mouse hosts could not be demonstrated despite a number of 
modifications to the desensitisation and transplantation protocols, and attempted 
validation in a second strain. However, problems were identified with transplant 
survival even in immune suppressed hosts and those receiving grafts of mouse tissue. 
This is suggestive of a problem with the mouse as a neural transplant host. 
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5.3 General experimental design 
The basic design of all experiments discussed in this chapter was the same, with 
minor modifications depending on the specific aims of each experiment. Figure 5.1 
below outlines the standard design of these studies. 
 
Figure 5.1 Outline of the basic design of mouse desensitisation and transplantation 
experiments 
5.3.1 Dissection and dissociation of hCTX and mWGE 
For xenografts; hPF tissue (8-12 weeks post-conception) was collected from 
mToP and CTX dissected. For mouse tissue grafts; E14 CD-1 mouse foetuses were 
collected and WGE dissected. All tissue was dissociated and prepared as cell 
suspensions. Viability greater than 75% was considered sufficient for tolerising and 
85% for transplantation. 
5.3.2 Neonatal desensitisation and adult transplantation 
To induce desensitisation; mice were injected neonatally with a suspension of 
hPF CTX from postnatal day 0-2 (P0-2) with the exception of the first experiment (i) 
where mice were injected at P3 due to lack of availability of human tissue. In 
standard experiments mice were injected with 1µl of suspension containing 
1x105 cells in DMEM/F12. In experiments testing greater cell numbers animals were 
injected with the total number of cells specified. In the case of an injection of greater 
than 5x105 cells, suspensions were administered in a volume of 2µl. 
As determined by experimental design, adult CD-1 mouse hosts either received a 
unilateral QA lesion to the right striatum, or the host tissue was left intact. According 
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to experimental group, two days to two months later adult mouse hosts received 
transplants into the intact or lesioned striatum of hCTX or mWGE to a total of 3x105 
or 5x105 cells in 2µl. Survival of transplants was assessed 6 to 12 weeks after 
transplantation 
5.3.3 Quantification and statistical analyses 
Positive graft survival was determined through assessment of CV staining of 
1:12 sections by two independent assessors blind to condition. Where possible, 
survival of transplants was confirmed with further immunohistochemical staining of 
HuNu (for xenografts) and a mature neuronal marker (NeuN) for all sections. Due to 
loss of tissue sections in storage at 4oC the host immunological response to 
xenografts could only be assessed for Experiment iv) (see Appendix 5 for details). 
Iba1 microglial staining was graded according to the rating scale detailed in 
Chapter 2. 
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5.4 Experiment i) Striatal grafts of human and mouse tissue in untreated and 
desensitised mouse hosts 
5.4.1 Experimental Design 
A total of 32 (15 female, 17 male) CD-1 mice were either “desensitised” or 
“untreated” and received a transplant of hPF CTX (3x105cells) or E14 mWGE 
(3x105cells) into the intact or QA lesioned right striatum from 8 weeks of age 
(weighing >20g). Mice were desensitised (n=16) neonatally with an i.p. injection of 
1x105 hCTX cells at postnatal day 3 (P3). Untreated mice (n=16) received no 
neonatal injection and were not treated with any other immunosuppression 
throughout the experiment. Two groups of untreated and desensitised animals 
(n=4 per group) were not transplanted and were kept as lesion only controls. Mice 
were perfused at 6 to 12 weeks post transplantation and brains taken for assessment 
of graft survival (Table 5.1). 
Group Treatment Lesion Transplant Time post-transplantation 
Number of 
Mice 
1 Untreated QA hCTX 
6 weeks 4 
12 weeks 4 
2 Desensitised QA hCTX 
6 weeks 4 
12 weeks 3 
3 Desensitised None hCTX 
6 weeks 3 
12 weeks 2 
4 Untreated QA mWGE 8 weeks 4 
5 Untreated QA None N/A 4 
6 Desensitised QA None N/A 4 
Table 5.1 Mouse hosts included in each condition for Experiment i) 
Chapter 5  Neonatal desensitisation (mouse) 
116 
5.4.2 Results 
To identify surviving grafts in transplanted hosts, sections from all animals were 
first stained with CV. Confirmation of transplanted human cells was achieved using 
immunohistochemical staining for HuNu. Staining of Nissl bodies with CV showed 
dense staining in the grafted area in a few animals, suggestive of surviving human 
grafts (Figure 5.2; A, B, E, and F). However, the majority was found in the 
immediate vicinity of the needle track resembling scarring rather than a larger, 
healthy looking graft (Figure 5.2; A and E). Comparable staining with CV could 
also be seen in animals which received lesions only and no transplants (Figure 5.2; 
C, D, G and H). Subsequent staining with HuNu did not clearly show positive 
staining of human cells, thus poor graft survival was observed across all groups. One 
animal appeared to clearly have a surviving graft in CV sections (Figure 5.2; B, F) 
but HuNu showed high background staining causing difficulty in the detection of 
specific positive staining of human cells (Figure 5.3). Additional stains could not be 
carried out due to contamination and degradation of all tissue sections stored in TBZ 
at 4oC (See Appendix 5). 
Surviving grafts were counted based on careful examination of CV staining due 
to unreliability of HuNu staining and are outlined in Table 5.2. Due to problems 
with HuNu staining and a lack of specific antibody or cell label for mouse grafts, it is 
possible that numbers of surviving grafts are overestimates. Figure 5.4 shows 
examples of CV staining in hosts receiving transplants of mouse tissue, including the 
only surviving transplant (A). This surviving transplant was small and thin in 
appearance and could not be definitely demonstrated to contain surviving 
transplanted cells due to the lack of specific label. Despite the potential for 
overestimation of surviving transplants, only very few were identified, therefore no 
statistical analyses were carried out.  
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Treatment Lesion Transplant 
Weeks post TX/ 
Total % 
6 8 12 
None QA hCTX 0/4 
 
1/4 1/8 12.5 
Desensitised QA hCTX 1/4 
 
1/3 2/7 28.5 
Desensitised None hCTX 1/3 
 
0/2 1/5 20 
None QA mWGE 
 
1/4 
 
1/4 25 
Table 5.2 Surviving transplants in mouse hosts from Experiment i) 
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Figure 5.2 Photomicrographs of CV stained sections from mice 
tolerised with hCTX and transplanted with hCTX into the unlesioned 
striatum at 12 weeks post -transplantation (A, B, E, F), and lesion only 
controls (C, D, G, H). Staining that can be seen in animals with no 
transplants (G,H) was comparable to that in some transplanted animals 
(A), suggestive of only a needle tract. Staining in one host animal 
showed a clear large surviving graft, which had filled the striatum but 
did not seem to integrate, pushing into the ventricle (B, F). 
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Figure 5.3 Staining for CV (A, B) and HuNu (C, D) in sections from 
mice desensitised and transplanted with hCTX (unlesioned). Lower 
power images are inset. HuNu staining showed a high background, 
making it hard to distinguish positive staining of grafted cells.  
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Figure 5.4 Photomicrographs of CV stained sections from mice 
transplanted with mWGE. A) shows a small potential surviving mouse 
transplant, and B) shows a transplant which has been rejected, with no 
clear surviving graft. Lower magnification images are inset, and higher 
magnification is displayed to the right 
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5.4.3 Discussion 
Low numbers of surviving transplants were identified in Experiment i) through 
CV staining, however these could not be confirmed with HuNU staining. One 
transplant in a host tolerised with hCTX appears to have definitely survived to 12 
weeks post transplantation, as a large dense area of staining can be seen on Nissl 
stained sections which is comparable to that seen in rat transplants. However, 
positive HuNu staining in these sections could not be verified as staining is too dark 
to distinguish from background. Additionally, survival of mouse transplants could 
not be confirmed due to the lack of marker for mouse donor cells. Although staining 
with NeuN and DARPP-32 (MSNs) in a QA lesioned mouse brain may have 
revealed the presence of a surviving graft, this was not possible due to the loss of 
tissue sections as discussed in Appendix 5. Therefore although one surviving mouse 
graft was identified in this experiment based on comparison with previous surviving 
mouse transplants (Precious, SV. unpublished data; Kelly et al. (2007)) it is not 
possible to confirm this with CV staining alone due to this lack of definitive 
labelling. This surviving graft was found to be thin and pencil-like in appearance 
with the only staining possibly representing transplanted cells to be close to the 
needle track and cell deposit rather than showing graft development and integration 
into the host tissue as may be expected in rat tissue transplants. 
A number of problems can be identified from the findings of Experiment i). The 
lack of an immunosuppressed control group (e.g. treated with CsA) does not allow 
determination of whether human grafts would have survived if hosts were treated 
with a conventional immunosuppressant as compared to desensitised hosts. 
However, the fact that survival of mouse tissue was also found to be poor suggests 
that a xenograft would be most likely rejected. Additional problems are evident in 
the identification of surviving grafts. CV staining of Nissl bodies appears to be an 
unreliable method alone of detecting surviving grafts, since staining in these sections 
was not distinguishable from lesion only controls and grafts which were possibly 
rejecting. In this instance; staining with a human specific antibody proved 
problematic due to high background staining. This is likely due to cross-reactivity of 
the anti-mouse secondary antibody used. Sections in this experiment also appear 
underfixed, suggestive of a problem with perfusion. This also may be related to the 
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deterioration of remaining sections which has prevented subsequent staining of 
stored brain sections. Therefore numbers of surviving transplants may be 
overestimates due to the lack of a definitive marker for transplanted cells. 
The findings of this experiment prompted the design of Experiment ii) in which 
the survival of human xenografts in tolerised hosts was compared to survival in CsA 
treated and untreated hosts. Since Experiment i) showed poor survival; a CsA treated 
group was included to identify whether poor survival of xenografts was due to a lack 
of successful desensitisation, or poor transplant survival overall even in immune 
suppressed hosts. As mouse graft survival was also poor; an untreated and CsA 
treated mouse transplant group were included to determine whether immune 
suppression would promote survival of an allo-transplant of mWGE. 
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5.5 Experiment ii) Striatal mouse and human grafts in untreated, desensitised, 
and CsA treated mouse hosts 
5.5.1 Experimental Design 
A total of 51 CD-1 mice were included in this experiment (25 male and 26 
female). 20 mice were injected neonatally with 1x105 cells (hCTX) with remaining 
animals receiving no neonatal injection. At 6-8 weeks of age all mice received 
unilateral quinolinic acid lesions to the right striatum. Grafts of hCTX or mWGE 
(3x105 cells) were then transplanted into the lesioned striatum of desensitised and 
untreated mice. Those mice that were not desensitised were treated daily with CsA 
starting from the day prior to transplantation, or received no treatment. Graft survival 
was assessed at 6 weeks post-transplantation for all groups, with an additional 
desensitised group kept until 10 weeks post transplantation. The design is detailed in 
Table 5.3 below. 
Group Treatment Transplant Time post-transplantation Number  
1 Desensitised hCTX 
6 weeks 10 
10 weeks 10 
2 CsA hCTX 6 weeks 11 
3 Untreated hCTX 6 weeks 5 
4 CsA mWGE 6 weeks 7 
5 Untreated mWGE 6 weeks 7 
Table 5.3 Treatment and transplant conditions for mice in Experiment ii) 
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5.5.2 Results 
Numbers of surviving transplants based on CV staining in all groups are 
outlined in Table 5.4. As with Experiment i) some dense staining was seen in the 
graft area, mainly as a scar or needle track in all transplant groups (Figure 5.5, 
Figure 5.6). In mice receiving grafts of mWGE tissue a number of surviving 
transplants were identified from CV staining (5/7), however these were small pencil 
grafts and could potentially have been rejected transplants (Figure 5.5). Transplants 
of mouse tissue delivered to hosts treated with daily CsA did not yield improved 
survival, in fact survival was found to be lower than those in untreated hosts 
(1/7 - Table 5.4) 
In hosts receiving xenografts of hCTX tissue; HuNu immunohistochemistry in 
desensitised and CsA treated xenografted hosts revealed positive staining in only 
three grafts (Table 5.4; Figure 5.6); two in desensitised animals, and the other in a 
host treated with CsA. In CsA treated animals, a number of sections showed dense 
staining with CV, however the majority resembled rejecting transplants with 
vascularisation and often damage to the tissue (Figure 5.7)  
Treatment Lesion Transplant 
Number of surviving grafts 
(weeks post TX) Total % 
6 weeks 10 weeks 
Desensitised 
hCTX QA hCTX 2/10 1/10 3/20 15 
CsA QA hCTX 7/13 - 7/13 54 
None QA hCTX 1/5 - 1/5 20 
CsA QA mWGE 1/8 - 1/8 13 
None QA mWGE 5/7  5/7 71 
Table 5.4 Surviving transplants in mouse hosts from Experiment ii) based on CV 
and HuNu staining of sections. 
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Figure 5.5 CV stained sections from mouse to mouse striatal grafts in two untreated 
hosts (A-F). Grafts are small and pencil-like in structure, possibly only representing 
rejected cells. Deposits of haemosiderin could be seen in a number of grafted areas 
(arrowheads in F). 
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Figure 5.6 Human to mouse xenografts in hosts desensitised and transplanted with hCTX at 6 (A, B, E, F, I, J) and 10 weeks 
post transplantation (C, G, K) or treated daily with CsA at 6 weeks post transplantation (D, H, L). Sections are stained with 
CV(A-H) and HuNu (I-L). Positive staining could only be seen in three surviving transplants and was very hard to distinguish 
from background (I,J,L). Staining resembling transplants on CV sections did not always result in positive staining with HuNu
(G,K) 
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Figure 5.7 Photomicrographs of CV stained sections from a mouse host transplanted with hCTX and treated daily with CsA. CV staining 
resembles rejecting transplants with badly vascularised and necrotic appearing dense staining in the grafted area 
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5.5.3 Discussion 
Experiment ii) was designed to compare the survival of xenografts in 
desensitised mouse hosts to those treated daily with CsA. As problems have been 
experienced previously in graft survival in mice (Experiment i)), immune suppressed 
controls transplanted with hPF cells were included to ensure any lack of survival was 
not due to the grafting protocol itself. Therefore the aim was to determine whether 
these parameters could be used to induce successful desensitisation to hPF tissue in 
mouse hosts. Additionally due to poor survival of mouse grafts in Experiment i), two 
groups of host animals in this experiment also received transplants of mWGE, one of 
which received daily treatment with CsA. 
Results from CV staining in sections from animals in xenograft groups suggested 
some survival of grafts in desensitised hosts as well as those treated with CsA. 
However, positive human specific staining (HuNu) could only be confirmed in a 
few. In view of these problems, in future experiments staining of immune markers is 
required to determine whether dense CV staining is observed due to an infiltration of 
immune cells as opposed to surviving transplanted tissue. Unfortunately this could 
not be carried out in this case due to degradation of tissue as described previously 
(Appendix 5). In mouse tissue transplant groups some survival was seen, however 
as in Experiment i) grafts were very small resembling needle tracks. Additionally 
these thin grafts appeared unhealthy and possibly rejecting, with deposits of 
haemosiderin clear on CV stained sections. CsA treatment did not improve the 
survival of mouse grafts in this experiment, with only one surviving transplant in this 
group.  
Since previous successful neonatal desensitisation has been shown only in the 
SD rat, it is possible that the method may need to be modified for successful 
desensitisation to be achieved in the mouse. Furthermore, poor survival of mouse 
tissue transplanted to the mouse brain suggests the grafting protocol itself may also 
require modification. The remaining experiments in this chapter address 
modifications to desensitisation protocols, by testing whether using an increased 
number of cells for desensitisation of hosts improves survival of subsequent 
transplants. As all previous successful studies have been carried out in the rat, it is 
possible that a different optimum cell number is required. 
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5.6 Experiment iii) Striatal xenografts in mouse hosts treated with CsA or 
desensitised with varying numbers of hPF cells 
5.6.1 Experimental Design 
CD-1 mice (40) were injected neonatally with 1x104; 1x105 or; 5x105 cells 
(hCTX) or received no injection. At 6-8 weeks mice received unilateral quinolinic 
acid lesions to the striatum and were grafted 8 days later with 5x105 cells (hCTX). 
The fourth group of animals was treated daily with CsA starting from the day before 
transplantation. Half of each group was taken at 6 weeks post-transplantation to 
assess graft survival. Remaining animals were kept until 12 weeks post-
transplantation (Table 5.5) 
P0
-
2 hCTX tissue (1x104cells) 
injected i.p. (n=6) 
hCTX tissue 
(1x105 cells) 
injected i.p. 
(n=11) 
hCTX tissue 
(5x105 cells) 
injected i.p. 
(n=11) 
No neonatal 
injection. Treated 
daily post-TX with 
CSA (n=12) 
8-
12
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Animals sacrificed and brains cut for histological examination 
Table 5.5 Design of Experiment iii), to validate the neonatal desensitisation method 
in the mouse using different cell numbers for neonatal injections. Hosts were 
desensitised between P0-2, received QA lesions from 8-10 weeks of age, and were 
unilaterally transplanted with hCTX 7 days post-lesion. Survival was assessed at 
either 6 or 12 weeks post-transplantation. 
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5.6.2 Results 
Initial investigation of CV staining suggested some graft survival in all groups, 
with much healthier looking staining than observed in previous experiments (Figure 
5.8, A-C, G-I). This was primarily observed in sections from animals which had 
been neonatally desensitised with the highest number of cells (5x105). However, this 
was again not reflected in HuNu staining, which showed one large graft, and little 
staining on other transplanted sections where only a few positive cells could be seen 
in contrast to the apparently large graft indicated by CV (Figure 5.8, D-F, J-L). Total 
numbers of surviving transplants are listed in Table 5.6.  
Cells injected 
neonatally/treatment 
Number of surviving grafts 
Total (%) 
6 weeks 12 weeks 
5x105 0/6 1/5 9% 
1x105 2/6 0/5 18% 
1x104 0/3 1/3 16% 
CsA 2/6 3/6 41% 
Table 5.6 Number of surviving grafts in different transplant groups from 
Experiment iii) based on CV and HuNu staining. 
Other methods of detection of transplanted human cells were unsuccessful as in 
Experiment ii). Problems with high background staining were again experienced 
with this mouse tissue. A number of attempts were made to reduce this via the 
methods described in Table 5.7. The most successful method of accurate detection 
of transplanted human cells was found to be by using a biotin conjugation kit 
(Lightning Link, Innova Biosciences) to avoid the use of the anti-mouse secondary; 
reducing background staining (Figure 5.9). Despite these improvements to staining 
protocols, CV was still the main method of detection of surviving transplants, again 
suggesting overestimates may have been made in the number of surviving 
transplants, especially in the mouse graft groups. Surviving mouse transplants were 
small and pencil like, often with haemosiderin deposits. They could not be confirmed 
as surviving transplants and it is possible they show scarring and rejecting or rejected 
transplants with infiltration of host immune cells. No differences were observed in 
sections from hosts sacrificed at 6 or 12 weeks post transplantation (4/21 vs 5/19 
across all treatment groups for each survival time). 
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Figure 5.8 CV Staining in mouse hosts transplanted with hCTX after 
desensitisation with 5x105 hCTX cells (A-C), or daily treatment with CsA 6 weeks 
after transplantation (G-I). CV staining appeared to show a number of surviving 
transplants however this was not confirmed with HuNu staining (D-F), where only a 
few positive cells could be seen (F-Arrowheads). G-L Shows a surviving transplant 
with clear positive HuNu staining. 
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Method Finding 
Alternative antibody 
Human NCAM High background for all, still not 
possible to detect/quantify 
surviving human cells 
SC121 
NF70 
Fluorescent secondary – May be clearer to 
identify positive cells than with DAB High background, as above 
Increase quench time to reduce binding to 
endogenous peroxidases No noticeable improvement 
Block with non-biotinylated anti-mouse 
secondary to bind non-specific binding sites 
Some reduction in background but 
still not possible to detect/quantify 
Antigen retrieval No improvement 
Biotin conjugate HuNu antibody 
(Lightning Link Biotin Conjugation Kit) 
Reduced background and 
identification of surviving human 
cells (Figure 5.9) 
Table 5.7 Methods tested to improve immunohistochemical staining of transplanted 
human cells in mouse tissue 
Figure 5.9 HuNu staining with biotinylated anti-mouse secondary (A, B) or with 
direct biotin conjugated primary and no secondary antibody (C, D) in two surviving 
human transplants in tolerised mice. Direct biotin conjugation reduced background 
staining and allowed clearer detection of human cells. 
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5.6.3 Discussion 
For Experiment iii) protocols were modified to attempt to improve the survival 
of striatal xenografts. The number of cells neonatally injected was varied to 
determine the optimum number required to promote graft survival in this species. 
Other examples of the induction of neonatal tolerance in mice have used large 
numbers of spleen cells (e.g. 1.5x107 – 1x108) injected neonatally (Ando et al. 1991; 
Peiguo et al. 2012), and studies suggest injecting larger cell numbers increases the 
potential of inducing tolerance (Peiguo et al. 2012). Successful induction of 
tolerance in neonatal hosts is thought to be dose-dependent, with the injection of low 
numbers of cells resulting in the opposite effect; priming of CTL (Adkins et al. 
2004). This difference is thought to be due to the ratio between the number of 
injected donor cells and the number of circulating potentially responsive T cells 
within the host. To induce tolerance, all T cells which may be responsive must be 
switched off (Ridge et al. 1996). As successful neonatal desensitisation to neural 
transplants has to date been demonstrated using injections of 1x105 human cells 
(Kelly et al. 2009b) in rats this is the number of cells which has been used as 
standard for the experiments in this thesis. It may be that injecting a higher or lower 
number of cells produces more consistent desensitisation and this could account for 
variability even in rat transplant experiments. 
Additional modifications were made to the transplant protocol itself to attempt 
to improve graft survival. A higher number of cells were transplanted; 5x105 as 
opposed to 3x105, to improve the likelihood of survival of donor cells. Recent 
findings from our laboratory group have also suggested that grafting into the mouse 
striatum soon after the lesion (7-10 days) increases the chances of survival, agreeing 
with reports from others suggesting that a shorter time between lesion and transplant 
may be beneficial (Johann et al. 2007). In this study, allogeneic NSC transplants 
were delivered to the QA lesioned mouse striatum 2, 7 and 14 days after the lesion. 
Although looking at relatively small animal numbers, the authors reported some 
astrogliosis and microglial activation 2 days after the lesion which was significantly 
elevated at 7-14 days. Larger surviving grafts were found in early transplants which 
were attributed to this, suggesting that a change in morphology of microglia may 
indicate a switch from a neuroprotective to neurotoxic role. Earlier grafting time-
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points were therefore used in this experiment as an additional attempt to improve 
graft survival by avoiding potential neurotoxic effects of activated microglia 
following the lesion. 
On initial investigation of CV stained sections from this experiment, it was 
thought that a number of transplants had survived and primarily in hosts which had 
been injected neonatally with the highest number of cells (5x105). This would be in 
line with previous research into neonatal tolerance, demonstrating the induction of 
tolerance to allogeneic skin grafts in adulthood following a neonatal injection of a 
suspension of a high number of cells (between ~1.5x106 and 107) (Adkins et al. 
2004; Modigliani et al. 1997; Ridge et al. 1996; West et al. 1994). Based on this CV 
staining, which was suggestive of good transplant survival, Experiment iv) was 
started, in which the number of cells injected neonatally was increased further. 
However HuNu staining from Experiment iii) was subsequently found to be 
minimal, as in previous experiments. It was unclear whether this was due to 
problems with immunohistochemical staining protocols or due to a lack of surviving 
human cells, since CV staining was convincing as to the presence of surviving grafts. 
In order to identify why this may be the case; antibodies for a panel of immune 
markers were tested. Sections from this experiment, as well as from a pilot 
experiment carried out with BL/6 mouse hosts were used to evaluate these stains. 
Details for this pilot experiment can be found in Appendix 7, in which BL/6 mouse 
hosts were desensitised with human tissue to determine whether successful 
transplant survival could be promoted in this strain of mouse. Although survival was 
again poor, this allowed the detection of an intense infiltration of microglia in the 
transplanted area corresponding to the CV staining. This highlights a potential 
problem with the use of CV staining in the detection of transplanted cells where 
there is no specific antibody or cell label available, and suggests that a lack of 
HuNu+ cells in these “graft” areas is due to an elevated inflammatory response. 
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5.7 Experiment iv) Striatal xenografts in mouse hosts desensitised with hPF cell 
numbers increased above Experiment iii) 
5.7.1 Experimental Design 
Four litters of mice (n=40; 21F, 19M) were injected neonatally with a 
suspension of differing numbers of cells from hCTX tissue (Table 5.8). Hosts either 
received QA lesions to the right striatum in adulthood (n=20), or the tissue was left 
intact (n=20). This was followed by a transplant either 2 or 8 days later of hCTX 
tissue (5x105 cells) as in previous experiments. All groups were split equally 
between desensitisation, lesion and transplant conditions. Survival was then assessed 
12 weeks after transplantation.  
P0
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2 hCTX tissue 
(5x105 cells) 
injected i.p. 
(n=11) 
hCTX tissue 
(1x106 cells) 
injected i.p. 
(n=11) 
hCTX tissue 
(2.5x106 cells) 
injected i.p. 
(n=10) 
hCTX tissue 
(5x106 cells) 
injected i.p. 
(n=11) 
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Animals sacrificed and brains cut for histological examination 
Table 5.8 Design of Experiment iv) Desensitisation of mouse hosts with large 
numbers of hCTX cells  
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5.7.2 Results 
Sections were stained with CV to identify surviving grafts. Subsequent staining 
with HuNu (biotin conjugated) revealed few surviving grafts overall (10%) despite 
additional modifications to the desensitisation and transplantation protocols. 
Numbers of surviving grafts are displayed in Table 5.9. The greatest number of 
surviving grafts were seen in animals desensitised with the lowest number of cells 
(5x105), however as there were still only 2 out of a total of 10 transplanted this 
cannot be considered to be conclusive. Figure 5.10 shows the largest surviving graft. 
Some sections from other animals showed staining with CV; however no human 
cells could be detected with immunohistochemical staining for HuNu. These are 
displayed in Figure 5.11 in comparison to the positive staining found in the largest 
transplant.  
Cell number injected 
neonatally Lesion 
Number of surviving 
grafts Total % 
5x106 
QA 1/5 
10% 
None 0/5 
2.5x106 
QA 1/4 
11% 
None 0/5 
1x106 
QA 0/6 
0% 
None 0/5 
5x105 
QA 1/5 
20% 
None 1/5 
  Total 10% 
Table 5.9 Numbers of surviving xenografts in desensitised mice from Experiment 
iv) 
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Figure 5.10 Surviving human graft 12 weeks after transplantation in a mouse 
tolerised with 5x105 human foetal neural cells. A) shows a series of sections stained 
with CV with the grafted area outline. B) shows comparable sections stained with 
HuNu, showing surviving transplanted human cells. Few surviving transplants were 
found but were often large like this one, spanning the whole striatum 
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Figure 5.11 Sections from mice tolerised with 5x106 (A,E,I), 2.5x106 (B,F,J), 1x106 (C,G,K) and 5x105 hCTX cells (D,H,L) stained 
with CV (A-H) and HuNu (I-L). Positive HuNu Staining can be seen in L, other sections show either no staining, or dead 
cells/scarring as in J despite the appearance of surviving transplants on CV stained sections 
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Figure 5.12 Iba1 staining of microglia in the grafted area in desensitised mice. Staining shows microglial infiltration into the grafted 
area in sections where no surviving human cells were identified (A-C, E-G, I-K) with an activated appearance (I). Staining was still 
increased around the area of a surviving transplant, however the majority of cells resembled ramified resting microglia (D, H, I) 
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To study the immune response to neural xenografts, a 1:12 series of sections was 
stained for the microglial marker Iba1. The extent of immunoreactivity was graded 
according to the rating scale used previously (Duan et al. 1995; Larsson et al. 1999). 
This is presented in Figure 5.13, showing a strong microglial response to hCTX 
transplants in desensitised hosts. In particular, in the case of rejected grafts dense 
infiltration of activated microglia was observed correlating with the graft area as 
shown in CV stained sections (Figure 5.12 A-C, E-G, I-K) as compared to the 
ramified microglia observed surrounding the surviving transplant in Figure 5.12 
(D,H,L). 
Figure 5.13 Iba1 immunoreactivity showing microglial activity around 
the grafted area in mouse hosts transplanted with hCTX following 
desensitisation with varying numbers of cells. Each circle corresponds to 
one host animal, with red circles showing surviving transplants 
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5.7.3 Discussion 
Mouse hosts included in this experiment were desensitised neonatally with 
large numbers of hCTX cells in order to attempt to promote the survival of human 
xenografts subsequently transplanted to the adult striatum. This experiment was 
started during the assessment of data from Experiment iii), when it was thought that 
desensitisation using a higher number of cells was successful. In line with previous 
data, showing that very large numbers of allogeneic cells injected neonatally induced 
tolerance to transplants of tissue from the same strain of mouse (Adkins et al. 2004; 
Modigliani et al. 1997; Ridge et al. 1996; West et al. 1994), up to 5x106 hCTX cells 
were injected neonatally. Experiment iii) attempted to improve graft survival by 
transplanting 10 days after the lesion due to previous data from this group suggesting 
that this timepoint improved survival into mouse hosts (unpublished data). A recent 
study tested the optimum time for delivery of cell transplants into the QA lesioned 
mouse striatum with stem cells transplanted at 2, 7 and 14 days post-lesion (Johann 
et al. 2007). The authors found that the best survival was observed in transplants 
delivered 2 days after the lesion, and suggest this to be due to the presence of only 
moderate host astrocytic and microglial activation at this time-point as compared to 
the others. Therefore, in this experiment equal numbers of hosts either received no 
lesions, or were transplanted only 2 or 8 days post-lesion.  
Assessment of graft survival, however, showed very few surviving grafts 
(10%) overall. Data suggests that, in fact, the lowest number of cells used for 
neonatal desensitisation (5x105) promoted the best survival. However since there 
were still only 2 surviving grafts identified in this group it is more likely that 
desensitisation was not successful overall. With regards to the lesion conditions; 
again since survival was so low it was impossible to attribute any survival 
differences to the time transplants were delivered after the lesion, or indeed whether 
animals received QA lesions at all.  
The host immune response was studied through subjective quantification of 
microglial staining. A dense infiltration of activated microglia was observed in a 
number of transplants, the majority of which had not survived. This finding was 
consistent with the staining observed in a study of hCTX transplant survival in 
desensitised BL/6 hosts (Appendix 7). Together these findings suggest an effect of 
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the inflammatory response in rejection of transplants to the mouse striatum, which 
agrees with the findings from Experiments i-iii), in which CsA treatment did not 
improve graft survival.  
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5.8 Combined Results 
The results of each experiment for this chapter have been reported individually 
showing small numbers of surviving transplants in all experiments. Here the data has 
been compiled together from groups testing the same transplant conditions in order 
to identify any trends. Table 5.10 shows all of these data grouped by treatment and 
lesion/transplant condition. Additionally, total numbers of surviving transplants are 
calculated for both mouse grafts (7/18) and xenografts (27/137). Graft survival is 
grouped together irrespective of the time between lesion and transplant, and the time 
post-transplant at which survival was assessed. These data highlights the poor levels 
of survival in transplanted mice, despite the expectation that mouse tissue transplant 
groups, desensitised groups, and CsA treated groups may all tolerate surviving 
transplants. 
5.8.1 Effect of treatment type on transplant survival 
Comparing graft survival following treatment with CsA, neonatal desensitisation 
with hCTX (all cell numbers), and untreated hosts showed no difference in survival 
between desensitised animals and those receiving no treatment (16% and 15% 
respectively; Figure 5.14). Mice treated with CsA showed the highest rate of 
xenograft survival (46%) as compared to desensitised or untreated hosts. The effect 
of CsA treatment on both mouse graft and human xenograft survival is compared in 
Figure 5.15. Treatment with CsA did improve survival of xenografts as compared to 
untreated hosts, however only increasing survival up to 48%, as compared to 18% in 
untreated hosts. However, hosts receiving mouse tissue transplants which were 
treated with CsA daily had lower numbers of surviving grafts than those which were 
untreated (12.5% vs 54.5%). 
5.8.2 Desensitisation with varying cell numbers 
Desensitised hosts in Experiments iii) and iv) received neonatal injections of 
varying numbers of hCTX cells (between 1x104 and 5x106) followed by transplants 
in adulthood of hCTX tissue (5x106 cells). Low survival was seen in all transplant 
groups, therefore data were not statistically analysed. Figure 5.16 shows the data 
from these experiments, suggesting that graft survival is optimal using around 1x104 
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and 1x105 cells and poorer with the use of higher cell numbers to desensitise, 
although these are only based on very low numbers of surviving transplants. 
5.8.3 Transplants to the lesioned or intact striatum 
A range of different lesion and transplant designs were used in the experiments 
in this chapter. Some transplants were delivered to the intact striatum, whereas the 
majority were delivered into QA lesioned hosts. Again, although surviving transplant 
numbers were not high enough to elucidate whether this had a statistically significant 
effect on graft survival, data compiled from all experiments and represented in 
Figure 5.17 suggests that lower numbers of grafts survived when transplanted to the 
intact striatum. However; as discussed in Experiment i), since CV staining in lesion 
only animals was often observed to be comparable to that found in transplanted hosts 
and positive identification of surviving transplants was not obvious, firm conclusions 
cannot be drawn. 
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Treatment group Number of cells for desensitisation Lesion type 
Transplanted 
tissue type 
Number of cells 
transplanted 
Number of grafts surviving 
(% of grafts surviving) 
DhCTX 1 x 104 QA hCTX 5 x 105 1/6 (17%) 
DhCTX 1 x 105 QA hCTX 5 x 105 2/11 (18%) 
DhCTX 5 x 105 QA hCTX 5 x 105 1/16 (6%) 
DhCTX 5 x 105 - hCTX 5 x 105 1/5 (20%) 
DhCTX 1 x 106 QA hCTX 5 x 105 0/6 (0%) 
DhCTX 1 x 106 - hCTX 5 x 105 0/5 (0%) 
DhCTX 2.5 x 106 QA hCTX 5 x 105 1/4 (25%) 
DhCTX 2.5 x 106 - hCTX 5 x 105 0/5 (0%) 
DhCTX 5 x 106 QA hCTX 5 x 105 1/5 (20%) 
DhCTX 5 x 106 - hCTX 5 x 105 0/5 (0%) 
DhCTX 1 x 105 QA hCTX 3 x 105 5/27 (19%) 
DhCTX 1 x 105 - hCTX 3 x 105 1/5 (20%) 
- - QA hCTX 3 x 105 2/13 (15%) 
CsA - QA hCTX 3 x 105 7/13 (54%) 
CsA - QA hCTX 5 x 105 5/12 (42%) 
- - QA mWGE 3 x 105 6/11 (55%) 
CsA - QA mWGE 3 x 105 1/8 (12.5%) 
  
Total hCTX survival 
Total mWGE survival 
27/137 (20%) 
7/18 (39%) 
Table 5.10 Data compiled from Chapter 4, showing number of surviving transplants in each group and total number of surviving transplants 
across groups. hCTX = human embryonic cortex, mWGE = mouse embryonic whole ganglionic eminence, QA = quinolinic acid lesion, DhCTX 
= desensitisation with hCTX cell suspension, CsA = immunosuppression with daily injection of cyclosporine A. (Reproduced from Roberton et 
al 2013) 
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Figure 5.14 Comparison of treatment groups in mice receiving xenografts 
of hCTX to the striatum. Survival percentages are displayed at the base of 
bars, with the number of hosts in each group at the top. 
Figure 5.15 Comparison of CsA immunosuppression in mWGE and hCTX
transplant groups. Survival percentages are displayed at the base of bars, 
with the number of hosts in each group at the top. 
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Figure 5.16 Comparison of graft survival in mouse hosts desensitised with 
a range of cell numbers. Survival percentages are displayed at the base of 
bars, with total numbers shown at the top. 
Figure 5.17 Survival of transplants of allogeneic and xenogeneic tissue 
into the lesioned and unlesioned mouse striatum. Survival percentages are 
displayed at the base of bars, with total numbers shown at the top. 
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5.9 Chapter Discussion 
The aim of this chapter was to validate the neonatal desensitisation method for 
use in mouse hosts. It was hypothesised that mice injected (i.p) neonatally with cell 
suspensions of hPF tissue would show greater survival rates of subsequent neural 
transplants of the same tissue type than those mice which were untreated. The 
combined results from these experiments do not show successful desensitisation of 
CD-1 mouse hosts, and highlight a problem with poor survival of both mouse grafts 
and human xenografts in the mouse striatum. 
5.9.1 Desensitisation in mouse hosts 
Experiment i) aimed to test the survival of human xenografts in hosts which had 
either been desensitised to human tissue in the neonatal period or untreated. A mouse 
transplant group was included to confirm the success of the transplantation protocol 
itself, however due to the initial assumption that xenograft survival in immune 
suppressed hosts was consistently successful; a CsA treated group was not included 
in this experiment. Data showed poor graft survival in desensitised hosts, with 
positive staining of human cells hard to identify. Due to the absence of a CsA treated 
control group, it was not possible to confirm whether this poor graft survival could 
be attributed to the unsuccessful desensitisation of hosts, or to problems with donor 
tissue or other aspects of the xenograft procedure. There was also poor survival of 
mouse transplants, potentially indicating a problem with the transplant procedure 
more generally. 
In order to address these problems, Experiment ii) included an immune 
suppressed control group, receiving daily injections of CsA (10mg/kg) to inhibit the 
T cell response to transplanted cells. A group of hosts in this experiment also 
received transplants of mouse donor tissue from the same strain, half of which were 
treated with CsA to try and promote survival. Again, poor survival was found in all 
groups. Survival of mouse grafts was not improved by CsA treatment, and in fact 
appeared worse than in untreated hosts. CsA treatment also did not promote survival 
in xenografted hosts. A poor effect of CsA as an immunosuppressant in neural 
transplantation has been reported previously (Jablonska et al. 2013; Larsson et al. 
2001b; Walczak et al. 2004), however in our hands the use of CsA promotes fairly 
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consistent transplant survival in rat hosts. Since transplant survival was poor in all 
groups, including those receiving allogeneic tissue, a number of modifications were 
made to attempt to improve transplant survival. This included adjusting the number 
of cells transplanted and the time between lesion and transplant, as discussed below. 
Experiments iii) and iv) tested the use of increased number of cells for 
desensitisation of neonatal mouse hosts. As discussed this was based on previous 
literature on neonatal desensitisation in mice to peripheral transplants of allogeneic 
tissue. Despite success using this method, it has not yet been successful using 
xenogeneic tissue. This could be due to species specific differences between donor 
and host tissue, for example due to the presentation of antigen on donor cells by 
foreign MHC which may not be recognised by the host. By taking advantage of a 
transgenic mouse model expressing the human MHC molecule HLA-B7 it has 
previously been demonstrated that specific tolerance could be induced to HLA-B7. 
This suggests the structure of xenogeneic donor MHC molecules may not be the 
preventative factor in the reliable induction of neonatal tolerance to xenogeneic 
tissue (Borenstein et al. 2004). In assessing the levels of chimerism through staining 
of host spleen cells for HLA-B7, the authors found HLA-B7+ cells in peripheral 
lymphoid organs (albeit at low levels) suggesting engraftment of donor cells into 
recipient bone marrow. This implies a correlation between chimerism and tolerance. 
In our model it is possible that this induction of chimerism has not been achieved 
and therefore the induction of tolerance is unsuccessful. 
Following successful induction in mice of tolerance to allogeneic tissue 
following i.v. injection of donor splenocytes in adulthood, Wang et al attempted to 
induce tolerance to islet xenografts (rat) using the same method. Prolonged survival 
of xenotransplants was found, however tolerance could not be achieved without 
transient B cell depletion with a CD20 antibody. Following this depletion, a later 
challenge showed the hosts were no longer capable of generation of anti-rat 
antibodies (Wang et al. 2013b). However as these studies were carried out in adult 
hosts it is not clear whether the same would apply in this case of neonatal tolerance 
to xenogeneic tissue.  
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5.9.2 Modification to transplant protocols 
In order to improve the survival of transplants into mouse hosts, a number of 
modifications were made to the transplant protocol, as well as changing the numbers 
of cells used to desensitise neonatally. In initial mouse experiments; hosts received a 
transplant of 3x105 cells between 1-2 months after a QA lesion. In attempts to 
improve survival the number of cells transplanted was increased to 5x105 cells; the 
number of cells used as standard to transplant into rat hosts. However, no 
improvement was found in transplant survival in those animals transplanted with 
higher cell numbers. It is possible that instead of increasing the chances of some 
cells surviving, the number of cells was too high. The lesioned striatum of the mouse 
host is smaller than that of the rat and may not be able to support a deposit of such a 
large cell number, actually increasing the chance of rejection.  
In addition to modifying the number of cells transplanted, the time between 
lesion and transplant was altered in a number of transplant groups in this chapter. 
Döbrössy et al found good transplant survival of mouse tissue implanted 10 days 
after a lesion (Döbrössy et al. 2011), which has been replicated in this lab group 
(Harrison D.J., unpublished data) and Johann et al compared the survival of cells 
transplanted at 2, 7, and 14 days post-lesion and found the greatest survival in their 
earliest transplant time-point (Johann et al. 2007). In the studies presented here, no 
improvements were observed in transplants delivered at shorter time-points 
following the lesion, even up to 2 days. It appears that survival of transplants in 
lesioned hosts is better than those implanted into the intact striatum; however this 
analysis was complicated by problems with the identification of transplanted cells, as 
discussed below.  
Another consideration was the transplant co-ordinates used. In all studies 
transplant co-ordinates used were the same as those used for QA lesions. In contrast 
to rat lesions which are delivered to two sites in the striatum, in the mouse only one 
site is used. Therefore, whereas in the rat transplant scar tissue from the previous 
surgery is avoided, the mouse transplant is delivered to the same site due to the small 
target area. Therefore it is possible the transplant is deposited into a more hostile 
environment. 
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5.9.3 Identification of grafted cells 
Difficulties in the positive identification of transplanted cells were experienced 
in all experiments in this chapter. Initial identification of surviving grafts in all cases 
was performed using CV staining to determine the presence of a dense deposit of 
cells within the striatum. In transplants into the rat striatum, large transplants can 
clearly be identified in this way (see Chapters 3 and 4). In transplants into mouse 
hosts this is less clear, with smaller surviving grafts frequently observed (El-
Akabawy et al. 2012; Johann et al. 2007; Kelly et al. 2007), more resembling a thin 
pencil shaped graft or a needle track/scar of a rejected transplant. In the case of 
transplants of mouse cells, which have not been labelled prior to transplantation, 
clear identification is only possible in transplants into the QA lesioned striatum 
where a clear margin of lesion can be seen beyond all graft borders. In this case a 
clear deposit of transplanted cells can be identified with antibody staining for NeuN-
positive neurons and labelling with DARPP-32 to identify the presence of mature 
MSNs. Sections containing mouse tissue transplants from these experiments were 
damaged prior to staining with these markers, making it impossible to confirm the 
presence of surviving transplanted cells (See Appendix 5). 
Although with xenografts of human cells a number of human specific antibodies 
are available, problems were experienced with the use of these in identification of 
surviving transplants. Experiments i) and ii) found poor antibody staining, 
potentially due to underfixing of tissue sections. Additionally the majority of these 
human specific antibodies are raised in mouse, requiring the use of a biotinylated 
anti-mouse secondary antibody to visualise positively stained cells with DAB. Due 
to the nature of the experiments, damage has been sustained to BBB as a result of 
surgery for lesions or transplants. Although this repairs after a variable period of 
time, dependent on the inflammatory response to lesions and transplants (Sanberg et 
al. 1988; Wakai et al. 1986), it is likely that immunoglobulins will have passed 
through the BBB and be present in the brain, specifically in the transplanted area. 
This causes high background staining from the anti-mouse secondary antibody, 
making it difficult to identify positive staining. Due to these difficulties in labelling, 
numbers of surviving grafts recorded may be overestimates identified from 
examination of CV stained sections. 
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Although some improvement was found with the use of a biotin conjugation kit, 
allowing avoidance of the use of the anti-mouse secondary, positive staining of 
transplanted human cells still did not correlate with CV staining. Staining in 
Experiment ii) of lesion only control animals showed comparable staining to that 
observed in a number of grafted animals, and indeed to that previously considered to 
be indicative of surviving mouse grafts. In light of this, when human cells could not 
be positively identified despite the appearance of a surviving graft in CV stained 
sections, attempts were made to determine whether this staining was due to the 
presence of immune cells in the transplanted area. This was carried out on sections 
from desensitised BL/6 hosts transplanted with hCTX (Appendix 7). Staining 
showed a lack of NeuN positive neurons in the CV stained area, but dense microglial 
staining. This suggests the transplant has been infiltrated by host microglia and is 
undergoing rejection. 
5.9.4 Graft survival in mouse hosts 
It is not clear why graft survival in mouse hosts is so poor in comparison to the 
rat. Even in hosts receiving mouse tissue transplants in these experiments, although 
survival was higher than xenograft groups, it still only reached ~50%. There are a 
number of possibilities as to why this may be the case which are currently 
undergoing investigation. It may be due to the size of the mouse brain, i.e. it cannot 
support a transplant of this number of cells, and even 3x106 cells is too many to 
produce a healthy surviving transplant. Alternatively, there may be something 
innately different about the mouse immune system. A recent paper highlights the 
role of the innate immune response in the rejection of cells transplanted into the 
mouse brain (Phillips et al. 2013). It has been assumed that since donor cells used in 
neural transplantation generally express low levels of MHC-I and II, they are 
relatively protected from rejection by the immune system. However this may not be 
the case, since up-regulation of MHC molecules occurs in response to pro-
inflammatory cytokines upon transplantation, moreover this may not necessarily be 
beneficial. Phillips et al confirmed this, finding that the responses from NK cells in 
mouse hosts is elevated on encountering cells with low MHC expression (Phillips et 
al. 2013).  
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Data from these experiments suggests a strong microglial response to 
xenotransplants of hPF tissue in the mouse striatum (Experiments iii) and iv)). 
Although this is suggestive of an increased inflammatory response, staining for T 
cells (CD4+ and CD8+) did not show a large number of lymphocytes in or around the 
grafted area. Aside from presenting antigen to T lymphocytes, it is possible for 
microglia themselves to act as cytotoxic effector cells or innate phagocytes 
(Armstrong et al. 2001; Davis et al. 1994; Fanger et al. 1989). The administration of 
CsA daily did not improve survival of transplants greater than 50%, or appear to 
reduce the amount of microglial staining in and around the grafted area. This agrees 
with a previous study in which the administration of transient or continuous CsA to 
promote survival of hNSCs in an ischemic rat model was not found to reduce the 
inflammatory response as measured by Iba1 staining, even in animals which only 
received lesions (Rota Nodari et al. 2010). Investigating the phenotype of the 
microglia present at the transplantation site will give insight into this phenomenon 
and allow further understanding of the rejection response in the mouse and targeting 
of relevant immune suppression treatments. Additionally, it has been reported that 
high doses of CsA are required for successful immunosuppression in mice, although 
this is difficult to achieve successfully due to side effects (Larsson et al. 2001b). The 
problems of transplant survival observed here do not appear to be isolated to findings 
in this lab group, with the majority of other centres using immune compromised 
hosts to successfully carry out transplants of human donor cells, presumably due to 
issues with rejection in wild type mouse hosts (De Filippis et al. 2007; Espuny-
Camacho et al. 2013; Liang et al. 2013; Ma et al. 2012; Wang et al. 2013a). 
A recent paper aimed to determine whether mouse hosts could be desensitised 
neonatally to a range of cell types including hiPSCs and hNPCs (Mattis et al. 2014). 
The authors did not find any survival of human grafts in their desensitised hosts 
beyond 2 weeks post-transplantation. These experiments also investigated the 
survival of transplants of human iPSC derived NPCs (iPSC-NPCs) and foetal NPCs 
(hfNPCs) in neonatal mouse hosts. Again, rejection of human donor cells was 
observed, as compared to transplants into NOD/SCID mice which survived up to 62 
days after transplantation. The authors also conclude the survival of transplants in 
mice to be poorer to rat, and attribute unsuccessful neonatal desensitisation to this. 
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Moreover the authors note a large host microglial response to the human xenografts 
(Mattis et al. 2014), as found in the studies presented here. 
A further consideration from these studies is the characteristics of surviving 
human transplants. Although very few in number, the majority of transplants which 
did survive were very large. This could result from the preparation of cell 
suspensions for transplantation, in which tissue may not have been adequately 
dissociated into a single cell suspension and may instead contain small portions of 
tissue. In this scenario; when transplanting each host animal from one cell 
suspension, one or more may receive transplants of these tissue portions whereas 
others may receive very few cells at all. The delivery of pieces of tissue may mean 
that one host animal receives the majority of cells from the cell suspension, or that 
the cells have a better chance of surviving when delivered in this way. Although 
previous work has looked into the effect of transplantation of tissue pieces as 
opposed to single cell suspensions in rat hosts, this has not been performed in mice. 
These issues are addressed in Chapter 6, in which the preparation of mouse donor 
tissue for transplantation into the mouse brain is investigated to determine whether 
delivering cells as tissue pieces has an effect on graft survival.  
Similarly large grafts were seen in human to rat transplants in previous studies 
presented in this thesis which were found to be due to extensive proliferation of 
developing cortical tissue, thus this provides an alternative explanation for the 
marked variability in hCTX graft sizes in mouse hosts. As large numbers of cells 
were transplanted in mouse hosts (up to 5x105) to try and improve survival, further 
proliferation of this tissue would result in large grafts. If the survival of transplants 
could be improved this number may be reduced to produce slightly smaller 
transplants. This also may not be an issue with the use of striatal tissue transplants 
from WGE. 
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5.10 Conclusions and future work 
The objective of the studies described in this chapter was to determine whether 
mouse hosts could be successfully desensitised in the neonatal period to human 
cortical tissue to a sufficient extent to promote survival of a neural xenograft in 
adulthood from 6-12 weeks post-transplantation. Successful desensitisation could not 
be demonstrated. In addition to this, poor graft survival was found in the majority of 
mouse hosts. This has identified a potential problem with the use of mouse hosts for 
testing donor cells for transplantation in neurodegenerative disease. Ideally 
transplants could be delivered to lesion or genetic models of disease in order to 
measure safety and efficacy of donor cells. However, data from this chapter suggests 
that the immune system of the mouse host may not provide an ideal environment for 
cell transplantation. Chapter 6 aims to address problems identified with mouse 
tissue transplant survival, before research can be redirected to identify whether 
neonatal desensitisation to xenogeneic tissue in the mouse may be a possibility. 
In addition to the mouse to mouse transplant experiment described in Chapter 
6, future studies will look to improve survival of human xenografts in mouse hosts. 
Specifically; a systematic investigation into the mouse (CD-1) immunological 
response to striatal transplants of hCTX will be carried out, with a direct comparison 
to the response in the rat (SD). The response to transplants will be investigated in 
both untreated and immune suppressed hosts treated daily with CsA, with an 
investigation of the T cell and microglial response to transplants at various time-
points following transplantation. This study will aim to identify differences in the 
response of mouse and rat hosts to transplants of human tissue, and therefore allow 
immune suppression treatments to be more specifically targeted to the relevant 
rejection processes. An additional investigation of survival of human xenografts in 
mouse neonates would be of interest, as previous findings have suggested rejection 
under these circumstances (Mattis et al. 2014), which may have a detrimental effect 
on the potential for neonatal desensitisation. 
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Chapter 6  
Improving graft survival in the mouse striatum 
6.1 Summary 
Although Chapter 5 aimed to determine whether a method of neonatal 
desensitisation could be successfully applied in mouse hosts to achieve long term 
survival of primary human foetal tissue transplants, poor survival of human 
xenografts and mouse transplants prevented this from being investigated effectively. 
Consistent survival of neural transplants in the mouse host has been found to be a 
problem by others using a range of cells, including mouse PF tissue and ESC derived 
neurons. The aim of the work described in this chapter was to address these 
problems since the parameters for mouse donor cell survival need to be resolved 
before xenografts can be investigated further. Thus two key variables were explored 
that have been shown to be important for rat to rat transplant survival; the gestational 
age of donor cells and the cell preparation method. Four groups of mice were 
transplanted with different types of mouse PF tissue. Two different donor ages were 
compared (E12 and E14), to determine whether younger donor tissue would improve 
survival as well as graft phenotype according to the relevant Carnegie staging of 
mouse foetuses compared to rat. In addition two cell preparation methods were 
tested to identify whether the reduced trituration of tissue following digestion could 
improve graft survival and morphology as compared to heavily triturated quasi 
single cell suspensions‡. Good graft survival was found in all groups, although still 
not 100% as may be expected in rat tissue transplants in rat hosts. This implies either 
a difference between the rat and the mouse as transplant hosts, or an issue with 
survival of mouse donor tissue following transplantation.  
                                                          
‡
 Declaration 
The experiment discussed in this chapter was carried out in collaboration with another PhD 
student; DJH. Data discussed here relates to CD-1 mice. An additional cohort of BL/6 mice 
underwent the same procedures and these data will be discussed as part of DJH’s PhD thesis. 
Dissection of mouse tissue and the majority of dissociation and preparation of cells for 
transplantation were carried out by Ngoc-Nga Vinh (NNV). 
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6.2 Introduction 
As discussed in Chapter 5, mice are desirable transplant hosts for a number of 
reasons, including the availability of genetic models of disease. However, as can be 
seen from the results of the experiments described in Chapter 5, survival of 
transplants of mouse tissue in mice is more variable than may have been expected. 
These findings are not exclusive to the experiments presented here; other data from 
our lab group shows difficulty in achieving success using mouse hosts, including 
with grafts of mouse tissue (unpublished data, Evans AE; Kelly CM) and examples 
of mouse grafts in the literature also tend to be small in comparison to those seen in 
the rat (El-Akabawy et al. 2012; Johann et al. 2007; Kelly et al. 2007). Without 
being able to achieve successful transplant survival it is not possible to test whether 
desensitisation can be induced in the mouse. Therefore this chapter aims to 
investigate whether modifications to the transplantation protocol will improve 
survival of mouse tissue transplanted into the mouse brain, before re-examining 
xenograft survival.  
Many of the current conditions for preparation of donor cells for transplantation, 
including donor age, dissection parameters and cell preparation have been developed 
and optimised mainly for transplantation in the rat (Barker et al. 1995; Schmidt et al. 
1981). This includes the foetal donor age used for transplantation of mouse tissue 
and the preparation of cell suspensions. For rat WGE transplanted into the rat 
striatum, donor tissue is dissected from the foetus at E14-15 in order to collect cells 
at the right point in striatal development so they will differentiate after 
transplantation into MSNs expressing DARPP-32 (Watts et al. 1997). Numerous 
experiments have shown this to be successful, demonstrating integration and 
functional improvement of E14-E15 tissue transplanted to the QA lesioned rat 
striatum (Brasted et al. 1999a; Brasted et al. 1999b; Döbrössy and Dunnett 1998; 
Nakao et al. 1998; Nakao et al. 1999). Additional studies have demonstrated similar 
recovery following lesion with alternative excitotoxins or metabolic toxins (see 
Dunnett et al. (2000) for a review). In the mouse, WGE from E14 tissue has also 
been used for striatal transplants, however due to differences in development 
between these species this may not be the optimum age of donor tissue to transplant. 
Comparing the Carnegie stages of development between mouse and rat, mouse 
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E12.5 corresponds to rat E14 (Figure 6.1). Although striatal transplants of donor 
tissue of varying donor ages have been compared in the rat (Fricker et al. 1997; 
Schackel et al. 2013), this has not yet been systematically explored in the mouse. It 
has been shown that even in rat grafts the use of younger donor tissue (E13) 
produces better behavioural improvements and more phenotypically accurate grafts 
containing a greater area of DARPP-32 positive ‘P zones’ (Schackel et al. 2013). 
In addition to the effect of donor age, modifications to the preparation of cell 
suspensions have been considered with regard to rat transplants (Watts et al. 2000a), 
and in clinical trials, but not in the context of mouse tissue transplants. It has been 
concluded that transplanting tissue as a single cell suspension, rather than tissue 
pieces reduces the likelihood of rejection since tissue pieces contain intact donor 
vasculature which may contain donor APCs which activate host lymphocytes. This is 
thought to provoke a stronger host immune response than transplanting single cells 
(Chen et al. 2011). However; transplants of tissue pieces have been utilised in the 
clinic for both PD (Freed et al. 2001; Olanow et al. 2003) and HD (Bachoud-Lévi et 
al. 2000; Bachoud-Levi et al. 2000; Hauser et al. 2002; Kopyov et al. 1998). Post-
mortem data from a number of clinical transplants in HD has shown survival of 
grafts, with some inflammatory infiltration though not sufficient to cause rejection of 
all graft deposits under variable immunosuppression regimes (Capetian et al. 2009; 
Cicchetti et al. 2009; Freeman et al. 2000; Keene et al. 2007). 
This experiment therefore aimed to compare an earlier gestation than normally 
used, E12, to E14 mouse striatal grafts to determine whether transplants from E12 
foetal tissue may promote better survival and yield an internal organisation more 
similar to that of the normal striatum. Additionally, we examined the effect of 
modifying the cell suspension in mouse grafts by comparing a standard single cell 
suspension (CS) as used in previous chapters to a “partial tissue pieces” style 
suspension where striatal tissue was digested but not triturated into a single cell 
suspension (referred to as “TP”). Although this did not involve transplantation of 
traditional “chopped” pieces of tissue, the reduction in trituration was intended to 
reduce the severity of treatment of tissue, and therefore improve donor cell viability 
and survival. This method has previously been demonstrated to yield greater 
functional improvements with grafts of rat GE to the QA lesioned rat striatum (Watts 
Chapter 6  Striatal transplants (mouse) 
159 
et al. 2000a) and improved survival of human VM transplants (Rath et al. 2013). The 
resulting preparation consisted of small pieces of tissue which were only triturated 
sufficiently to allow the pieces to be drawn up into a syringe for transplantation. 
These conditions were compared at both foetal ages with the aim of determining the 
optimum transplantation paradigm to promote the best survival of mouse grafts. 
Modifications described in Chapter 5 from findings from xenograft experiments 
were also included, with transplants delivered 10 days after QA lesions, and an 
increased number of cells used for transplantation. The findings from this experiment 
also aim to address whether poor graft survival in Chapter 5 may be in part related 
to the treatment of the donor tissue, as opposed to being primarily due to the mouse 
host environment. The improvement of mouse tissue survival is required to 
demonstrate sufficient transplant survival in mouse hosts before re-addressing the 
issue of xenografting and the desensitisation of mouse hosts. 
Chapter 6     Striatal transplants (mouse) 
160 
Figure 6.1 Differences in Carnegie stages between mouse and rat during foetal development. 
The red dashed line indicates the foetal age used for striatal transplants in the rat (E14) and 
how this compares to the mouse. Data from Hill (2013) 
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6.3 Experimental Design 
A total of 30 adult male CD-1 mice (>20g) were used in this study. All received 
QA lesions to the right striatum and 10 days later were split into one of 5 groups as 
shown in Table 6.1 below. E12 partial tissue pieces preparations (E12TP) were 
transplanted as a pair of striatae, treated with trypsin for just 10 minutes and 
resuspended in DMEM/F12 to a total volume of ~4µl per transplant with minimal 
trituration. E14TP were prepared in the same way, this time transplanting one 
striatum per host. This was based on an aim to keep cell number consistent between 
transplant groups, since E12 WGE is significantly smaller than E14, and cell 
suspension groups were all transplanted with 5x105 cells we reasoned that 
transplanting a smaller quantity of tissue at E14 would be more comparable. Both 
E12 and E14 cell suspensions were made up as in previous chapters and as described 
in Chapter 2. Mice in these groups received transplants of 5x105 cells in 2µl 
DMEM/F12.  
Condition Number of Mice 
E12 partial tissue pieces 7 
E12 cell suspension 6 
E14 partial tissue pieces 7 
E14 cell suspension 7 
Lesion only control 3 
Table 6.1 Numbers of mice in each condition 
6.3.1 Histology and Immunohistochemistry 
12 weeks after transplantation, mice were transcardially perfused with fresh ice 
cold 4% PFA and the brains collected for histological analysis. Brains were 
sectioned as previously at 40µm and stored in anti-freeze at -20oC. 1:12 series were 
mounted and Nissl bodies stained with CV, and further 1:12 or 1:6 series were 
stained for immunohistochemistry using NeuN (1:2000), DARPP-32 (1:4000), Iba1 
(1:8000) and CD3 (1:500) as described in Chapter 2. 
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6.3.2 Quantification and statistical analyses 
Graft volume was calculated by measuring graft areas on each section stained 
with NeuN on Image J and calculated with formulae described in Chapter 2. Total 
cell number was counted manually on Image J, and differences between graft 
volume and cell number were investigated by ANOVA. Immune marker staining 
was graded (0-4) and grades were compared between transplant groups with non-
parametric Kruskall-Wallis tests. 
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6.4 Results 
6.4.1 Graft survival at 12 weeks post-transplantation 
Surviving grafts were identified in the first instance using CV staining to detect 
denser areas of staining thought to be typical of the presence of a graft. Numerous 
previous studies have shown grafted tissue to have a different organisation of CV 
compared to the surrounding host tissue. The presence of NeuN+ cells was used to 
confirm neuronal differentiation. In the majority of cases the graft was placed 
entirely within an area denuded of neurons by the QA lesion, allowing NeuN 
staining to provide a good level of evidence that this corresponds to surviving 
transplanted cells. Transplants which were identified as NeuN+ within the lesioned 
striatum were all counted with no minimum cut off for graft size. Although some 
grafts were smaller than others, there was little variability found within groups. The 
number of surviving grafts is outlined in Figure 6.2 (A, B). In contrast to findings in 
previous experiments, relatively good survival of mouse transplants was found in all 
conditions, therefore the number and phenotype of surviving transplanted cells was 
quantified. Graft volume was estimated and total numbers of surviving neurons 
(NeuN+) were counted and corrected with the Abercrombie correction. Comparisons 
of graft volume and the number of surviving cells between transplant groups can be 
found in Figure 6.3. Measurement of graft volume and DARPP-32+ patch volume is 
also displayed here. Photomicrographs of representative surviving transplants are 
shown in Figure 6.4 and Figure 6.5.  
A univariate ANOVA was run comparing the number of NeuN+ cells in the 
graft between the two donor age groups (E12 and E14) and two tissue preparation 
groups (TP and CS). This showed a significant effect of age; 
F (1,16) = 5.516, p<0.05, but not the method of cell preparation; 
F (1,16) = 0.220, p = 0.645. The same pattern was reflected in graft volume, with a 
significant difference found between E12 and E14 transplants; 
F (1,16) = 6.025, p < 0.05 but not between TP and CS; F (1,16) = 0.061, p = 0.809. 
These significant differences in NeuN+ cells and graft volume are due to the presence 
of larger surviving grafts in those hosts receiving transplants from E12 donors 
(Figure 6.3 A, C). Although transplants appeared largest in hosts transplanted with 
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E12 TP, there was no significant interaction between the effect of donor tissue age 
and cell preparation (Max F (1,16) = 2.974, p = 0.104). 
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6.4.2 Phenotype of surviving transplanted cells 
Staining for DARPP-32 revealed the presence of mature MSN-like neurons in 
the surviving transplanted cells (Error! Reference source not found. and Error! 
Reference source not found.; I-L). The areas of DARPP-32+ patches (p-zones) 
within the graft area were measured to calculate their total volume in each 
transplanted animal (Error! Reference source not found.; D, F). The percentage of 
total graft volume occupied by these p-zones was then calculated for comparison 
between groups Error! Reference source not found. (E, F). 
Univariate ANOVAs were again carried out to compare the number of 
DARPP-32+ cells in the transplant, and the volume of p-zones within grafts between 
the two donor ages and cell preparations. No significant effects of donor age 
(F (1,16) = 0.546, p = 0.471) or cell preparation (F (1,16) = 1.742, p = 0.205) were 
found in the number of D32+ cells. There were also no significant differences in 
patch volume between the two donor ages, however significantly larger areas of 
p-zones were found in transplants of TP than CS; F (1,16) = 5.884, p <0.05 (Error! 
Reference source not found. B, D). Again no significant interaction was found 
between the effect of donor age and cell preparation 
(Max F (1,16) = 1.548, p = 0.231). Interestingly, the percentage of the grafts 
occupied by DARPP-32+ patches appears to be greatest in E14 TP transplants, 
although as this only consisted of 3 surviving grafts this cannot be confirmed. 
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Transplant group Number of 
surviving grafts 
(%) 
Mean graft 
volume (µm3) 
Mean number of 
NeuN+ cells (x103) 
Mean number of 
D32+ cells (x103) 
Average volume of 
p-zones within 
transplant (µm3) 
% of graft 
occupied by 
D32+ patches 
E12 TP 5 (85.7%) 2.9x108 18.5±7.5 4.6±3.8 1.4x108 49.0% 
E14 TP 3 (42.8%) 1.5x108 7.6±3.2 4.1±0.5 1.2x108 79.3% 
E12 CS 5 (83.3%) 2.3x108 12.6±6.1 1.7±1.0 0.4x108 17.4% 
E14 CS 6 (85.7%) 1.9x108 11.0±4.0 4.0±1.8 0.8x108 39.7% 
A 
Figure 6.2 Surviving mouse transplants in CD1 mouse hosts 
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Figure 6.3 Mean total cell number of surviving cells in mouse grafts (NeuN+, A), and number 
of D32+ cells in the grafted area (B). Mean graft volume (C) and the total volume of D32 
patches (p zones) in the graft (D). Percentage of total graft volume occupied by D32+ patches 
(E). Examples from Image J of measurements of total graft area and patch areas used to 
calculate total graft and patch volume (F). Marker indicates the centre of a p-zone and the 
yellow line is the boundary of the p-zone used in the volume calculation. TP = Tissue pieces 
transplants; CS = Cell suspension transplants 
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Figure 6.4 Photomicrographs of typical sections from mouse hosts transplanted with E12 mWGE and stained with 
CV (A-D), NeuN (E-H), and DARPP-32 (I-L). Donor tissue was prepared either as a tissue pieces style preparation 
(TP - left panels: A,B,E,F,I,J); or cell suspension (CS - right panels: C,D,G,H,K,L). Grafts are circled on low 
magnification images, and graft-host border is highlighted with arrows on high magnification images. 
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Figure 6.5 Photomicrographs of typical sections from mouse hosts transplanted with E14 mWGE and stained with 
CV (A-D), NeuN (E-H), and DARPP-32 (I-L). Donor tissue was prepared either as tissue pieces (TP - left panels: 
A,B,E,F,I,J); or cell suspension (CS - right panels: C,D,G,H,K,L). Grafts are circled on low magnification images, 
and graft-host border is highlighted with arrows on high magnification images. 
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6.4.3 Mouse host immune response to striatal mouse grafts 
To assess the mouse host response to transplants of mWGE, sections were 
stained for the microglial marker Iba1. Sections were graded according to the rating 
scale described in Chapter 2. The highest grade assigned to a section for each animal 
was recorded, and these are presented by group in Figure 6.6. Figure 6.7 shows 
representative Iba1 staining for each grade; grade 0 is not shown since no section 
received this grade. The microglial response in the majority of hosts was low, with 
staining in only a few animals showing greater immunoreactivity than that seen in 
lesion only controls. The data was analysed using a non-parametric Kruskall-Wallis 
test, showing no significant differences in grades of microglial staining between 
groups; H (4) = 9.337, p = 0.053. 
Figure 6.6 Grading of Iba1 immunoreactivity in each transplant host. 
Each circle corresponds to 1 mouse host; red circles denote rejected 
transplants. “E12TP” = E12 tissue pieces, “E14TP” = E14 tissue pieces, 
“E12CS” = E12 cell suspension, “E14CS” = E14 cell suspension, 
“Lesion” = Lesion only controls. 
Chapter 6  Striatal transplants (mouse) 
171 
Figure 6.7 Examples of immune marker staining grades (1-4) for Iba1 in mice 
grafted with mWGE. Images for grades 1 and 2 were from hosts transplanted with 
E14TP and grades 3 and 4 from hosts transplanted with E14CS. Earlier grades 
mostly show the presence of resting, ramified microglia, with later grades showing 
increased density around the graft site with retraction of distal processes 
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6.5 Discussion 
This chapter aimed to test the mouse striatal transplant protocol using mouse 
tissue and determine whether modifications to the cell preparation regime and 
variations in donor tissue age would improve the poor levels of survival observed in 
Chapter 5. CD-1 mice were transplanted with either a single cell suspension (CS), 
as used in previous mouse and rat transplant experiments or with a dissociated tissue 
pieces suspension (TP) where trituration of the cells was kept to a minimum. 
Additionally, both cell preparations were tested using two different foetal donor 
ages; E12 and E14 to determine whether survival may differ with the use of younger 
donor tissue. Due to the concerns with the reliability of CV staining for the detection 
of graft survival, discussed in Chapter 5, antibody staining with the mature neuronal 
marker NeuN was used to confirm the presence of surviving cells. With NeuN and 
DARPP-32 staining, the structure of surviving grafts could clearly be identified 
within the lesioned striatum. 
In contrast to previous mouse to mouse transplants presented in this thesis 
(Chapter 5), good survival was found in all transplant groups in this chapter. It is 
not clear why survival should be improved in this experiment which used the same 
E14 cell suspension preparation as those in Chapter 5, where survival previously 
was so poor, although there are a number of potential reasons. It is possible that with 
experience, cell preparation and transplantation techniques were improved, 
increasing the likelihood of transplant survival. However this is unlikely since 
successful transplantation was readily achieved in rat hosts. Alternatively; the trypsin 
digest of tissue was modified slightly for this experiment, with incubation for 
10 minutes rather than 20, as it was considered sufficient for dissociation of tissue. 
In transplants of VM tissue, in particular from mouse, it has been noted that the 
tissue is sensitive to prolonged enzymatic treatment (Breger et al, unpublished 
observations). Potentially this could have had a similar effect on the striatal tissue 
used here and explain the improved survival in this study as compared to those in 
Chapter 5. This would also agree with the poor survival of mouse to rat xenografts 
seen in immune compromised hosts in Chapter 4. 
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6.5.1 The effect of donor age 
Donor tissue from two different foetal ages (E12 and E14) was transplanted into 
mouse hosts in this experiment. These ages were chosen based on previous protocols 
used for striatal transplantation in HD. Most transplant work has been carried out in 
the rat, with E14 identified as the optimum donor age based on the phenotype of 
surviving transplanted cells and functional recovery (Fricker et al. 1997). However 
using Carnegie stages, the comparable gestational age in the mouse would be E12.5, 
rather than E14, in order to procure tissue at the same developmental stage. This 
study therefore aimed to compare transplants from both donor tissue ages to 
determine whether the use of younger donor tissue would yield better graft survival, 
with larger grafts and more surviving cells of MSN-like phenotype. In addition to 
this study, another experiment has used E12 donor tissue prepared as a TP style 
preparation using the same method described here to transplant mWGE into a mouse 
QA lesion model, finding improved graft survival as compared to E14 CS 
(Unpublished data, Evans AE).  
The results of the present study showed significantly larger graft volumes along 
with higher cell numbers in grafts of tissue from E12 WGE compared to those from 
E14 WGE as measured from NeuN staining of mature neurons. There was no 
interaction between donor age and cell preparation, although the largest surviving 
transplants were seen in hosts transplanted with E12 TP. These data are in line with 
the previous literature discussed, showing that E14 rat WGE grafts yield larger 
transplant volume than from donor tissue of a greater gestational age (Schackel et al. 
2013), as well as agreeing with concurrent findings from experiments in this lab. 
Donor age has also been shown to have an effect on the phenotype of transplants, 
with reports of younger rat donor tissue yielding transplants with greater volumes of 
P-zones within the graft (Fricker et al. 1997). P-zones are representative of striatal-
like tissue within grafts containing a heterogeneous population of cells (Campbell et 
al. 1995; Wictorin et al. 1989). The volume of P-zones within the graft has also been 
demonstrated to be strongly correlated with recovery on motor behaviour tasks 
(Fricker et al. 1997; Nakao et al. 1996). The improvement in graft survival found in 
this study is also logical given comparisons between gestational stages in rat and 
mouse foetuses. With regard to the phenotype of transplanted cells at 12 weeks; 
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mature MSN like cells were identified in all surviving transplants with DARPP-32 
staining, however no significant differences were found when comparing the two 
donor ages. 
Previous work has suggested an effect of donor tissue age on the survival of 
grafts, since younger tissue may contain less microglial precursor cells which can 
present donor antigen following transplantation (Brevig et al. 2008; Dalmau et al. 
1997). This has been confirmed in the assessment of the rat host to transplants of 
mouse tissue, in which improved survival was found from younger donors (Zimmer 
et al. 1988). Additionally, WGE grafts from younger foetuses contain more 
proliferating cells would have normally gone on to populate the cortex (during 
normal development proliferating cortical precursors in the subventricular zone 
migrate through the WGE on their way to the cortical mantle, and are more 
numerous at E12 than E14). This could produce larger grafts but with an overall 
reduced proportion of striatal-like tissue, as may be the case here, with larger grafts 
seen from E12 donors, although potentially a higher percentage of DARPP32+ 
patches from E14 transplants. 
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6.5.2 The effect of donor cell preparation 
In addition to comparing the differences in transplant survival between E12 and 
E14 donor tissue, the cell preparation protocol was also investigated. Routinely, 
tissue for transplantation is dissociated by enzymatic digestion and trituration to 
produce a quasi-single cell suspension. The number of cells can then be calculated 
and standardised for each host. This method has been developed over a number of 
years and is successfully applied when transplanting into rat hosts. Although studies 
into the optimum cell preparation for rat transplant survival have been carried out 
(Watts et al. 2000a; Watts et al. 2000b), the same is not reflected in the literature for 
mouse transplants. Standard protocols have been developed directly from those used 
in the rat but without systematic validation in the mouse. One of the aims of this 
study was therefore to compare the survival of mWGE prepared as “tissue pieces” or 
cell suspension from both E12 and E14 donor tissue. For transplantation of E12 
gently triturated TP preparations; a pair of striatae were transplanted, whereas in the 
E14 groups, just one was transplanted. The aim of doing this was to transplant 
approximately the same amount of tissue in each condition (E12 striatae are much 
smaller than at E14) and estimated cell counts suggest that 2:1 for E12 to E14 is 
reasonable.  However, this is a difficult parameter to control, as E12 tissue is likely 
to have a greater proliferative potential, and currently there is no recognised way of 
adjusting for this or for potential differences in the vulnerability of the two cell 
populations at the two different gestational ages. 
The two preparations used in this study both included trypsinisation of the 
mouse PF donor tissue, but were followed by different trituration conditions. CSs 
were prepared following the standard protocol, following the trypsin digestion with 
trituration into a quasi-single cell suspension. Trituration of TPs was kept to a 
minimum; sufficient to allow the pieces of tissue to be drawn up into the transplant 
needle. Thus the TP group described here is not identical to chopped tissue pieces 
preparations which have been used previously (Bachoud-Levi et al. 2000; Redmond 
et al. 2008). This condition does provide, however, a less harsh treatment of the 
mouse donor tissue than traditional CS preparation protocols (Rath et al. 2013; Watts 
et al. 2000a). In comparing surviving transplants between tissue preparation 
conditions in this study, no differences were found in graft volume or the number of 
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surviving cells. As mentioned previously, E12 TP produced the largest grafts, but 
since E14 TP yielded the smallest grafts there was no improvement reflected 
statistically with the use of tissue pieces over all. As fewer grafts survived in the E14 
groups, firm conclusions cannot be made regarding these data, although a trend 
towards increased volume of DARPP32+ patches in TP preparations was seen. 
However when looking at the percentage of the total graft volume occupied by these 
patches, the E14 TP was the highest. 
No significant differences were found between cell preparations in the number 
of DARPP-32+ cells in the transplants, however significantly larger areas of p-zones 
within the transplants were produced from transplanted TP. This may be due to the 
reduced trituration and disruption of striatal tissue, allowing better formation of 
striatal-like tissue within the grafts. The effect of cell preparation on survival, 
integration and behavioural recovery has been investigated recently in human to rat 
VM transplants (Rath et al. 2013). The authors found that VM transplants to the 
striatum of tissue pieces produced the optimum survival and reversal of rotational 
bias. In our experiment, the number of DARPP-32+ cells and P-zones developing 
within the grafts could be affected by minor differences in the dissection between 
donor tissues, since non-patch zones may also be dissected along with WGE. In 
general transplants from WGE alone yield 30-50% P-zones as a proportion of total 
graft volume, as compared to the lateral GE (LGE); producing 80-90% P-zones and 
the medial GE (MGE); 25% P-zones. Large variation between transplant groups is 
seen in this study in the percentage of total graft volume occupied by P-zones. This 
could suggest variations in dissection of tissues, although the extent of this is 
unclear, since animals receiving cell suspension grafts were transplanted with a cell 
suspension of tissue pooled from multiple donor foetuses, and in tissue pieces 
transplant groups; hosts were each transplanted with tissue from a different donor. 
However percentages could also be expected to vary dependent on donor age. 
Although no behavioural testing was carried out on host animals in this study, 
previous data has shown a correlation between the level of behavioural improvement 
observed following transplantation and the volume of P-zones within the transplants 
(Fricker et al. 1997; Nakao et al. 1996; Schackel et al. 2013). This suggests that 
although some transplant protocols may yield larger surviving grafts, this may not be 
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the optimum protocol to offer functional improvement. Future work would be 
necessary to determine which transplant condition provides the best function. Data 
here are still suggestive of E12 TP as providing the optimum transplant condition 
regarding the size of graft and patch volume; however the percentage of the whole 
graft itself occupied by DARPP-32+ patches was found to be greater in the E14 TP 
group. 
6.5.3 Mouse host immune response to striatal transplants of mWGE 
Staining for the microglial marker Iba1 identified a consistent presence of 
microglia in and around the grafted area in sections from all groups. No differences 
were found in the extent of immunoreactivity, including in those animals which 
received lesions only, and no transplant. This shows that transplants of allogeneic 
tissue induce no more of a microglial response than a QA lesion and that no 
differences in the host immune response are found between different cell preparation 
groups. Previous studies have suggested that the transplantation of tissue pieces may 
provoke a stronger immune response due to the presence of intact donor vasculature 
and APCs (Chen et al. 2011). This has been reflected in reports of a stronger 
microglial response to VM transplants of tissue pieces from non-human primates 
into rat hosts, and a lack of optimal re-innervation of the host striatum (Redmond et 
al. 2008). However, although the TP group described in this study may not be 
comparable to this due to the differences in preparation, a number of clinical trials 
have used tissue pieces for transplantation with some reports of inflammation but 
without complete rejection of donor cells following variable immunosuppression 
(Capetian et al. 2009; Cicchetti et al. 2009; Freeman et al. 2000; Keene et al. 2007). 
Although an increased microglial presence may not necessarily be detrimental to the 
graft, with microglia also offering protective properties, quantification in these 
studies has used assessment of activated microglia which presents a different 
morphology to resting and is described in Appendix 7. 
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6.6 Conclusions 
Data demonstrates that E12 tissue produces larger surviving grafts than E14 (as 
measured by NeuN counts and graft volumes), in line with previous data in the rat. 
This result could be anticipated given that this developmental stage of tissue would 
be expected to contain more proliferating striatal precursor cells than the later stage. 
Although no significant difference in NeuN counts was identified between the TP 
and CS preparations, TP preparations produced significantly larger P-zones, 
suggesting that they may produce more functional grafts.  Further exploration of this 
is warranted to replicate these results and to empirically test the effect of age and cell 
preparation on behavioural function. Another important consideration that emerges 
from this chapter is whether the modifications to enzymatic digestion of tissue may 
be beneficial.  The fact that graft survival improved across the board and yet the only 
modification that applied to all groups was the reduction in trypsin digestion time to 
10, from 20 mins, suggests that this modification may be important and deserves 
further attention. 
 There was still a problem of graft variability within groups, which adds noise to 
the data. As TPs were prepared as individual striata (or pairs of), one aliquot of 
donor tissue was assigned to each host animal and all tissue pieces were drawn up 
into the syringe and transplanted. However following the regular protocol for cell 
suspension transplants, one “master” cell suspension was made up from which 2µl 
was taken to transplant each host. Although cell suspensions were gently agitated 
between transplants to prevent settling of cells it cannot be ruled out that hosts were 
transplanted with variable numbers of cells from this suspension and this could 
account for variability of graft size. For future transplant experiments it may be 
beneficial to prepare CSs as separate aliquots to ensure that the total number of cells 
is transplanted into each host. Further analysis would look at the profile of the 
immune response to different transplants in greater detail. 
The findings in this chapter show that the mouse host can support good-sized 
transplants of mouse tissue if the conditions are right. Data from this experiment 
provide a solid basis for further work to improve the survival of xenografts in mouse 
hosts using a variety of immunosuppressive regimens, including testing the potential 
of the neonatal desensitisation method itself. 
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Chapter 7  
General Discussion 
Cell replacement therapy provides a novel treatment strategy for a range of 
diseases, including the neurodegenerative disorders PD and HD. To date, a large 
amount of pre-clinical data has provided evidence for the potential efficacy of this 
therapy with grafts of rodent tissue showing integration and function. The length of 
time required for differentiation of human donor cells and the need for adequate 
long term immunosuppression of rodent hosts has resulted in a limited amount of 
functional data for human primary tissue, and even less for alternative cell sources 
including human ESC and iPSC derived neuronal cells. The issues of 
immunosuppression complicate the long term assessment of these donor cells, in 
particular their functional potential. In order to test the safety and efficacy of human 
donor cells, we have proposed a novel method of promoting long term xenograft 
survival without conventional immunosuppression by use of neonatal desensitisation 
to xenogeneic cells. The experiments presented in this thesis aimed to further 
characterise and validate this method to allow its use in the prevention of rejection 
of novel human donor cell sources for CNS transplantation.  
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7.1 Is desensitisation specific to donor tissue type and species? 
To date, neonatal desensitisation has been shown to be effective in the SD rat, 
with successful desensitisation to hPF cortical tissue, human foetal brain derived 
NPCs and hESC derived NPCs (Kelly et al. 2009b). Although this demonstrates the 
success of a novel method of promoting xenograft survival in the rat brain, further 
validation is required to allow routine use of the method in the testing of potential 
human donor cells for transplantation. The experiments discussed in Chapter 3 of 
this thesis aimed to determine whether desensitisation with hPF donor tissue could 
be achieved with cells of a different source to those used for adult transplantation. 
On a practical level, the availability of human cells for injection of neonatal hosts is 
a constant limitation to the number of desensitisation experiments which can be 
conducted. Moreover, knowing whether cells must be from the same species as for 
the adult transplants is interesting in terms of beginning to understand the underlying 
mechanisms.  
My initial findings suggested that transplants of hCTX could not survive 
following neonatal desensitisation of rat hosts with non-neural tissue, specifically 
with hSkin, with survival only reaching ~17% as compared to 66% in those 
desensitised with neural tissue. Further investigation aimed to determine whether this 
was due to the use of ‘non-neural’ tissue, or whether some feature of hSkin renders it 
unsuitable tissue for desensitisation. This was addressed by testing the potential for 
desensitisation in rat with a range of non-neural tissues. This experiment 
demonstrated successful desensitisation with both hLiver and hKidney, with 100% 
survival of hCTX grafts in these hosts, indicating that some tissue types may be 
more favourable for desensitisation than others. Reasons behind the unsuccessful 
desensitisation seen in hosts inoculated with hSkin as compared to those desensitised 
with hCTX, hLiver and hKidney are unclear since the mechanisms of the method 
have not yet been determined. Previous research into neonatal tolerance to allografts 
in mice has provided some potential suggestions as to why this may be the case 
(discussed below), however since neonatal desensitisation may not be assumed to 
represent tolerance the relevance of this is hard to determine. Studies have 
emphasised the relevance of the cell population injected neonatally, suggesting that 
the presence of mature APCs may result in an immunising effect rather than 
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tolerising (Matzinger 1994; Ridge et al. 1996). Thus potentially the large population 
of resident DCs in skin cells could have resulted in this type of immunising effect as 
opposed to successfully desensitising neonatal rat hosts. In contrast a neonatal 
injection of liver cells, known to contain populations of APCs which secrete 
immunosuppressive signals including IL-10, (Knoll et al. 1995; Sato et al. 1996) 
may be more likely to induce successful desensitisation. 
A much lower than expected number of grafts was found to survive in hosts both 
desensitised and transplanted with hCTX (36%), compared to previous experiments 
to date (Roberton VH, unpublished observations, and Kelly et al 2009), although in 
the experiments described in Chapter 4 100% survival of hCTX transplants into 
desensitised rat hosts was seen. This highlights some variability in the successful 
desensitisation of hosts. As the mechanisms underlying the method are not known it 
cannot be determined which variables are important for consistent successful 
desensitisation of hosts. For example, if the number of cells injected is on the 
borderline of an effective dose, small changes could have a large effect. 
Additionally, potential differences in age of donor hCTX used for desensitisation 
between experiments may mean variability in the population of cells injected. As 
discussed in Chapter 4; younger donor tissue is thought to contain fewer microglial 
precursors which have the potential to act as APCs (Brevig et al. 2008; Dalmau et al. 
1997). This may have a detrimental effect on the successful desensitisation of hosts 
as previously discussed. 
Transplants of mWGE were not found to survive in this experiment, even in 
immunosuppressed controls, therefore success of desensitisation with mWGE could 
not be replicated as has previously been shown (Kelly et al. 2009b). However an 
interesting finding from this chapter was survival of at least 50% of hCTX 
transplants in hosts which were desensitised with mWGE. This finding was not 
anticipated and it is unclear why this would be the case, whether the neonatal 
injection has induced some kind of general reduction in the adult immune response 
to transplants, or whether desensitisation to some common epitope has been 
achieved. This experiment requires replication to confirm these findings and further 
studies to determine the underlying biology behind them. 
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In both Chapter 3 and Chapter 4 hCTX transplants were found to be very large 
at 12 weeks post-transplantation, in some cases resembling overgrowing transplants. 
Staining with Ki67 confirmed that some cells towards the core of the grafts were still 
proliferating at 12 weeks. Use of further staining methods are required to determine 
whether these are proliferating neuronal cells, as opposed to connective tissue or 
meninges which may have been dissected in error due to their close proximity to the 
cortical tissue being dissected. The experiments described here require replication 
with the relevant donor tissue type, in most cases WGE, to ensure that no differences 
in survival are due to the use of hCTX at a particular age. As found in Chapter 4, 
the donor age of the foetal tissue can affect the size and proliferation of surviving 
transplants, and the affect this has on survival has not been determined. It has been 
reported that the use of younger donor tissue may improve survival of transplants 
due to a lower number of microglial precursor cells which may act as donor APCs 
following transplantation (Brevig et al. 2008; Dalmau et al. 1997; Freeman et al. 
1995; Zimmer et al. 1988). 
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7.2 Neonatal desensitisation to hCTX in mice 
One of the main aims of the work presented in this thesis was to determine 
whether neonatal desensitisation to human neural xenografts could be successfully 
achieved in mouse hosts. This would be a valuable step; demonstrating the method 
to be successful across species, and allowing its use in transplant experiments in 
mouse models of a range of diseases unavailable in the rat. The ability to 
successfully desensitise mice would also allow the use of various Tg models with 
modifications to their immune systems in order to investigate the mechanisms of the 
method. Currently these models are not available to the same extent in rats, thus 
restricting the ability to investigate these mechanisms.  
A number of experiments were carried out in Chapter 5, beginning with testing 
the original desensitisation protocol in mouse hosts (Kelly et al. 2009b). Poor graft 
survival in this experiment, including in mouse tissue transplant control groups, led 
to various modifications to the transplantation and desensitisation protocols in 
subsequent experiments to attempt to improve graft survival in control groups, and 
determine whether desensitisation could be achieved by modifying the original 
protocol optimised in rats (Kelly et al. 2009b). These included testing inoculation 
with varying numbers of hCTX cells in the neonatal period, and modifications to the 
transplant protocol itself; increasing the number of cells transplanted and reducing 
the time between QA lesion and transplant. Although it has been reported that 
delivering transplanted cells at a shorter time post-lesion may improve the survival 
due to the host environment at this stage (Döbrössy et al. 2011; Johann et al. 2007), 
no improvements in graft survival were found in transplants delivered 2 days, 7 days, 
or 10 days after QA lesions, or indeed into the unlesioned striatum. Graft survival 
was poor across all groups, including those treated daily with the conventional 
immunosuppressant CsA. 
Although successful desensitisation was not demonstrated in these experiments, 
since grafts in control animals, transplanted with hCTX and immunosuppressed with 
daily CsA injections, did not survive to greater than ~50% it cannot be determined 
whether this was due to the poor graft survival observed overall. However when 
compiling the data from all experiments conducted, the findings suggest that 
desensitisation does not improve survival to any greater degree than that found in 
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untreated hosts (~15% in contrast to 50% in CsA treated hosts). However the fact 
that graft survival was poor even with blocking of the T cell response with CsA is 
suggestive of some difference in the mouse brain as a host environment to that of the 
rat. Although it cannot be demonstrated with certainty that the loss of transplants 
was due to rejection, it is most likely that this is the case since up to 50% of mouse 
grafts and human xenografts in CsA treated hosts were found to survive, 
demonstrating that donor tissue could survive under some circumstances, albeit to a 
lesser extent than expected.  
Much work has been carried out to characterise the response to neural 
xenografts in rat hosts transplanted with mouse (Finsen et al. 1991), porcine 
(Armstrong et al. 2001; Larsson et al. 2000) and human tissue. Some work by 
Larsson et al has aimed to understand the rejection responses to porcine tissue 
transplants in mice (Larsson et al. 2001a; Larsson et al. 2002; Larsson et al. 1999; 
Larsson et al. 2001b), however less detail is available concerning human tissue 
transplants. These investigators have suggested a difference in the immune response 
to neural xenografts between mice and rats; with a faster, more severe response 
observed in mouse hosts (Larsson et al. 2000). Moreover it has been reported that the 
use of high doses of CsA is required to promote xenograft survival in mice, although 
due to side effects this cannot be tolerated by the animals for long, prompting the 
authors to seek alternative methods, such as co-stimulatory molecule blocking 
(Larsson et al. 2002; Larsson et al. 2000). The findings of the work presented in this 
thesis, using human rather than porcine PF tissue support the notion that there is a 
difference in the response to neural xenografts between rats and mice. There is an 
indication of a strong microglial response to human xenografts in the mouse brain, as 
found in this thesis and by other groups (Mattis et al. 2014), although the precise 
differences between the two species has not yet been fully characterised. 
Other groups have attempted to desensitise mouse hosts to human tissue, with 
little success (Janowski et al. 2012). These authors attempted to desensitise rat and 
mouse hosts to two different human cell types; an immortalised luciferase expressing 
glial restricted precursor cell line (hGRP) and a neural stem cell line derived from 
human cord blood and found poor survival in all conditions. Desensitisation with 
hGRP cells allowed detection of the cells in vivo with bioluminescence imaging 
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(BLI), showing that grafts were lost after two weeks in both desensitised and 
untreated mouse hosts. This was shown to be due to rejection of the cells, via dense 
infiltration of CD45+ immune cells. Transplants into rag2-/- mice were shown to 
survive up to 3 weeks post-transplantation, but no longer time-points were assessed, 
thus no confirmation was demonstrated that their donor cells were capable of 
surviving in the long term following transplantation into the rodent brain. Survival of 
donor cells in immunocompetent hosts with the use of a conventional 
immunosuppression regime was also not shown (Janowski et al. 2012). Interestingly, 
BLI showed rapid signal loss following neonatal i.p. injections (Janowski et al. 
2012). It is not clear how long cells injected to induce desensitisation in rats are 
present in the neonatal host, although it has been suggested that for tolerance 
induction, as with the natural development of “self” tolerance, the persistent 
presence of donor or “self” cells are required during the development of the 
immature immune system. 
Other studies have suggested that neural xenografts do not survive in mouse 
neonates (Mattis et al. 2014), in contrast to the known survival of these transplants in 
rat neonates (Englund et al. 2002). If this is the case, then it appears that xenogeneic 
donor cells are rapidly rejected in both the CNS and the periphery of neonatal mice. 
This presumably would prevent the persistence of donor antigen during immune 
system development in the mouse host, and if this were the mechanism through 
which desensitisation is achieved then this could explain the difficulty in 
demonstrating desensitisation in this species. Assuming this to be so, then it may 
indicate that the immune system develops quicker in the mouse host than the rat and 
is more developed by birth, or is more equipped to reject the presence of human 
donor cells. However, until the issues of reliable transplant survival in adult 
immunocompetent mouse hosts are resolved it cannot be determined whether the 
neonatal desensitisation method can be modified for successful application in mouse 
hosts. 
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7.3 Transplants of mouse tissue to the mouse striatum 
Experiments using xenografts of human tissue in Chapter 5 allowed the 
identification of a general problem of graft survival in mouse hosts. These 
experiments included some hosts receiving mouse tissue transplants in order to 
ensure graft survival could be achieved in these conditions. Although some survival 
was observed, this was far lower than would be expected from neural transplants of 
rat tissue in rat hosts, which generally survive reliably without immunosuppression 
(Marion et al. 1990). As graft survival proved to be a limiting factor in the 
examination of the desensitisation method, this required further investigation of 
transplant protocols in mice. 
Chapter 6 describes a mouse experiment designed to investigate whether poor 
survival of mouse tissue transplants in Chapter 5 could be improved with alternative 
preparation of donor tissue, or with the use of tissue of a different donor age. A 
systematic experiment was designed to compare modifications to these variables 
with the standard protocol of transplantation of E14 quasi single cell suspensions. 
The rationale for using a different donor age was that the optimal gestational age for 
WGE in a rat transplant is around E13-15, with E14 being the most commonly used 
age which corresponds more closely to E12.5 in the mouse. The rationale for testing 
a different cell preparation was that digested tissue pieces improved survival of 
human VM grafts transplanted into rats (Rath et al. 2013), and that improvements on 
behavioural tasks are greater in rat WGE grafts (Watts et al. 2000a), therefore 
supporting the rationale for investigation of this preparation in Chapter 6. 
Two cell preparation methods were used, a trypsinised “tissue pieces” style 
suspension (referred to as TP) in which a 10 minute trypsin digest was followed by a 
minimal trituration to leave small pieces of tissue rather than single cells, as 
described previously for preparation of rat LGE (Watts et al. 2000a) and human VM 
(Rath et al. 2013) and a standard trypsinised quasi-single cell suspension (referred to 
as CS) prepared using our standard trituration procedure. In order to allow 
comparison between the trituration parameters, the CS preparation was also subject 
to a 10 minute trypsin digest, which is shorter than the usual digest of 20 minutes. It 
is important to emphasise that the preparation labelled as TP in this thesis is not the 
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same as “tissue pieces” preparations used in clinical studies in which tissue is not 
trypsinised but is manually chopped into small pieces (Bachoud-Levi et al. 2000).  
CD-1 mouse hosts received transplants of mWGE derived from either E12 or 
E14 donor embryos prepared as CS or TP, as described above, to systematically 
determine whether improvements in graft survival could be achieved. Initial analysis 
revealed better survival universally than in previous experiments. Findings were 
suggestive of a higher percentage of graft survival and larger graft volumes in 
transplants derived from E12 donors, irrespective of cell preparation type. However 
the different cell preparation groups did not result in differences in graft volume or 
phenotype, with no significant difference in the number of DARPP-32+ cells or 
volume of patches. Although differences were not significant, a trend towards a 
higher volume of DARPP-32+ patches in transplants from TP preparations was 
observed. When examining the percentage of the graft as a whole that was occupied 
by these patches, E14 TP transplants appeared to have the greatest; 79% of the graft 
as compared to 49% in the next highest group (E12 TP). These data require 
replication since this group contained only 3 surviving grafts and investigation of 
function is necessary to determine what graft composition produces the greatest 
functional benefit. 
Good graft survival was seen in all transplant groups, including those hosts 
receiving E14 cell suspension transplants; the standard cell preparation protocol used 
for all mouse tissue transplants in Chapter 5. Although this may seem to conflict 
with the data from Chapter 5, in addition to the group differences in donor age and 
cell preparation, all tissue dissociation carried out in Chapter 6 was conducted with 
a 10 minute trypsin digestion, as opposed to the 20 minutes used previously. This 
was in order to allow sufficient digestion for dissociation of the cell suspension 
groups into single cell suspensions, without breaking up the “tissue pieces”. There 
has also been a suggestion of improvement in rat VM transplants which also used 
reduced digestion times in trypsin (Breger, L. Unpublished data). This could explain 
why graft survival was greatly improved generally in comparison to Chapter 5. 
Indeed, this may explain findings from Chapter 4, in which no surviving mouse 
transplants were detected in rat hosts, even in hosts which had been neonatally 
desensitised to mouse tissue or treated daily with CsA.  
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These findings lead to a conclusion that the mouse as a transplant host may not 
have been the only difficulty faced in Chapter 5. Since mouse graft survival in 
Chapter 6 was fairly consistent across groups, and surviving transplants were of a 
good size, it is clear that transplants can survive in the mouse striatum. These data 
are suggestive of issues with the mouse donor tissue itself, which may be more 
sensitive to harsh cell preparation protocols than rat tissue. Reducing the trypsin step 
in the dissociation protocol, and perhaps the harshness of trituration of the tissue 
may prevent poorer tissue integrity. No differences in the immune response to 
transplants of mouse tissue were found in Chapter 6 across the different donor age 
or cell preparation methods, suggesting no one preparation induces a stronger 
response than any other; therefore it is possible that the integrity of the donor tissue 
itself also has a detrimental effect on graft survival. 
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7.4 Methodological issues 
7.4.1 Identification of mouse donor cells 
A problem faced in Chapter 5 was in the identification of mouse transplants in 
the mouse host brain. Without prior labelling of the cells, there is no way to clearly 
identify tissue of graft origin other than basing measurements on the presence of a 
deposit of cells within the lesioned striatum. In the case of Chapter 6 lesions were 
quite clear and grafts were large enough to clearly be identified. However in 
Chapter 5 this was not the case, with surviving grafts either being much smaller in 
size, or lesions producing insufficient cell loss to distinguish between graft and host. 
Additionally, due to the loss of tissue sections in these studies only CV staining 
could be used to identify surviving grafts. Although valuable in transplants in rats for 
initial identification of graft survival, and other aspects of graft morphology, it is 
clear that a large amount of staining may also be attributed to immune cells 
surrounding or infiltrating the graft. Further staining with neuronal and striatal 
specific markers is required to confirm the presence of surviving grafted cells within 
the lesioned striatum in the absence of a donor specific label. The lack of label for 
mouse cells also caused issues in the analysis of Chapter 4, as there was no clear 
way to confirm the absence of mouse donor cells in the rat brain. Although the only 
staining seen on CV stained sections from this chapter resembled a needle tract, the 
possibility of a few remaining mouse cells could not be ruled out as no confirmatory 
staining could be carried out. Since the hosts were not lesioned, no staining could be 
performed as in Chapter 6 to distinguish between graft and host. Previous studies 
have used M2 and M6 antibodies, reported to be specific to mouse neurons and glia 
respectively (Olsson et al. 1997), however although these antibodies were not used 
in this study they have been reported in the literature (and confirmed in our 
laboratory) not to be specific to mouse. In addition the specificity of these two 
antibodies has been questioned with overlap being reported in detection of neurons 
and glia. 
7.4.2 Subjective quantification of immune marker staining 
To assess the immune response to striatal transplants in this thesis, immuno-
staining was conducted for various immune markers. The variability in this staining, 
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dependent on the immune response between sections within one experiment makes 
manual quantification a challenge. The staining in one host may require counting 
only a few cells, whereas another might have a dense infiltration of cells which 
would require stereological analysis for adequate quantification. In order to avoid the 
problem, an established subjective rating scale was used, which has been extensively 
employed in the analysis of the immune response to neural transplants (Armstrong et 
al. 2001; Duan et al. 1995; Larsson et al. 2001b). In this analysis all sections from a 
series (e.g. 1:6/1:12) are graded for each host animal, the highest grade scored is then 
assigned to this animal for comparison with the rest. Although adopted as the best 
current standard, this potentially is not the most fair representation of the host 
response, since one section may contain a high grade of scoring resulting in that host 
being assigned a high grade, whereas another may have a lower grade, spanning a 
much larger amount of sections and therefore area of the brain, but resulting 
ultimately in a lower score. Alternative analysis such as optical density or automated 
counting would provide a more objective method of quantification. These methods 
are currently being optimised for future analyses. 
7.4.3 Transplant host strains 
With the exception of the C57BL/6J mice used in Appendix 7 all the transplant 
hosts used for the experiments presented in this thesis were from outbred stock 
(CD-1 mice and LH/SD rats). SD rats have been used historically for successful 
neural transplantation experiments (Björklund and Stenevi 1979) and are still 
commonly used as transplant hosts today. LH rats have been subsequently selected 
for transplantation experiments which demand more thorough behavioural 
assessment of graft integration and function due to their inquisitive nature, and 
because the albino SD rats are known to possess lower visual acuity (Prusky et al. 
2002). However unlike inbred rats which are genetically identical within colonies, 
removing variation at the MHC locus, outbred stocks are highly variable. Inbred 
strains allow for greater phenotypic uniformity and increase the potential to detect 
biological effects within a cohort of animals (Kacew and Festing 1996). Using 
outbred stocks for transplantation experiments increases the variability within 
groups, and may reduce survival of rat transplants as well as having an effect on 
survival of human transplants. 
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In some of the experiments described in this thesis, variability has been 
observed in survival rates in hosts desensitised with the same tissue types between 
experiments. In Chapter 3, for example, only 36% of hCTX transplants were found 
to survive in hosts desensitised with hCTX as compared to 100% in Chapter 4. 
Since hosts are desensitised to specific tissue types within litters to remove the need 
for identification of individual rat pups, there is no way to control for variability 
between these litters in outbred stocks. Although there are likely to be broad genetic 
differences between host animals, more similarities are likely to exist within litters, 
therefore one litter may be more amenable to graft survival than another. For the 
investigation of neonatal desensitisation in rodent hosts it would be valuable to use 
an inbred strain, where one source of variability in the data could be reduced, as 
control of human donor tissue haplotype is not possible. Unfortunately there is no 
obvious candidate for an inbred rat strain which would be ideal for transplantation 
and behavioural testing. If the method were to be optimised in an inbred strain, one 
which was suitable for behavioural assessment of graft function would be ultimately 
required.  
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7.5 Conclusion and future work 
Although there is a need for replication of the findings discussed in this thesis, the 
data presented here has provided valuable validation of the neonatal desensitisation 
method in rat for its use in preclinical models for transplantation in 
neurodegenerative disease. The novel finding that hosts can be successfully 
desensitised using non-neural tissue types will allow desensitisation to be carried out 
with peripheral tissues, reserving neural tissue for transplantation. Further analysis 
will be needed to elucidate the reasons for this finding. The survival of human 
transplants in hosts desensitised to mouse tissue raises interesting questions about the 
specific mechanisms involved in neonatal desensitisation.  
With regards to desensitisation in mouse hosts, although this has not been 
proven one way or another, the experiments presented here have revealed issues with 
both the mouse host and mouse donor tissue in transplantation experiments and the 
resolution of these issues will now allow directed modifications to the desensitisation 
protocol to determine why it has been unsuccessful so far and whether it can 
realistically be achieved. Addressing these issues with mouse tissue transplants has 
primarily provided potential improvements to transplantation protocols into mouse 
hosts in terms of tissue preparation and the improvement of the resulting phenotype 
of transplants, which can now be applied to improve survival of human xenografts in 
mouse hosts. The logical progression for further investigation in these areas is 
discussed here. 
7.5.1 Rat 
The experiments from both Chapter 3 and Chapter 4 require replication to 
confirm findings. Due to the long duration of most of these experiments (commonly 
9-12 months from the time of neonatal desensitisation to the analysis of grafts) it was 
important to carry out experiments in parallel and thus it was not always possible to 
fully assess one experiment and replicate finding before addressing another question. 
Furthermore, whilst every effort was made to ensure group sizes would be sufficient 
for meaningful analysis to be carried out, I was limited by; litter sizes (which varied 
from 10-15 pups in the rat and 8-12 in the mouse), the availability of human tissue, 
and the less than 100% accuracy of the method. Hence some experiments fall short 
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in completeness due to resulting small group sizes. For Chapter 3 it is necessary to 
increase numbers of hosts desensitised with non-neural tissue types to confirm that 
this successfully promotes survival of human neural xenografts, specifically to hPF 
WGE transplants, as opposed to cortex. Furthermore, to understand this finding 
further, it would be beneficial to further immunologically characterise the population 
of cells injected neonatally, and what disparity there may be between those which 
induce successful desensitisation as opposed to those which do not. This could be 
carried out by fluorescence activated cell sorting (FACS) analysis of donor cell 
suspensions to identify populations of, for example, antigen presenting cells, 
proliferating cells, and cells of a hematopoietic lineage. Populations of cells could be 
confirmed with immunocytochemistry for these markers on fixed primary donor 
cells. The experiment described in Chapter 4, to determine whether desensitisation 
is specific to the species of donor cells injected, requires replication to determine 
whether survival of human transplants in hosts desensitised with mWGE persists in 
comparison to untreated controls, and with transplants of hPF WGE instead of 
hCTX. These experiments would be conducted following optimisation of the 
preparation of mouse donor tissue discussed in section 7.5.2.  
As well as defining the parameters for the desensitisation method, it is important 
to understand the mechanisms that underlie it. An experiment will attempt to 
investigate these mechanisms by testing organ samples from desensitised hosts using 
PCR and Western blotting, at various time points following neonatal injection for the 
presence of human genes/protein. Furthermore, it would be valuable to study 
additional characteristics of desensitised hosts such as the induction of peripheral 
chimerism, since this has been shown previously to be correlated with the successful 
induction of neonatal tolerance to allografts in mice (Borenstein et al. 2004; Chan et 
al. 2007). Optimisation of techniques has been achieved alongside the transplant 
experiments presented here. This work can now be carried out, and will provide data 
regarding the mechanisms involved in neonatal desensitisation to add to the 
characterisation reported in this thesis. 
Following the finding that desensitisation can be achieved with tissue of a 
different type to that used to transplant the adult host; it is necessary to confirm that 
desensitisation can also be sufficient to promote long term survival of hESC and 
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hiPSC derived neuronal cells. Long term assessment of the success of the method is 
also required to demonstrate functional benefit in desensitised hosts with hPF tissue, 
and novel cell sources if possible. To this end experiments will aim to demonstrate 
this; with desensitisation of neonates which will host transplants of hESC derived 
MSNs or hPF WGE and undergo a battery of motor behavioural tasks to identify any 
functional improvements after transplantation. This has not yet been demonstrated 
since conventional immunosuppression does not allow such long term assessment of 
human graft potential. 
7.5.2 Mouse 
Findings from this thesis identified problems with rejection of human xenografts 
in the mouse brain, even under conventional immunosuppression. The recent finding 
that human xenografts are also rejected in neonatal mice implies there are differences 
between rat and mouse immune responses to neural transplants (Mattis et al. 2014). 
Therefore, future work aims to address this by comparing the rat and mouse host 
immune response to human transplants at various time-points post-transplantation. 
At present, a pilot experiment is being analysed, in which untreated or CsA 
immunosuppressed mouse and rat hosts received transplants of hCTX and were 
sacrificed 10 days post-transplantation in order to characterise the immune response 
to xenografts. Additionally, I aim to replicate the findings reported by Mattis et al, 
by transplanting human cells into neonatal mice of various post-natal ages 
comparing the response with that of the rat, or immune compromised mouse 
neonates (Mattis et al. 2014). The findings from this study will give insight into the 
problems faced with attempts to desensitise mouse hosts neonatally to human tissue, 
since a more severe host immune response in the neonatal period may prevent 
successful desensitisation. 
As well as addressing problems identified with the mouse host, ongoing work 
also aims to resolve potential issues with the preparation of mouse donor tissue. 
Since findings from Chapter 4 and Chapter 6 are suggestive of sensitivity of mouse 
tissue to prolonged enzymatic treatment or trituration of donor tissue, an ongoing 
experiment aims to compare the effect of various treatments on the viability and 
development of cells in vitro. Subsequently, this will then be characterised further 
in vivo, with both human and mouse tissue to determine the optimum cell 
Chapter 7  General discussion 
195 
preparation protocol for delivery of neural transplants. Although this has been 
addressed previously and optimised for rat transplants (Schmidt et al. 1981), the 
findings in this thesis suggest that further optimisation may be beneficial to promote 
survival of mouse and human donor tissue, in particular in the mouse host. Finally, 
the dissociation of tissues and cells for potential application in the clinic requires the 
use of animal-free reagents, therefore optimisation of the use of products such as 
TrypLE (Invitrogen) rather than bovine trypsin is required. 
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7.6 Final conclusions 
The work presented in this thesis provides further validation of a novel method 
of promoting xenograft survival in the adult rat brain without the use of conventional 
immunosuppression. A method to achieve long term xenograft survival in the 
healthy rodent brain is crucial and is achieved by this method. It has been 
demonstrated that the rat can be desensitised to human donor tissue using various 
tissue types, sufficient to promote survival of hPF CTX up to 12 weeks after striatal 
transplantation. These experiments provide further validation for the method and for 
its use in the long term assessment of donor cells. 
These experiments also highlight an issue with striatal transplantation into 
mouse hosts, in particular with xenografts. Much work is conducted under the 
assumption that transplantation protocols can be directly translated to mouse hosts; 
however I have found this not to be the case. I propose that CNS transplantation in 
mice requires more detailed investigation, in particular to investigate the rejection 
response to neural xenografts, and additionally the treatment of mouse donor tissue 
for transplantation. These studies are required before further comment can be made 
as to whether neonatal desensitisation can be successfully achieved in mice.
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Appendix 1  
Reagents and suppliers 
Reagent Supplier Address 
Cyclosporine A 
(Sandimmun) 
Novartis Hampshire, UK 
DMEM-F/12 Gibco Paisley, Scotland 
Diazepam CP Pharmaceuticals Wrexham, UK 
DNase Sigma Poole, Dorset, UK 
Euthatal Merial Animal 
Research 
Harlow, Essex, UK 
HBSS Gibco  
Isoflurane Primaral Healthcare Northumberland, UK 
Metacam Boehringer Ingelheim Ingelheim, Germany 
Penicillin Streptomycin Gibco  
Trypan blue Sigma  
Trypsin Worthington Freehold, New Jersey, USA 
Trypsin inhibitor Sigma  
Company Location 
Abcam Cambridge, UK 
AbD Serotec Oxford, UK 
BD Pharmingen Oxford, UK 
Harlan Bicester, UK 
Invitrogen (Molecular Probes) Paisley, UK 
Millipore Molsheim, France 
Santa Cruz USA 
Vector Peterborough, UK 
Wako Neuss, Germany 
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Appendix 2  
Recipes 
Tissue dissociation 
Cell suspension Media  
DMEM-F/12  
1% Penicillin streptomycin  
DNase solution Trypsin solution 
0.05% DNase 0.1% trypsin 
In HBSS 0.05% DNase 
 In HBSS 
Perfusion and tissue storage 
Prewash Buffer (PBS-1L) Paraformaldehyde (PFA) solution (1L) 
18g di-sodium hydrogen phosphate 15g PFA (1.5%)/40g PFA (4%) 
9g sodium chloride 1L Prewash buffer 
1L distilled water Heat to dissolve 
pH 7.3 (orthophosphoric acid) pH 7.3 (orthophosphoric acid) 
Sucrose (25%-1L) Antifreeze Solution (800ml) 
250g sucrose 4.36g sodium phosphate (dibasic) 
1L Prewash buffer 1.256g sodium phosphate (monobasic) 
pH 7.3 Dissolve fully in 320ml distilled water, then 
add: 
 240ml ethylene glycol 
 240ml Glycerol 
All stored at 4oC  
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Histology and Immunohistochemistry 
4X Tris buffered saline (4X TBS-2L) 1X Tris buffered saline (1X TBS -2L) 
96g Trizma base 500ml 4X TBS 
72g sodium chloride 1500ml distilled water 
2L distilled water (total) pH 7.4 
pH 7.4  
0.2% Triton X-100 in TBS (TXTBS) Tris non-saline (TNS) 
0.5ml Triton X-100 6g Trizma base 
250ml TBS 1L distilled water 
pH 7.4 pH 7.4 
Endogenous Peroxidase Quench 0.01% azide in TBS 
10ml methanol 500ml 1X TBS 
10ml hydrogen peroxide 2.5ml 2% sodium azide 
40ml distilled water  
Cresyl violet working solution Acid alcohol 
7g Cresyl violet 5ml glacial acetic acid 
5g sodium acetate (anhydrous) 200ml 95% alcohol 
600ml distilled water  
pH 3.5 (glacial acetic acid)  
Make up to final volume of 1L  
Cresyl violet staining protocol Differentiation and dehydration 
Using Shandon processing machine On removal from the machine 
70% alcohol 5 mins 70% alcohol 5 mins 
95% alcohol 5 mins 95% alcohol 5 mins 
100% alcohol 5 mins Acid alcohol for destain if necessary  
50/50 chloroform/alcohol 20 mins 95% alcohol 2 mins 
95% alcohol 5 mins 100% alcohol 5 mins 
70% alcohol 5 mins Xylene 5 mins 
Distilled water 5 mins Coverslip sections using DPX 
Cresyl violet 5 mins   
Distilled water Finish   
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Drugs 
Cyclosporine A Concentration 
5ml ampoule Sandimmun 5mg/ml = 250mg total 
Dissolved in 20ml sodium chloride 10mg/ml 
Inject 1ml/kg 10mg/kg 
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Appendix 3 
Cardiff Foetal Tissue Bank (CFTB) standard operating procedure for staging of embryos. Showing expected CRL in mm calculated 
from gestational age on day of ultrasound (left), and days between ultrasound and 1st tablet (top). The white area indicates predicted 
CRL between 10-40mm which may be considered for clinical studies. (CFTB 2012) 
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Appendix 4  
Antibodies 
Primary antibody Type Supplier Concentration Blocking serum Secondary Antibody (all at 1:200) 
CD4 (Mouse) 550278 
(Mouse CD4+ helper T cells) Rat monoclonal BD Pharmingen 1:500 (IH) Goat Rabbit anti-rat 
CD4 (Rat) Ab8167 
(Rat CD4+ helper T cells) Mouse monoclonal Abcam 1:500 (IH) Horse Horse anti-mouse 
CD8 (Mouse) ab22378 
(Mouse CD8+ cytotoxic T cells) Rat monoclonal Abcam 1:1000 (IH) 
Goat 
(Invitrogen) 
Rabbit anti-Rat  
(BA-4000 Vector) 
CD8 (Rat) MCA48GA 
(Rat CD8+ cytotoxic T cells) Mouse monoclonal Serotec 1:500 (IH) Horse Horse anti-mouse 
CD11b (Rat) MCA275G 
(Rat macrophages and microglia) Mouse monoclonal Serotec 1:1000 (IH) Horse Horse anti-mouse 
DARPP-32  Mouse Cornell University 1:10000 Horse Horse anti-mouse 
F4/80 ab90247 
(Mouse macrophages) Rat monoclonal Abcam 1:1000 Goat Rabbit anti-rat 
HuNu MAB1281 
(Human nuclei) Mouse monoclonal Millipore (Chemicon) 1:1000 (IH) 
Horse 
(Invitrogen) 
Horse anti-mouse 
(BA-2001 Vector) 
Iba1 0919-19741 
(Mouse macrophage/microglia) Rabbit polyclonal Wako 1:8000 Goat 
Goat anti-rabbit 
(BA-1000) 
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Appendix 5  
Problems with storage and degradation of tissue sections 
In the Brain Repair Group established protocols are used for the processing and 
sectioning of brain tissue and subsequent storage, histological and 
immunohistochemical staining. As such, shared solutions are used which are made 
up by all users and technicians and stored and restocked where required to prevent 
wastage. The protocol for processing and storing brain tissue sections is outlined 
below. This was the protocol established for use by all users at the time of 
undertaking this PhD.  
Perfusion and sectioning 
• 50-100ml Prewash to flush all the vessels 
• 200-250ml 1.5% PFA delivered over 5 minutes with a peristaltic pump 
• Removal of brain and post-fix overnight (24hr) in 1.5% PFA 
• Transfer to sucrose for storage until sectioning at 40µm 
All animals (rats and mice) are transcardially perfused with 1.5% PFA rather 
than 4% as it was found that for a number of antibodies tested, 1.5% PFA improved 
full thickness staining, enabling clearer quantification of positively stained cells 
(Torres et al. 2006).  
Storage 
Fixation at 1.5% was considered to be adequate for tissue sections cut and stored 
in 96 well plates in TBZ at 4oC (1 brain per plate). Sections can be stored long term 
in these conditions, provided levels of TBZ are monitored and topped up as required. 
TBZ is therefore prepared by all users when necessary and used as a shared solution.  
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Problems 
Although these methods have been successfully implemented in this lab group 
for a considerable amount of time with no problems experienced, for unclear reasons 
I encountered severe deterioration of tissue sections from brains across a number of 
my experiments, as shown in Table 5.1. This has limited the histological assessment 
possible for these experiments, and therefore a number of experiments described in 
this thesis are lacking data. However, all experiments which showed interesting data 
and for which further staining could not be carried out have been repeated where 
possible and are quantified to the best level within the timeframe available. More 
extensive quantification of interesting data can be carried out prior to publication. 
There are a number of potential causes for these problems; however it is most 
likely that a combination of these contributed to the degradation of tissue sections: 
• Fixation 
It is possible that fixation with 1.5% PFA was insufficient for storage of tissue 
sections at 4oC. However this cannot account for why some sections from each 
experiment remained fine in storage long term when processed in exactly the same 
way. Batches of brains wrapped and stored together were affected while other 
batches cut on the same day and stored in the same fridge were not affected. 
Additionally some sections degraded after some time in storage, whereas others 
began to deteriorate almost immediately, making them unusable by 1-2 weeks.  
• Storage (TBZ) 
The recipe for TBZ can be found in Appendix 2. The basic solution is made up 
as 0.01% azide in TBS. The azide in this solution should preserve tissue sections and 
prevent the growth of bacteria. As the tissue sections which were damaged were 
processed either over a period of a couple of months, or storage plates may have 
been topped up over this time period, it may be that the solution used was made up 
incorrectly or the water was not clean enough meaning stored sections became 
contaminated in the fridge. 
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Contamination 
If either of the above two points occurred, then tissue sections would either be 
underfixed, or inadequately protected from contamination by bacteria during storage 
at 4oC. This is possible since initial problems were observed in stacks of plates 
wrapped together, but not necessarily those around it. Not all sections stored in these 
fridges were affected; however had these been better fixed or stored effectively in 
azide, such contamination would not be a problem. 
Solution 
Where sections had begun to degrade attempts were made to fix prior to staining 
in 4% PFA, and carry out required stains as quickly as possible to try not to lose any 
data. However although antibody staining was successful in some cases, it was 
impossible to mount sections onto slides as they would disintegrate.  
For subsequent experiments, tissue sections were therefore stored at -20oC in 
Antifreeze in 48 well plates (4 brains per plate). Additionally, for the most recent 
experiment (Chapter 7), 4% PFA was used rather than 1.5%. No detrimental effect 
was observed on the antibody stains in these sections, and no difficulty was 
experienced in the quantification of positive staining. After these changes were made 
no further problems were experienced and tissue sections have been successfully 
stored long term at -20oC. 
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Table 5.1 Experiments affected by degradation of tissue sections 
Chapter Experiment Fixation/Storage Staining completed Staining not possible 
3 Experiment i) 1.5%/4oC CV, HuNu 
OX42 and CD8: complete but some damaged 
CD4: Very few and badly damaged 
Staining incomplete for some 
immune markers 
5 Experiment i) 1.5%/4oC CV, HuNu NeuN, immune markers 
5 Experiment ii) 1.5%/4oC CV, HuNu NeuN, immune markers 
5 Experiment iii) 1.5%/4oC CV 
HuNu: Not for all animals 
CD8: Only for a few animals 
Complete HuNu 
Immune markers 
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Appendix 6  
Proliferation of hPF cortical tissue following transplantation 
Surviving hCTX transplants in rat hosts were consistently large at 12 weeks 
after transplantation as identified by both CV and HuNu staining. To determine the 
phenotype of surviving grafted cells; staining for NeuN was carried out on sections 
from Chapter 4, which revealed the presence of mature neurons closer to the 
periphery of grafts, with far less towards the centre despite confirmation of the 
presence of human cells with HuNu antibody staining (Figure 1 A-C). To 
investigate this further, staining for Ki67 was conducted, revealing the presence of 
cells closer to the centre of the graft which were still proliferating at 12 weeks post-
transplantation (Figure 1; D,E). It is not clear whether the proliferative nature of this 
tissue is related to the effectiveness of hCTX as a source of cells for desensitisation. 
The presence of a viable, proliferative population of donor cells during immune 
system development may be more beneficial than an alternative tissue source. It is 
possible that differences such as these between donor tissues may have an effect on 
the host immune response to cells following transplantation. I aim to further 
investigate both of these factors by beginning to characterise the donor tissue used to 
desensitise and transplant and correlate this with the success of desensitisation and 
the survival/rejection of transplanted tissue. 
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Figure 1 Photomicrographs of a hCTX graft 12 weeks after transplantation in a host desensitised with hCTX tissue from Chapter 4
stained with CV (A), HuNu (B), NeuN (C), Ki67 (D), and NeuN and Ki67 merged (E). Images were manipulated in Adobe Photoshop 
in C-E to increase contrast and enhance visualisation of staining. E shows staining from subsequent sections in C and D overlaid to 
highlight the presence of immature proliferating cells in the centre of the graft and mature neurons around the periphery. This is typical 
of large hCTX grafts at 12 weeks from Chapter 3 and 4. 
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Appendix 7  
Desensitisation in C57BL/6J mice 
Experimental Design 
A cohort of C57BL/6J (BL/6) mice (n=13) were desensitised neonatally (P0-2) 
with hCTX (1x105 cells) from two embryonic donors as described in Chapter 2. All 
mice received QA lesions to the right striatum followed by a transplant of hCTX 
(5x105 cells) 8 days later. Survival of transplants was assessed 6 weeks after 
transplantation and compared to a small control group (n=3) of untreated mice who 
received the same lesions and transplants. 
Results and Conclusions 
Following perfusion (1.5% PFA) and collection of brains as described 
previously, sections were cut at 40µm and, due to previous problems with 
degradation of tissue sections (Described in Appendix 5), stored at -20oC. Sections 
were stained with CV to identify surviving grafts, and with HuNu to confirm this. As 
in previous experiments, survival of human xenografts transplanted to the striatum of 
desensitised animals was found to be poor, with no surviving grafts identified. This 
experiment was conducted concurrently with those described in Chapter 5; thus 
sections from desensitised BL/6 hosts were used to test and improve antibody 
staining. As described in Chapter 5, in the majority of cases where CV staining was 
suggestive of good transplant survival, no staining could be found in HuNu stained 
sections. It was reasoned that if transplant survival could not be confirmed with this 
human specific antibody, then it may be possible to determine whether this staining 
represents a transplant by showing the inverse; that this dense staining is not due to 
the infiltration of immune cells. 
Sections from desensitised BL/6 hosts were therefore stained with a range of 
antibodies (described in below). Staining with these antibodies suggests that there is 
poor survival of transplanted cells, since little positive staining for NeuN was 
observed in the grafted area. Staining with Iba1 shows that the dense staining 
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observed in CV sections is potentially indicative of large microglial infiltration and 
rejection of the graft (Figure 7.1; A,E,I,C,G,K). Initial staining for cytotoxic (CD8+) 
and helper (CD4+) T cells did not show a large number of positive cells in the 
grafted area. To ensure this was not due to poor optimisation of the antibody in 
mouse tissue, a pan T cell marker (CD3) was subsequently used. This showed a large 
number of positive cells in the vicinity of the graft site, as well as additional positive 
cells distributed around the brain (Figure 7.1; B,F,J,D,H,L). 
Although this experiment did not provide any positive data in determining 
whether desensitisation of BL/6 mice to hPF tissue can be achieved, findings were 
useful in determining the outcomes of experiments described in Chapter 5. The 
optimisation of antibody stains could be carried out to allow the identification of a 
strong immune response to xenogeneic human tissue transplants and highlighting 
that the presence of CV staining resembling surviving transplants is more likely to be 
due to the presence of these immune cells. A strong microglial response was 
observed in sections from both desensitised and untreated hosts, with the 
morphology of cells resembling a more activated microglial phenotype, as shown in 
Figure 7.2. This has also aided in the design of future experiments to further 
characterise this and with the aim of targeting immune suppression more 
appropriately. 
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Antibody Aim Finding  
CV: Nissl 
body stain 
To identify graft 
region 
Dense staining on 
some sections 
 
NeuN: Mature 
neuronal 
marker 
To detect neurons 
in the transplant 
area and see if 
this corresponds 
to CV staining 
The area identified 
as a graft in CV 
staining shows no 
staining with NeuN 
 
CD4: CD4+ 
Helper T cells 
To identify 
whether CV 
staining is due to 
dense lymphocyte 
infiltration 
Some positive 
staining for both T 
cell markers but 
insufficient to 
account for density 
of CV  
CD8: CD8+ 
Cytotoxic T 
cells 
 
CD3 : Pan T 
cell marker 
Large amounts of 
positive staining in 
the grafted area and 
distributed around 
the brain 
 
F4/80: Mature 
mouse 
macrophages 
and microglia To identify 
whether CV 
staining is due to 
an increased 
microglial 
response to 
transplant 
Increased staining 
of microglia but 
insufficient to 
account for CV 
staining 
 
Iba1: 
Microglia and 
macrophages 
Dense staining in 
grafted area 
corresponding to 
CV staining 
 
Table 7.1 Antibodies tested to identify source of dense CV staining
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Figure 7.1 Photomicrographs of sections from BL/6 mouse hosts transplanted with hCTX which had previously been 
desensitised (left panels) with hCTX tissue or were untreated (right panels). Sections are stained with the microglial marker Iba1 
(A,E,I; C,G,K) and pan T cell parker CD3 (B,F,J; D,H,L). Intense staining for both microglia and T cell immunoreactivity was 
seen in all hosts. 
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Figure 7.2 Iba1 immunoreactivity. A) Microglia in a mouse host transplanted with 
hCTX, showing resting, ramified microglia in the left striatum (black arrowheads) 
and activated microglia in the grafted area of the right striatum. B) Examples of the 
morphology of resting and activated microglia (from (VanGuilder et al. 2011)) 
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